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Objectives: To reconsider the aims of screening for
undiagnosed diabetes, and whether screening should be
for other abnormalities of glucose metabolism such as
impaired glucose tolerance (IGT), or the ‘metabolic
syndrome’. Also to update the previous review for the
National Screening Committee (NSC) on screening for
diabetes, including reviewing choice of screening test;
to consider what measures would be taken if IGT and
impaired fasting glucose (IFG) were identified by
screening, and in particular to examine evidence on
treatment to prevent progression to diabetes in these
groups; to examine the cost-effectiveness of screening;
and to consider groups at higher risk at which
screening might be targeted.
Data sources: Electronic databases were searched up
to the end of June 2005.
Review methods: Literature searches and review
concentrated on evidence published since the last
review of screening, both reviews and primary studies.
The review of economic studies included only those
models that covered screening. The new modelling
extended an existing diabetes treatment model by
developing a screening module. The NSC has a set of
criteria, which it applies to new screening proposals.
These criteria cover the condition, the screening test
or tests, treatment and the screening programme.
Screening for diabetes was considered using these
criteria.
Results: Detection of lesser degrees of glucose
intolerance such as IGT is worthwhile, partly because
the risk of cardiovascular disease (CVD) can be
reduced by treatment aimed at reducing cholesterol
level and blood pressure, and partly because some
diabetes can be prevented. Several trials have shown
that both lifestyle measures and pharmacological
treatment can reduce the proportion of people with
IGT who would otherwise develop diabetes. Screening
could be two-stage, starting with the selection of
people at higher risk. The second-stage choice of test
for blood glucose remains a problem, as in the last
review for NSC. The best test is the oral glucose
tolerance test (OGTT), but it is the most expensive, is
inconvenient and has weak reproducibility. Fasting
plasma glucose would miss people with IGT. Glycated
haemoglobin does not require fasting, and may be the
best compromise. It may be that more people would
be tested and diagnosed if the more convenient test
was used, rather than the OGTT. Five economic
studies assessed the costs and short-term outcomes of
using different screening tests. None examined the
long-term impact of different proportions of false
negatives. All considered the costs that would be
incurred and the numbers identified by different tests,
or different cut-offs. Results differed depending on
different assumptions. They did not give a clear guide
as to which test would be the best in any UK screening
programme, but all recognised that the choice of cut-
off would be a compromise between sensitivity and
specificity; there is no perfect test. The modelling
exercise concluded that screening for diabetes appears
to be cost-effective for the 40–70-year age band, more
so for the older age bands, but even in the 40–49-year
age group, the incremental cost-effectiveness ratio for
screening versus no screening is only £10,216 per
quality-adjusted life-year. Screening is more cost-
effective for people in the hypertensive and obese
subgroups and the costs of screening are offset in 
many groups by lower future treatment costs. The
Health Technology Assessment 2007; Vol. 11: No. 17
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cost-effectiveness of screening is determined as much
by, if not more than, assumptions about the degree of
control of blood glucose and future treatment
protocols than by assumptions relating to the screening
programme. The very low cost now of statins is also an
important factor. Although the prevalence of diabetes
increases with age, the relative risk of CVD falls,
reducing the benefits of screening. Screening for
diabetes meets most of the NSC criteria, but probably
fails on three: criterion 12, on optimisation of existing
management of the condition; criterion 13, which
requires that there should be evidence from high-
quality randomised controlled trials (RCTs) showing
that a screening programme would reduce mortality or
morbidity; and criterion 18, that there should be
adequate staffing and facilities for all aspects of the
programme. It is uncertain whether criterion 19, that
all other options, including prevention, should have
been considered, is met. The issue here is whether all
methods of improving lifestyles in order to reduce
obesity and increase exercise have been sufficiently
tried. The rise in overweight and obesity suggests that
health promotion interventions have not so far been
effective.
Conclusions: The case for screening for undiagnosed
diabetes is probably somewhat stronger than it was at
the last review, because of the greater options for
reduction of CVD, principally through the use of
statins, and because of the rising prevalence of obesity
and hence type 2 diabetes. However, there is also a
good case for screening for IGT, with the aim of
preventing some future diabetes and reducing CVD.
Further research is needed into the duration of
undiagnosed diabetes, and whether the rise in blood
glucose levels is linear throughout or whether there
may be a slower initial phase followed by an
acceleration around the time of clinical diagnosis. 
This has implications for the interval after which
screening would be repeated. Further research 
is also needed into the natural history of IGT, 
and in particular what determines progression to
diabetes. An RCT of the type required by NSC
criterion 13 is under way but will not report for about
7 years.
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Background
The National Screening Committee (NSC) is
responsible for providing advice on screening
policy to all parts of the UK. A review of policy on
screening for type 2 diabetes is due shortly, and
this document was commissioned by the NHS
R&D HTA Programme in order to support that
review.
It is known that a proportion of people with type 2
diabetes are undiagnosed. Blood glucose levels
can rise to diabetic levels with little or nothing in
the way of symptoms. Sometimes by the time
people are diagnosed with diabetes, they have
developed complications such as the eye damage
known as retinopathy, due to an effect of diabetes
on small blood vessels (microvascular disease).
However, the main risk to health in undiagnosed
type 2 diabetes is an increased risk of
cardiovascular disease, in particular ischaemic
heart disease, because of damage to the arteries
(macrovascular disease). Early detection of
diabetes would lead to measures to reduce the risk
of heart disease, such as the use of statins to lower
cholesterol, and also reduction of blood glucose
levels by, initially, diet and exercise, supplemented
with hypoglycaemic drugs if necessary. 
Microvascular disease such as retinopathy is
specific to diabetes. However, the macrovascular
disease seen in diabetes is broadly the same
disease as seen in people without diabetes; the
difference in diabetes is the increased risk. An
important issue when considering whether there
should be screening for diabetes is that unlike with
retinopathy, the increase in risk starts below the
level of blood glucose used to define diabetes.
There are groups of people who have higher than
normal blood glucose levels but who are not
diabetic. They are classified according to whether
their blood glucose level is raised when fasting
[impaired fasting glucose (IFG)] or is normal 
when fasting but raised after meals, or after
testing with a 75-g glucose drink. The second
group are said to have impaired glucose 
tolerance (IGT).
The risk of heart disease is increased slightly in
IFG but by about 60% in IGT.
Hence if reduction of heart disease is one of the
aims of screening, then we should consider
screening not just for diabetes, but also for IGT. 
Objectives
The objectives of this review were as follows:
● to reconsider the aims of screening for
undiagnosed diabetes, and whether screening
should be for other abnormalities of glucose
metabolism such as IGT, or the ‘metabolic
syndrome’
● to update the previous review for the NSC on
screening for diabetes, including reviewing
choice of screening test
● to consider what measures would be taken if
IGT and IFG were identified by screening, and
in particular to examine evidence on treatment
to prevent progression to diabetes in these
groups
● to examine the cost-effectiveness of screening,
by a review of previous economic models, and
by new modelling to take account of recent
developments in treatment such as the use of
statins
● as part of the economic analysis, to consider
groups at higher risk at which screening might
be targeted
● to identify research needs.
Methods
The literature searches (carried out up to the end
of June 2005) and review concentrated on
evidence published since the last review of
screening, both reviews and primary studies. The
review of economic studies included only those
models that covered screening. The new
modelling extended an existing diabetes treatment
model by developing a screening module.
The NSC has a set of criteria, which it applies to
new screening proposals. These criteria cover the
condition, the screening test or tests, treatment
and the screening programme. Screening for





As was known before this review, undiagnosed
diabetes can be detected by screening several years
before it would become apparent after the
development of symptoms. Earlier detection and
treatment reduces the development both of
specific diabetes problems such as eye disease and
of cardiovascular disease. Treatment to reduce the
risk of cardiovascular disease has become much
less costly since the arrival of generic statins,
which are now very cheap.
Detection of lesser degrees of glucose intolerance
such as IGT is worthwhile, partly because the risk
of cardiovascular disease can be reduced by
treatment aimed at reducing cholesterol level and
blood pressure, and partly because some diabetes
can be prevented. Several trials have shown that
both lifestyle measures and pharmacological
treatment can reduce the proportion of people
with IGT who would otherwise develop diabetes.
Screening could be two-stage, starting with the
selection of people at higher risk, based on
primary care records of age, weight and other
indicators of metabolic risk such as hypertension.
Screening might be targeted at those above a
certain body mass index threshold, while
recognising that any cut-off would be an arbitrary
line on a continuum of risk. The second-stage
choice of test for blood glucose remains a
problem, as in the last review for NSC. All of
fasting plasma glucose, the oral glucose tolerance
test and glycated haemoglobin would be
acceptable, but none is perfect. The best test is the
oral glucose tolerance test (OGTT), but it is the
most expensive, is inconvenient and has weak
reproducibility. Fasting plasma glucose would miss
people with IGT. Glycated haemoglobin does not
require fasting, and may be the best compromise.
It may be that more people would be tested and
diagnosed if the more convenient test was used,
rather than the OGTT.
A review of previous economic models showed that
screening for diabetes appeared to be cost-
effective. The models differed in some aspects but
reached broadly similar conclusions. The strongest
and most comprehensive came from the USA, and
there were some doubts over their applicability to
the UK.
Five previous modelling studies examined the
costs and benefits of identification and screening
of people with IGT. All predicted that diabetes
prevention measures would provide good value for
money. One was conducted from a UK
perspective. Diet and exercise treatment is the
most cost-effective option. Treatment with
metformin may be less cost-effective than lifestyle
changes, but would be appropriate in some
groups. To some extent, the models may have
underestimated benefit by focusing mainly on
prevention of diabetes, and not taking full account
of the benefits of lifestyle changes on risk factors
for cardiovascular disease. 
Five economic studies assessed the costs and short-
term outcomes of using different screening tests.
None examined the long-term impact of different
proportions of false negatives. All considered the
costs that would be incurred and the numbers
identified by different tests, or different cut-offs.
Results differed depending on different
assumptions. They did not give a clear guide as to
which test would be the best in any UK screening
programme, but all recognised that the choice of
cut-off would be a compromise between sensitivity
and specificity; there is no perfect test.
The modelling exercise concluded that:
● Screening for diabetes appears to be cost-
effective for the 40–70-year age band, more so
for the older age bands than the 40–49-year
band, but even in the 40–49-year age group, the
incremental cost-effectiveness ratio for
screening versus no screening is only £10,216
per quality-adjusted life-year.
● Screening is more cost-effective for people in
the hypertensive and obese subgroups.
● The costs of screening are offset in many groups
by lower future treatment costs.
● The cost-effectiveness of screening is
determined as much by, if not more than,
assumptions about the degree of control of
blood glucose and future treatment protocols
than by assumptions relating to the screening
programme.
● The very low cost now of statins is an important
factor.
Although the prevalence of diabetes increases with
age, the relative risk of cardiovascular disease falls,
reducing the benefits of screening.
Screening for diabetes meets most of the NSC
criteria, but probably fails on three:
● criterion 12, on optimisation of existing
management of the condition
● criterion 13, which requires that there should be
evidence from high-quality randomised
Executive summary
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controlled trials showing that a screening
programme would reduce mortality or
morbidity
● criterion 18, that there should be adequate
staffing and facilities for all aspects of the
programme.
It is uncertain whether criterion 19 – that all other
options, including prevention, should have been
considered – is met. The issue here is whether all
methods of improving lifestyles in order to reduce
obesity and increase exercise have been sufficiently
tried. The rise in overweight and obesity suggests
that health promotion interventions have not so
far been effective.
Conclusions
The case for screening for undiagnosed diabetes is
probably somewhat stronger than it was at the last
review, because of the greater options for
reduction of cardiovascular disease, principally
through the use of statins, and because of the
rising prevalence of overweight and hence type 2
diabetes. However, there is also a good case for
screening for IGT, with the aim of preventing
some future diabetes and reducing cardiovascular
disease.
Research needs
One key uncertainty concerns the duration of
undiagnosed diabetes, and whether the rise in
blood glucose levels is linear throughout or
whether there may be a slower initial phase
followed by an acceleration around the time of
clinical diagnosis. This has implications for the
interval after which screening would be repeated.
Another uncertainty is the natural history of IGT,
and in particular what determines progression to
diabetes. 
Research needs include the above, and
● Research into ways of reducing the prevalence
of insulin resistance. For example, what forms
and amounts of exercise are required to prevent
or reduce insulin resistance?
● How can public health campaigns on lifestyle
measures be made more effective? Most cases of
type 2 diabetes are preventable. What balance
should be struck between the public health,
prevention by lifestyle approach, and the more
medical model of care focused on the individual?
● If screening were to be introduced, should it be
repeated, and, if so, at what interval? More data
on the natural history of IGT may emerge from
current research.
● If a decision were taken in principle that
selective screening should commence, further
modelling as suggested in Chapter 5 could help
with selection.
● A trial in which populations were cluster
randomised by practice to different screening
tests, with economic evaluation built in, might be
useful for showing which test was best in terms of
both screening parameters and practicality.
A randomised controlled trial of the type required
by NSC criterion 13 is under way but will not
report for about 7 years.
The purpose of this review is to underpinforthcoming discussions at the UK National
Screening Committee (NSC) on a review of policy
on screening for type 2 diabetes mellitus (T2DM).
The main aim was to look at evidence which had
emerged since the last review, and so the first aim
was to examine recent reviews and any new
primary evidence not included in these reviews.
However, as discussed in more detail below,
screening for diabetes could, depending on the
cut-off chosen for tests being positive, detect more
people with lesser degrees of glucose intolerance,
such as impaired glucose tolerance (IGT), than
with diabetes. The main aim of screening is to
reduce the burden of disease from cardiovascular
disease (CVD), to which people with diabetes are
more susceptible. Those with IGT are also at
increased risk, and although their relative risk
(RR) is less than those with diabetes, there are far
more of them than there are people with
undiagnosed diabetes, and so there will be more
cardiovascular events in those with IGT than in
those with diabetes. They are also at risk of
progression to diabetes.
Screening is therefore addressed from a somewhat
wider perspective than in some previous reviews. 
A section has also been included that covers recent
evidence on prevention of diabetes in those with
what has been called ‘pre-diabetes’, although since
most will not become diabetic, the term is not
entirely satisfactory. 
A key issue (details later) is that there is a
continuum of CVD risk across all levels of blood
glucose (BG). Hence there is no simple 
threshold at which people can be split into at risk
and not at risk. In such circumstances, the final
decision on whom to screen and treat (or at what
level of risk to do so) can be illuminated by
economic analysis, since that can provide data
indicating when interventions become cost-
effective.
Reviews of previous economic models of screening
have been included. Considerable new modelling
has also been carried out.
Finally, the extent to which screening for diabetes
and IGT meets the NSC criteria is also considered.
Screening for type 2 diabetes –
the issues
The NSC reviewed screening for T2DM a few
years ago, and the current policy statement is on
the NSC website (www.nsc.nhs.uk). The case for
screening was assessed, as usual, against clearly
defined criteria, looking in turn at;
● the condition
● the screening test
● the treatment
● the screening programme.
This review therefore does not start from a zero
base, but from the present NSC policy,
underpinned by the work of Wareham and Griffin1
for the last policy review.
An assessment of the case for screening, judged
against the criteria, and based on the previous
review, is available on the NSC website. Many of
the criteria were met, but there were concerns or
doubts over:
● whether all the cost-effective primary
prevention interventions had been applied
(criterion 3)
● the screening test, and in particular which
threshold of BG should be used, bearing in
mind the need to focus more on large vessel
disease such as ischaemic heart disease (IHD)
(criterion 6)
● whether screening and treatment should be
specifically aimed at diabetes, or a wider 
range of factors predisposing to IHD risk
(criterion 11)
● whether treatment of existing diabetes was
optimised (criterion 12)
● the lack of randomised controlled trials (RCTs)
of screening (criterion 13)
● the balance between benefits and harms of
widespread screening (criterion 15)
● the ability of the NHS to cope with a large
number of people with newly diagnosed
diabetes (criterion 18).
Note that the NSC criteria are updated from time
to time, for example to cover new scenarios such
as genetic testing, and the numbering used above
Health Technology Assessment 2007; Vol. 11: No. 17
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Chapter 1
Background
reflects the current set, which are different from
those used at the time of the last review. The
current criteria are listed for convenience in
Appendix 2.
In this review, the case for screening will be
assessed against the criteria, but focusing mainly
on those where there were concerns last time, or
on those where the evidence base may have
changed. We do not address type 1 diabetes,
where screening is not required, or gestational
diabetes, which was the subject of a previous
review.2
The NSC criteria now fall into groups as follows:
● the condition (criteria 1–4)
● the test (criteria 5–9)
● the treatment (criteria 10–12)
● the screening programme (criteria 13–22).
Some of the criteria are not applicable to this
review. Criteria 4, 9 and 22 deal with genetic
screening. Criteria 17, 18 and 20 are concerned
with the running of screening programmes and
need not be addressed until a decision in principle
to provide it is taken. 
The criteria that seem most important to the
current review are discussed below. The others that
are relevant, and the evidence which relates to
them, will be dealt with in Chapter 6. 
The condition
NSC criterion 1 – the condition should
be an important health problem
The importance of T2DM has not diminished.
Indeed, the trend in the prevalence is upwards,
with a rise in all-age prevalence due to
demographic change, and almost certainly a rise
in age-specific prevalences due to increasing levels
of obesity. It has been estimated that there will be
an increase in prevalence of 16% for England
between 2001 and 2010, based on ONS census
projections and current obesity trends.3
However, it may be worth reflecting on what we
would be trying to achieve by screening for T2DM.
People with T2DM are less prone than those with
type 1 diabetes to the acute metabolic
complications such as diabetic ketoacidosis, which
still causes deaths in the young. However, if good
glycaemic control is not achieved, they are at risk
of the specific diabetic microvascular
complications such as retinopathy and
nephropathy. An increasing proportion (in some
centres over half) of diabetic people on renal
dialysis have T2DM.4
However, the biggest problem in T2DM is large
vessel disease, and most people with T2DM die of
coronary heart disease. Diabetes is also important
in peripheral vascular disease (PVD) and stroke.5,6
In most studies looking at the relationship
between BG and mortality in T2DM, the higher
the glucose level, the higher is the mortality, but
the rise per unit of glucose [e.g. per mmol/l of
fasting plasma glucose (FPG) or per 1% of
glycosylated haemoglobin (HbA1c)] is modest.
7
The importance of large vessel disease can be seen
in the end-points reported in the UK Prospective
Diabetes Study (UKPDS). Table 1 shows the
numbers for most of the end-points in the
conventionally treated group (UKPDS 33).8
Hence the majority of adverse events were due to
large vessel disease. Most of the microvascular
end-points were made up of retinal
photocoagulation for retinopathy, the risk of which
is probably less in the group who would be
detected by screening. It should be noted that
amongst the UKPDS patients, there were some
who might now be classified as latent autoimmune
diabetes in adults (LADA), rather than true
T2DM.
However, if we take only those who were in the
overweight group who were randomised to
Background
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Amputations and death from PVD 21
Microvascular
Death from renal disease 2
Renal failure 9
Blindness in one eye 38
Vitreous haemorrhage 10




metformin or conventional treatment if their FPG
at 3 months was higher than 6.0 mmol/l, and who
may be more similar to those who would be found
by screening, then the picture is similar.
Overweight was defined as more than 120% of
ideal body weight. Table 2 shows the numbers of
end-points in the control group (UKPDS 34).9
Again, the end-points are dominated by large
vessel disease.
Hence it could be argued (and has been in the
past – see reviews by Goyder and Irwig10 and
Jarrett11) that the most important reason for
screening for T2DM is in order to be able to
intervene earlier with a view to reducing the risk
of macrovascular disease, and mainly IHD. 
What is diabetes?
A digression into the underlying rationale for the
definition of diabetes is now necessary. 
The only constant feature of diabetes is a raised
BG level. There may or not be any of the classical
symptoms such as the passing of larger volumes of
urine and thirst. Many people with T2DM have no
symptoms when diagnosed. Conversely, many
people without diabetes report similar symptoms,
and so the symptoms, at least in milder forms, are
not specific to diabetes.12,13
However, the problem comes when defining what
is meant by ‘raised’.
Successive reports by working parties for the
WHO14,15 and the American Diabetes Association
(ADA)16,17 have examined the problems of
diagnostic criteria for diabetes. The earlier history
has been reviewed by Keen,18 who noted that the
classifications in the late 1970s, from the National
Diabetes Data Group (NDDG) in the USA,19 and
the second report of the WHO Expert
Committee20 were based on a hybrid approach,
being primarily based on clinical description
according to treatment, but with some elements
based on assumed aetiology. The classification
divided diabetes mainly into insulin-dependent
and non-insulin-dependent. However, these
reports did at least produce diagnostic criteria 
in terms of a threshold for true diabetes (a 
fasting blood glucose level of 7.8 mmol/l or over,
and a 2-hour post-load level of 11.1 mmol/l or
over), hence removing the uncertainty over 
what should be classed as diabetes. The term
‘impaired glucose tolerance’ (IGT) was used to
describe the situation where BG was raised 
above normal but was below the threshold for
diabetes. This replaced terms such as ‘borderline’
diabetes. However, the lower limit for IGT was left
somewhat vague.18 The normal FPG level is up to
5.6 mmol/l.
The key feature of the classifications was that the
diagnosis of diabetes was based on the level at
which the risk of retinopathy started. At the risk
of some over-simplification, people with glucose
levels below the threshold did not get retinopathy;
those above were at risk of retinopathy, with the
risk increasing as glucose levels rose further. This
was based on three studies, described in the report
of the ADA’s expert committee.17
Despite the rationalisation which the WHO and
ADA classifications brought to a previously
somewhat confused situation, some dissatisfactions
remained. One was the ‘hybrid’ nature of the
classification, and the confusion that arose because
many people with non-insulin-dependent diabetes
were being treated with insulin in order to achieve
better control. A second was that the classification
was too dependent on the oral glucose tolerance
test (OGTT), which is an inconvenient and
unphysiological test (involving drinking 75 g of
glucose in water over a short period) with poor
reproducibility. Another was that the two
thresholds – 7.8 mmol/l for fasting and 11.1 mol/l
for 2 hours after a glucose load – had imperfect
correlation, in that the fasting level implied a
greater degree of hyperglycaemia than the 2-hour
level.
The ADA and WHO14 groups reviewed their
classifications. Their conclusions were fairly
consistent (there was cross-representation between
the expert groups), and the new classifications
made a number of changes. First, diabetes was
subdivided clearly, according to the need for
insulin, into:
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TABLE 2 End-points in the overweight UKPDS group – controls
only (N = 411)
End-point Number
Macrovascular










● Type 1 diabetes, where insulin treatment was
required for survival, because the pancreatic
islets cells have been destroyed by the disease
process; this covers the insulin-dependent
group from the previous definitions.
● T2DM, where pancreatic insulin production
continues, but may be insufficient for control of
blood sugar levels; most of this group will be
treated with diet alone, or with tablets, but some
will need insulin for control of BG. In the
UKPDS patients, the trend was for glucose to
rise over time.21
Second, the ADA threshold for the FPG level at
which diabetes was diagnosed was lowered to
7.0 mmol/l, to be more compatible with the 2-hour
level. It was anticipated that fasting glucose levels
would be used as the main method of diagnosis,
being more convenient and more reproducible.
The ADA group envisaged that FPG would be the
main method of diagnosis, with OGTTs being
usually unnecessary.
The WHO group recommended the same fasting
and 2-hour cut-off levels but, for epidemiological
and screening purposes, preferred the 2-hour
value.
The new ADA classification gives four groups;
● Those with both fasting and post-load levels
above the thresholds – the diabetics, of whom
those with FPGs between 7.0 and 7.8 mmol/l
could be called the ‘new’ diabetics.
● Those with fasting above the upper limit of
normal (6.1 mmol/l) but below 7.0 mmol/l; this
group is said to have impaired fasting glucose
(IFG).
● Those with a normal fasting glucose under
6.1 mmol/l, but with the post-load level above
7.8 but under 11.1 mmol/l; this group is
described as having IGT. 
● Those with fasting levels under 6.1 and post-
load under 7.8 mmol/l, who are classed as
normal.
A collaborative project by the European Diabetes
Epidemiology Group, the DECODE study,22
pooled data from 13 cohort studies, in order to
examine the risks of mortality in the various
groups, relative to those with normal (defined as
under 6.1 mmol/l) glucose levels. Hazard ratios
were as given in Table 3.
Taking IFG and IGT statuses in combination, a
somewhat simplified version of some of their
findings is as given in Table 4.
Hence IFG alone, without IGT, is associated with a
slight increase in mortality [although the
confidence intervals (CIs) overlap with no
increase), but IGT carries more risk. Similar
findings were reported from a meta-analysis by
Coutinho and colleagues23 of 20 studies
examining cardiovascular mortality (19 studies) or
morbidity (four studies). A fasting glucose level of
6.1 mmol/l carried 1.33 times the risk of the
reference one of 4.2 mmol/l; a 2-hour glucose level
of 7.8 mmol/l carried an RR of 1.58 compared
with a 2-hour level of 4.2 mmol/l.
In both IFG and IGT, there is insulin resistance,
but with different distributions. Pima Indians with
IFG have higher fasting insulin levels than those
with IGT, but the latter have higher post-prandial
insulin levels.24 There are also differences in other
cardiovascular risk factors, with higher triglyceride
and fibrinogen levels in IGT than IFG, reflecting
the higher insulin resistance in IGT than IFG.25
IGT is common – it affects 17% of Britons aged
40–65 years.26 This has implications for choice of
a screening test – if FPG were to be used, a group
of people whose FPG is normal but who have IGT
would be missed. In the Rancho Bernardo study,27
the RR of a cardiovascular event in women aged
50–89 years with normal FPG but IGT was 2.9.
Similarly, a Paris study found that the heart
disease mortality rate in men with normal fasting
glucose but IGT was double that of those with
Background
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‘New diabetes’ 1.81 1.79a
a Those with fasting glucose between 7.0 and 7.8 mmol/l.
TABLE 4 Relative risks of mortality
IGT status
IFG status Normal 2-hour IGT
level
Normal fasting 1.0 1.56 (1.33 to 1.83)
level
IFG 1.18 (0.99 to 1.42)a
a 95% confidence intervals.
normal glucose tolerance.28 However, an earlier
paper from Paris29 noted that fasting insulin levels
were a better predictor of future heart disease than
glucose levels, presumably reflecting the varying
degrees of insulin resistance. 
The Helsinki Police Study found the same.30 In
the 22-year follow-up, 10% of those in the lowest
quintile of baseline insulin had an IHD event
compared with 25% of those in the highest insulin
quintile. Also, in the San Antonio Heart Study,
Haffner found that the baseline insulin level
predicted not only future T2DM, but also
hypertension, low high-density lipoprotein (HDL)
and high triglycerides.31
The DECODE group32 carried out a meta-analysis
of 11 studies and compared the cardiovascular
mortality in the highest and lowest quartiles of
plasma insulin levels. After adjustment for other
risk factors, the risks were 1.54 in men and 2.66 in
women in the highest quartiles.
In Japan, Tominaga and colleagues33 found that
IGT was a risk factor for CVD but that IFG was
not. Numbers of deaths were fairly low and CIs
wide, but by the 7-year follow-up, the cumulative
survival in those with IGT was significantly lower
then that of those with normal glucose levels,
whereas the survival in those with IFG was not
different from normal.
Unlike with retinopathy, there is no sudden
inflection in the risk curve according to blood
glucose levels, but rather a continuum of risk.
Indeed, even within what is regarded as being the
entirely normal range, higher BG levels correlate
with higher IHD rates. In the EPIC study in
Norfolk,34 the relationship between HbA1c and
cardiovascular risk started well within the non-
diabetic range (Table 5).
A similar finding was reported by Piche and
colleagues in Quebec,35 although using 2-hour
plasma glucose. They compared groups with low
normal 2-hour plasma glucose (PG)
(<5.6 mmol/l), ‘high normal’ (5.6–7.7 mmol/l) and
with IGT. The high normal group were more
obese (as measured by waist, visceral fat by
computed tomography (CT) scan, and
subcutaneous fat) than those with low normal PG.
Their cholesterol:HDL ratio was also higher.
The same applies to PVD. Muntner and
colleagues36 reported data from the 1999–2002
NHANES survey. The figures in Table 6 are after
multivariate adjustment. PVD was defined as an
ankle:brachial blood pressure ratio under 0.9.
However, the CIs were wide and only the last
figures had a 95% CI which did not overlap 
with 1.0.
There have been suggestions that the threshold
for IFG should be reduced to 5.6 mmol/l.37 This
would greatly increase the prevalence of IFG. For
example, in the DESIR study of French men and
women aged 30–64 years, the prevalence of IFG
would rise from the 13% in men and 4% in women
seen using the old IFG threshold of 6.1 mmol/l to
40% in men and 16% in women.38 Balkau and
colleagues38 noted that the risk of progression to
diabetes is much less in old IFG than in new
(Table 7). However the progression to IHD may
show a different gradient.
It may be that IGT and IFG reflect different
aetiologies. Piche and colleagues39 followed a
cohort of men who initially had normal glucose
tolerance for 6 years. Some developed IFG and
some IGT; most remained normal. Those who
developed IFG tended to be leaner than those
who developed IGT [baseline body mass index
(BMI) 26 versus 28], and on CT had much less
visceral fat. Those who developed IFG tended to
have lower baseline fasting insulin, whereas those
who developed IGT had higher levels. Hence IFG
may reflect a production problem with insulin
whereas IGT reflects insulin resistance. Numbers
in this study were small: eight with IFG and 12
with IGT.
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TABLE 5 EPIC study – relative risks by bands of glycated HbA1c






6.5–6.9 % 3.03 2.37
>7% (newly diagnosed diabetes) 5.01 7.96
Prior diabetes 3.32 3.36
TABLE 6 NHANES – relative risks of PVD by bands of HbA1c






The metabolic syndrome has been described as a
cluster of cardiovascular risk factors associated
with insulin resistance.40 An operational definition
was devised by the National Cholesterol Education
Program Adult Treatment Panel (NCEP-ATP),41
based on the presence of three or more of the
following:
● Abdominal obesity – waist circumference over
40 inches (~100 cm) in men, and 35 inches
(~90 cm) in women
● Triglycerides over 150 mg/dl (1.68 mmol/l)
● HDL cholesterol <40 mg/dl (1.03 mmol/l) in
men, <50 µg/dl (1.29 mmol/l) in women
● Blood pressure 130 or more systolic, 85 or more
diastolic
● Fasting glucose over 110 mg/dl (6.1 mmol/l).
Hypertension and diabetes are common
components, and about 40% of those with the
metabolic syndrome have diabetes.40 Others will
have lesser degrees of glucose intolerance.
However, some will have normal glucose tolerance.
The question therefore arises as to whether one
should be screening for the metabolic syndrome
because of the increased risk of CVD, rather than
just for abnormalities of glucose metabolism.
Another issue concerns the choice of treatment for
hypertension. People with hypertension have long
been known to be at increased risk of diabetes,
and in several studies it was noted that substantial
proportions of newly diagnosed diabetic patients
were on anti-hypertensive drugs (see Jarrett and
Fitzgerald42 for a review). This raised the
possibility that some of the older drugs for
hypertension such as thiazides might be causing
some diabetes.42
A meta-analysis of recent trials has cast new light
on this problem. Scheen43 pooled results from
eight RCTs of angiotensin-converting enzyme
inhibitors (ACEIs) and reported that ACEIs and
the more specific angiotensin receptor blockers
(ARBs) appear to reduce the incidence of diabetes,
albeit only modestly, from 9.6% in those not
treated with an ACEI or ARB to 7.4% in those who
were. This finding applied whether the controls
were given placebo or older drugs such as
thiazides. Those on thiazides or beta-blockers had
no greater incidence of diabetes than those on
placebo.
In a more recent meta-analysis, Gillespie and
colleagues44 included 14 trials of ACEIs or ARBs
and found that these drugs reduced the incidence
of T2DM by 22% [odds ratio (OR) 0.78; 95% CI
0.73 to 0.83].
Hence screening for diabetes might provide benefit
to those with hypertension who are found to have
IGT or IFG; their hypertensive treatment could be
changed to an ACEI or ARB, which should reduce
the risk of progression to diabetes. 
The WHO definition of the metabolic syndrome is
couched more in terms of insulin resistance:
● T2DM, IFG or IGT, or normal glucose level but
high insulin level plus two or more of
● elevated blood pressure – systolic 160 or over,
diastolic 90 or over
● elevated triglycerides – 1.7 mmol/l or over
● low HDL cholesterol – <0.9 mmol/l in men and
<1.0 mmol/l in women
● obesity – BMI >30, or central obesity with
waist:hip ratio >0 .90 in men and, >0.85 in
women 
● microalbuminuria.
Scuteri and colleagues45 from the Cardiovascular
Health Study in Americans over 65 years old
followed a cohort of 2175 subjects for just over
Background
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TABLE 7 DESIR study – incidence of diabetes according to glycaemic status at baseline.
Incidence of diabetes per 1000 person-years
IFG status Glucose level (mmol/l) 30–44 years 45–54 years 55–64 years
Men
Normal <5.6 2.3 1.7 1.1
New IFG 5.6–6.0 4.9 8.5 11.5
Old IFG 6.1–6.9 24.7 38.9 63.9
Women
Normal <5.6 0.4 1.4 0.7
New IFG 5.6–6.0 5.5 7.0 5.9
Old IFG 6.1–6.9 35.7 52.3 66.7
4 years. At baseline, 28% had the metabolic
syndrome by NCEP ATP III criteria and 21% had
it by WHO criteria; 81% of those considered to
have metabolic syndrome by one set of criteria also
had it by the other. Using the metabolic syndrome
alone gave RRs for CVD of 1.9 and 1.89 for NCEP
and WHO, respectively. Taking into account age,
sex, family history of myocardial infarction (MI),
smoking and low-density lipoprotein (LDL)
cholesterol, increased the RR with the NCEP
criteria to 2.04 (95% CI 1.7 to 2.5) but reduced the
RR with the WHO set to 1.63 (95% CI 1.3 to 2.0). 
The increased risk of vascular disease in the
metabolic syndrome has been reviewed recently by
Ford.46 The increase in risk depends on which
groups are included. If those with diabetes are
excluded, the RR is less (1.58) than if those with
diabetes are included (2.02). Overall, the RR of
cardiovascular risk is about 1.7–1.9.
Data from the National Health and Nutrition
Examination Survey (NHANES) (unpublished but
quoted by Haffner31) showed that in individuals
aged over 20 years, the prevalences of IHD were:
● without metabolic syndrome – 8.5%
● with metabolic syndrome by WHO criteria – 12.5%
● metabolic syndrome by ATP III (NCEP) criteria
– 16.6%.
In the San Antonio Heart Study, Stern and
colleagues47 found that the metabolic syndrome as
defined by NCEP was not as good a predictor of
future diabetes as the Diabetes Predicting Model
(which includes family history) or as good a
predictor of heart disease as the Framingham Risk
Score (which includes age, sex, smoking and
cholesterol), but information on those factors
could easily be collected at the same time. 
The prevalence of the metabolic syndrome has
been studied in middle-aged (40–69 years) people
in different ethnic groups in London (Brent and
Southall) using both definitions. Tillin and
colleagues48 found the highest prevalence amongst
South Asians (46% in men, 31% in women; WHO
definition) and the lowest in European women
(9%). However, the rates were not standardised for
obesity. Central obesity was much commoner in
the Asian groups. Hence their higher prevalence
may reflect obesity not ethnicity (although the
tendency towards central obesity could be due to
either genetic or lifestyle factors).
But would including screening for the metabolic
syndrome go far enough? Reaven49 pointed out
that many individuals who are both insulin-
resistant and dyslipidaemic do not meet the NCEP
criteria, but are still at increased risk of vascular
disease. The answer may lie in economics – at
what level of risk does screening and treatment
cease to be cost-effective?
The value of having a condition called the
metabolic syndrome, rather than just dealing with
the individual components, has been called into
question by a joint statement from the ADA and
the European Association for the Study of 
Diabetes (EASD), published simultaneously in
Diabetologia and Diabetes Care. The statement
concludes that:
Until much-needed research is completed, clinicians
should evaluate and treat all CVD risk factors without
regard to whether a patient meets the criteria for
diagnosis of the ‘metabolic syndrome’.
Kahn and colleagues (2005).50
The converse of the metabolic syndrome has also
been studied. Perry and colleagues51 from Cork in
Ireland identified factors, from previous studies,
which protected against diabetes: BMI <25;
waist:hip ratio <0.85 for women and 0.90 for men;
never smoking; medium- to high-level physical
activity; light drinking (3–5 to 7 units per week);
and a prudent diet. In their sample of middle-
aged Irish men and women, drawn from general
practice populations, 7.5% had none of these
protective factors. Insulin resistance was calculated
using the homeostasis model analysis (HOMA)
score (based on fasting levels of both insulin and
glucose). Taking the 7.5% with no protective
factors as the reference group, multivariate
analysis gave ORs for insulin resistance of 0.59
with one protective factor, 0.48 with two, 0.14 with
three and 0.04 with four or more. About 13% had
four or more protective factors.
Hence there is little doubt that lifestyle measures
could prevent most cases of T2DM. Weight loss
would also benefit those who already have
diabetes, or hypertension, and improvements can
follow even modest weight loss. Goldstein52
reviewed studies in which large and small amounts
of weight were lost, and concluded that even
modest weight reductions, of 10% or less, resulted
in significant benefit in a substantial subset. Even
loss of a few kilograms can provide benefit.
In addition to the total calorie intake, the quality
of the diet can affect the incidence of diabetes. In
the EPIC-Potsdam study, Heidemann and
colleagues53 found that a healthy pattern diet
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(high intake of fresh fruit and low intake of high-
calorie soft drinks, beer, red meat, poultry,
processed meat) reduced the incidence of diabetes.
ORs from the poorest to the best diet ranged from
1.0 to 0.26. Adjusting for BMI reduced the
difference only slightly, implying that those who
do not succeed in dieting to lose weight could still
reduce their risk of diabetes by changing the
content of the diet.
Decision point
Hence if the aim of screening is to reduce heart
disease, it could be argued that one should look
not only at diabetes, but at all degrees of glucose
intolerance, and perhaps wider still for the
metabolic syndrome.
This has implications for the test to be used, for
the choice of definitive test and for the treatments
to be given to screen-positives. The aims of
treatment might be:
1. For those with definite diabetes, reduction of
the risk of retinopathy and nephropathy, by
reduction of PG to normal, initially trying diet
and exercise, but using drug therapy when
indicated.
2. For those with PG levels in the IFG and IGT
ranges, prevention of progression to diabetes,
by diet and exercise, or by drug therapy if
indicated.
3. For all of the above, measures to reduce
cardiovascular risk, by measures other than the
glucose control measures already mentioned,
such as qualitative improvements in diet;
aspirin; cholesterol-lowering measures such as
statins; blood pressure control; and anti-obesity
measures. 
Decision analysis 1.
Should the aim of screening be to identify people with
diabetes, or should there be a broader aim to reduce heart
disease in a wider group, or both? Diabetes would then
be regarded as the higher glycaemic end of a spectrum of
glucose intolerance that is in turn part of a wider
metabolic syndrome.
NSC criterion 2 – the epidemiology and
natural history of the condition,
including development from latent to
declared disease, should be adequately
understood and there should be a
detectable risk factor, disease marker,
latent period or early symptomatic stage
If the condition is diabetes, then this criterion is
partially met, although the terminology is not
exactly right. Undiagnosed diabetes is not ‘latent’
in the sense that it can be causing damage (for
example, people with newly diagnosed diabetes
may already have retinopathy). It is latent only in
the sense of being asymptomatic (although some
may have mild symptoms such as polyuria without
realising the significance, or indeed that it is
abnormal). The ‘disease marker’ is BG, measured
in various ways.
The main reason for using the word ‘partially’ is
that there is uncertainty about the duration of
diabetes before diagnosis. 
The duration of undiagnosed diabetes
The most quoted estimate of the duration of
diabetes before diagnosis is from Harris and
colleagues,54 who used data from two population-
based groups, one in the USA (Wisconsin) 
and the other in Australia, supplemented with
data from published studies from other areas or
studies, including UKPDS and Edinburgh. In
brief, they plotted prevalence of retinopathy
against known duration, and then extrapolated
back to estimate when diabetes started. The
prevalences at diagnosis were different – 21% in
Wisconsin and 10% in Australia. Possible
explanations for the difference might be that the
Wisconsin group was very thoroughly studied by
Klein and colleagues55 in the series of studies 
from the Wisconsin epidemiology of retinopathy
study, and so they may have detected more.
Another contributor may have been that some
(7.5%) of the Australian group were not diabetic
by NDDG/WHO criteria of the time – some
probably had IGT.
In the UKPDS, the prevalence of retinopathy at
diagnosis (or, strictly, referral – but GPs were 
asked to refer newly diagnosed patients) was 
24%, close to that in Wisconsin (even though,
strictly, not all the UKPDS patients had diabetes
either – the entry criterion was an FPG of
6.0 mmol/l). It might be worth noting that the
UKPDS group was not population based, but
relied on referral to hospital clinics, and many had
hypertension, which would increase the risk of
retinopathy.
Extrapolating back gave estimates of onset of
diabetes of 6.5 years prior to diagnosis in
Wisconsin and 4.2 years in Australia. The 
authors concluded, cautiously, that onset 
occurred “at least 4–7 years” before diagnosis.
However, as they noted in the discussion, it takes
time for metabolic changes to give rise to




Ideally, studies of onset of retinopathy would start
from the actual onset of diabetes. This requires
prospective studies, and there are not many of
those. Jarrett56 followed up a cohort of men with
IGT, with repeated OGTTs, so that the date of
development of diabetes in those who progressed
could be more accurately determined. Most of the
men (180 of 240) did not develop diabetes over
10 years. Of the 60 who did, none had detectable
retinopathy in the first 5 years after onset. That
suggests that onset of diabetes could be 9–12 years
before clinical diagnosis.
Thompson and colleagues57 used data from Egypt,
and a similar backwards extrapolation method to
that of Harris and colleagues, but estimated that
the onset of retinopathy was only 2.6 years before
clinical diagnosis. The 95% CI was wide at 0.3 to
8.4 years; they had data on 218 patients.
Prevalence of retinopathy at diagnosis was 12%.
They estimated that onset preceded diagnosis by
7.6 years, using the data on duration of diabetes
to retinopathy from Jarrett’s study.
One method used for estimating date of onset
uses the data from UKPDS on decline of beta cell
function. UKPDS paper 1621 showed a steady rise
in HbA1c, irrespective of treatment, of about
0.22% per year. The mean HbA1c level in those
symptomatic at diagnosis was 9.6. The upper limit
of normal HbA1c in UKPDS was 6.1. Hence, if it is
assumed that the decline in beta cell function was
linear throughout, then one obtains an estimate of
16 years from first elevation above normal (note:
not the same as diabetes – there would be an
intervening period of IFG and IGT). 
Another UKPDS paper (UKPDS 6158) examined
initial FPGs. The patients in the lowest tertile of
initial FPG were more likely to be asymptomatic
and more likely to be found by screening (such as
at medical examinations for insurance or
employment purposes). However, their
progression of glycaemia was similar over time to
that of patients with higher initial levels, so it
appears that they may simply have been at an
earlier stage in the disease. A shift forward of
5 years would overlay the lowest tertile on the
highest, implying that there may be a gap of
5 years between their initial HbA1c of 6.7% and
the 10% in the highest, more symptomatic group.
That would suggest a rise per annum in HbA1c
of 0.6%
Another possible method is to use GP records
preceding the date of diagnosis. Gulliford and
colleagues59 used this approach to examine
contacts with and prescriptions from primary care
in the UK in the 5 years before diabetes was
diagnosed. However, they included only patients
who at some stage were treated with oral
hypoglycaemic agents (OHAs); those on diet alone
were excluded. They then compared the OHA
group with controls who never had any diabetes
medication. The diabetic group had higher
consultation rates 5 years before diagnosis and
more hypertension, hyperlipidaemia, obesity and
IHD. However, they were not (as far as is 
known from the GP data) screened for diabetes, 
so some may have had undiagnosed diabetes or
IGT. Records showed that 0.6% had IGT and 5%
had ‘hyperglycaemia’ recorded. The authors
concluded that none of the non-glycaemic factors
was sufficiently predictive of future diabetes –
which for our purposes means that these factors
cannot be used for retrospective estimates of
onset.
There are two problems with some of the above
estimations.
First, the means for HbA1c for such groups will
conceal variations within them. In particular, those
left on diet alone include both those who lost
weight and took exercise and those who did not.
UKPDS does not separate these subgroups. A
long-term model of beta cell decline has been
devised by Bagust and Beale60 using data from 
the Belfast diet study, in which patients who
managed to stay on diet alone for 6 years or more
had comparatively little decline in beta cell
function.
Second, it is not known if the decline in beta cell
function is linear throughout the course of the
condition. Is the decline in the ‘pre-diabetes’ and
undiagnosed diabetes stages at the same rate?
Bagust and Beale60 hypothesise that there are two
stages – an initial slow decline over perhaps
10 years or more, and then a rapid decline over
the next 10 years.
The rate of decline in the period before 
diagnosis (and hence the rate of increase of 
HbA1c and vascular damage) could have
considerable effects on the cost-effectiveness of
screening. This will be examined in the economic
model.
It may be worth considering the difference
between the duration of undiagnosed disease in
the natural history situation and the undiagnosed
duration in practice. The duration of undiagnosed
disease, that is, the interval between onset of the
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metabolic problem and the appearance of
symptoms, depends on the natural history and is
presumably fairly constant (unless other
contributory factors have changed over time, such
as levels of exercise). However, the undiagnosed
duration may depend on clinical or patient
behaviour, which may have changed over time
because of increasing awareness of risk factors,
public concern about undiagnosed diabetes
(prompted by campaigns such as the Diabetes UK
‘missing million’), and easy accessibility of glucose
testing. Hence the proportion undiagnosed now
may be less than in the past, although absolute
numbers may be greater, due to increasing
prevalence.
If the condition includes impaired glucose
tolerance, there is again reasonable understanding
of the condition – it is known that it can progress
to diabetes, and is associated with an increased
risk of CVD. It is known that many people go back
from IGT to normality. In the 10-year follow-up to
the Bedford study, far more men with IGT
returned to normal (128) than progressed to
diabetes (36).61 And as discussed above, it is not
known if the decline in those who do progress is
linear. 
However, we know that a sizeable proportion will
develop diabetes. Edelstein and colleagues62
analysed six studies, with 2389 individuals with
IGT, followed up for between 2 and 27 years, and
noted that 23–62% progressed to diabetes over
time, at a rate of 4–9% per year. Admittedly, the
higher progression rates were seen in ethnic
groups at particularly high risk, such as the Pimas
and Naurans. Progression was increased if BMI
was higher, but was not affected by age or family
history of diabetes.
The test
NSC criterion 5. There should be a simple, safe,
precise and validated screening test
NSC criterion 6. The distribution of test values in
the target population should be known and a
suitable cut-off level defined and agreed
NSC criterion 7. The test should be acceptable to
the population
NSC criterion 8. There should be an agreed
policy on the further diagnostic investigation of
individuals with positive test results and the
choices available to those individuals
Screening tests are addressed in Chapter 3. The
position as regards these criteria depends partly
on what we are screening for – T2DM, IGT and
IFG, or the metabolic syndrome.
Treatment
NSC criteria 10–12
Treatments for diabetes itself are soundly 
evidence based, and will not be addressed in this
review. However, Appendix 3 examines the
management of lesser degrees of glucose
intolerance such as IGT, since any screening
programme would find more people with that
than with diabetes.
Trends in overweight and obesity
The prevalence of T2DM is closely linked with
that of overweight. Data from the Health Survey
for England63 show that the proportion of the
population which is overweight or obese (BMI 30




TABLE 8 Health Survey for England: proportions of people who are overweight or obese trends over time
Men (%) Women (%)
BMI 25–30 BMI 30+ BMI 25–30 BMI 30+
1993 44.4 13.2 32.2 16.4
1994 44.3 13.8 31.4 17.3
1995 44 15.3 32.9 17.5
1996 44.6 16.4 33.6 18.4
1997 45.2 17.0 32.8 19.7
1998 45.5 17.3 32.1 21.2
1999 43.9 18.7 32.8 21.1
2000 44.5 21.0 33.8 21.4
2001 46.6 21.0 32.9 23.5
2002 43.4 22.1 33.7 22.8
The risks of being overweight are well known. Lew
and Garfinkel64 reported mortality data from a
very large study from the American Cancer Society
with over 750,000 men and women, classified in
terms of whether their weights were average,
above or below. The reference group comprised
those with weights 90–110% of average. Table 9
shows the mortality ratios for IHD and diabetes.
However, these figures will reflect a mixture of
overweight people – some just overweight, others
with diabetes or hypertension. It may be more the
diseases associated with overweight that increase
the risk. Obesity alone is less risky than obesity
with a co-morbidity, such as diabetes. Oldridge
and colleagues65 looked in the 1992 Health and
Retirement Study in the USA (it is not clear from
the results paper whether the study sampled
people only in Michigan) at the effects of obesity,
diabetes and hypertension in middle age
(51–70 years). Compared with people with none of
the three, those with obesity had a 24% increased
risk of hospital admission, whereas those with
diabetes and obesity had double the risk. Those
with all three had three times the risk. Some of the
obese probably had undiagnosed diabetes. The
diagnosis in the study was made if respondents
said that a doctor had previously told them that
they had diabetes.
Hence the main risk of obesity may be from the
increased risk of diabetes, rather than obesity
itself.
The prevalence of diabetes –
diagnosed and undiagnosed
The York and Humber Public Health Observatory
(YHPHO) (www.york.ac.uk/yhpho) has developed a
prevalence model for diabetes. The current
estimated prevalence of diabetes (diagnosed and
undiagnosed) is 4.37% of the population, 0.33%
under 30 years, 3.3% from 30 to 59 years and
13.8% in those over 60 years. Prevalence also
varies by ethnicity: whites 4.2%, blacks 5.6% and
Asians 6.6% (not corrected for obesity). The
YHPHO estimates that there are currently about
2.14 million people with diabetes in England, or
about 1 in 20 of the population.
By 2010, population ageing alone will have
increased the proportion to 4.63%. If overweight
trends continue, the proportion due to ageing and
weight combined will rise to 5.05%. If the
prevalence of overweight and obesity were to fall
to the levels before 1995, the expected prevalence
of diabetes would fall, to 4.24%, despite the
ageing change.
Rises in the prevalences of diabetes and IGT have
been reported in other Western countries.
Dunstan and colleagues in Australia66 reported a
prevalence in the over 25-year-olds of diabetes of
8% in men and 6.8% in women, with an additional
17% of men and 15% of women having IGT or
IFG. These data were based on a very large
population-based survey of 11,247 participants
who had the 75 g OGTT (the authors say that it is
the largest OGTT study in the world). Only 0.8%
were indigenous Australians.
Half of those identified as having diabetes were
undiagnosed. The prevalence of IFG was 8% in
men and 3.4% in women; for IGT the figures were
9% and 12%. The prevalence was much higher
than the 3.4% seen in two (smaller) previous
Australian studies (Busselton and Victoria, in 1981
and 1992, respectively)67,68 and than self-reported
diabetes in health surveys in 1989 and 1990 (2%).
The authors note that rises in obesity and the
ageing of the population explain part of the rise.
However, they conclude that these do not fully
explain the rise, and they hypothesise that two
other factors are reduced physical activity levels
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TABLE 9 Mortality by weight
Weight as percentage of average
<80% 80–89 90–109 110–119 120–129 130–139 140+
IHD
Men 0.88 0.90 1.0 1.23 1.32 1.55 1.95
Women 1.01 0.89 1.0 1.23 1.39 1.54 2.07
Diabetes
Men 0.88 0.84 1.0 1.65 2.56 3.51 5.19
Women 0.65 0.61 1.0 1.92 3.34 3.78 7.90
and obesity at younger ages (and hence longer
duration of obesity).
In Canada, a large study was carried out with the
aid of a sample of physicians who looked after a
representative sample of the population.69
Screening was sequential – a casual BG; those with
results over 5.5 mmol/l were asked to return for an
FPG; those with FPG 6.1–6.9 mmol/l were invited
back for a 2-hour post-glucose load sample.
However, screening was offered only to those who
attended for routine care for other reasons, who
by definition are less healthy than the rest of the
population, and may be at higher risk. That may
increase the proportion with diabetes. Conversely,
the number detected may have been reduced by
the failure of about one-quarter who had casual
BG levels over 5.5 mmol/l to return for an FPG,
and half those who did have an FPG did not have
the 2-hour post-load test.
It was believed that the prevalence of known
diabetes in Canada was 5%. This study found
another 2.2% with undiagnosed diabetes and at
least 3.5% with undiagnosed glucose intolerance
(based on IFG and IGT combined).
Similar results were reported from the NHANES
surveys in the USA,70 summarised in a Centers for
Disease Control and Prevention (CDC) report. The
prevalence of known diabetes in the over-20s was
5.9%; testing by FPG found another 2.2%. The
prevalence of IFG was 6.1%. No 2-hour post load
testing was done, so there may also have been
undiagnosed IGT.
The costs of diabetes
Some cost of illness studies include both type 1
and type 2 diabetes. Those which focus on type 2
include a review by Raikou and McGuire,71 who
noted some of the problems in such studies:
● Cost of illness studies based only on diabetes as
primary diagnosis will underestimate costs,
because most of the cost arises from
complications.
● Diabetes is under-recorded on hospital
discharge data, so costs will be underestimated.
● When considering the cost of complications, the
attributable proportion needs to be estimated,
rather than the total cost. This can be done by
estimating the excess treatment costs for people
with diabetes compared with a matched group
without diabetes (it could also be done using RR
– if the RR of a heart attack is 4, then 75% of
the cost could be attributed to diabetes).
Amongst the studies identified by Raikou and
McGuire71 as being of good quality, only one came
from the UK, and it only looked at drug costs.
Evans and colleagues in Tayside72 used
DARTS/MEMO data and showed that patients
with T2DM accounted for just over 7% of the total
drugs budget. However, they noted that the excess
prescribing costs were not just for diabetic
medications, and in particular that there was a
10% higher use of cardiovascular drugs than in
the general population.
Raikou and McGuire71 appear to have missed the
study by Bagust and colleagues,73 which reports
the creation of a model, and the results from
running it, for T2DM. The model appears well
thought out and inevitably complex. The authors
estimate that the lifetime cost of healthcare 
after people have been diagnosed with T2DM is
double that of the non-diabetic population.
However, the economics of screening are not
addressed.
Williams and colleagues74 noted that much of the
cost of healthcare for people with diabetes is not
for the diabetes itself, but for the complications.
Using data from the Cost of Diabetes in Europe
Type 2 study (CODE-2), they noted that 72% of
patients in the study had at least one
complication, of whom 34% had macrovascular
disease. In those with complications, the cost of
care was increased by up to 250% compared with
those without complications. Hence there are
financial reasons in addition to human factors for
seeking to prevent the complications of diabetes,
and the cost of complications has implications for
the cost-effectiveness of screening.
Background
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Some of the more important (recent) reviews aresummarised below, and position statements
from the ADA and Diabetes UK are also 
included.
Wareham and Griffin (2001)1
This paper1 summarises a review done for the UK
NSC, and is structured along the lines of the NSC
criteria (Appendix 2). Wareham and Griffin noted
that screening for T2DM meets many of the
criteria, but that a number of problems remain:
● The criterion that “cost-effective primary
prevention interventions should have been
implemented” is not met, because there are
known methods of reducing the incidence of
T2DM, such as diet and exercise.
● There is no clear threshold at which the risk of
CVD takes off (unlike with microvascular
disease), which is a problem if the aim of
screening is to reduce cardiovascular risk.
● The cost-effectiveness of screening would
probably depend mainly on that reduction in
cardiovascular risk, by a range of measures not
specific to diabetes, such as cholesterol and
blood pressure lowering.
● Universal screening would be unlikely to be
worthwhile, so target populations should be
identified.
● There are definite harms of screening, such as
being labelled as diabetic.
● The NSC criterion on optimising present forms
of care for the condition before finding new
cases was not met.75
● The criterion that screening should be
supported by evidence from RCTs was not met.
Wareham and Griffin concluded that on the
evidence available in 2001, it was not clear
whether screening would be worthwhile.
Engelgau and colleagues (2000)76
Engelgau and colleagues76 carried out a series of
reviews of screening for diabetes. In the version of
2000, they provide a thorough review examining
how well screening for T2DM matches the
screening criteria. Although this was a balanced
and well-argued review, it cannot be classed as
systematic; no details of search strategy, of
inclusion and exclusion criteria or indeed of any
methods were given.
They conclude that the criteria on whether the
disease is a significant health burden, the natural
history being known, and there being a
recognisable asymptomatic but detectable stage,
are met. That on whether early treatment has
advantages over waiting until symptoms appear is
probably met, but with some doubts over
compliance, and they note the absence of RCTs of
screening and early treatment.
They conclude that the criterion on a suitable test
is met, while recognising that none of the tests are
perfect. They regard urine testing as being of
limited value; consider that FPG is not as good as
post-prandial measurement because subjects with
undiagnosed diabetes are more likely to exceed the
2-hour cut-off than the FPG one; and conclude
that HbA1c is acceptable, although not as good as
the post-load PG, but that there is a need to
standardise methods. They conclude that
questionnaires are unsatisfactory, but they consider
these as a one-stop screening test, whereas they are
probably more useful as part of a two-stage screen.
They have considerable doubt as regards the
criterion on cost-effectiveness – possibly met with
opportunistic screening, but not with population-
based screening, even on a selective basis.
Their overall conclusion is that:
The effectiveness of screening for diabetes has not
been directly demonstrated.
They accept that the early detection of diabetes
and improved glycaemic control “may modestly
reduce” future microvascular disease, but that
there is little evidence for benefits in
macrovascular disease. However, they do note that
treatment of hypertension and hyperlipidaemia
may be of benefit. Their review was written before
some of the recent trials of statins in diabetes,
such as CARDS,77 DALI78 and HPS,79 were
published.
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Engelgau and colleagues76 noted that several
expert bodies have recommended screening but
that none of the recommendations had been
formally evaluated.
Harris and colleagues (2003)80
Note: The first author of this review is Russell
Harris, not to be confused with Maureen Harris,
another noted contributor to the debate on
screening.
Harris and colleagues80 provided a high quality
systematic review, with details on sources searched
and search strategy, study selection, data
extraction and synthesis and other aspects of
methods. One weakness is that only MEDLINE
was searched. This is a common American failing
and will lead to some trials being missed.81 They
seem to have searched the Cochrane Library but
only for reviews, not for trials in CENTRAL.
The review was published as a journal article,80
but is also available at the full technical report on
the website of Agency for Healthcare Research and
Quality (AHRQ).82
Harris and colleagues address several of the
screening issues. They recognise that there is an
asymptomatic but detectable stage, but note that
the true average length of this is unknown, and
that different people will have different durations
of this stage. They note that none of the tests are
perfect; that the 2-hour PG is regarded as the
reference standard but that it is less reproducible
than the FPG; and that there are fewer logistical
problems with HbA1c.
As regards the benefits of early treatment, they
summarise the trials of tighter control in T2DM
(with the UKPDS being by far the largest), but
correctly point out that these trials were mainly
about the benefits in those whose diabetes had
been diagnosed, and hence that the findings
might not be applicable to those detected by
screening and who would have lower glycaemia
levels. This is a fair point. Even if there is still
benefit at lower levels of glycaemia, the relative
benefits of lowering glucose might be similar in
terms of reducing microvascular complications,
but since the absolute benefits would be less, the
cost-effectiveness of intervention would be much
less.
The AHRQ review82 also addresses wider aspects
of risk reduction through screening, by
considering what benefits might accrue to those
found to be diabetic through treatments for
hypertension and hyperlipidaemia. The authors
note that the diagnosis of diabetes can affect both
how vigorously hypertension is treated and the
choice of drug. They report the findings of the
Hypertension Optimal Treatment trial,83 that the
optimal level of blood pressure may be lower for
those with diabetes than those without. They also
report on the controversy as to whether ACEIs are
more beneficial than other anti-hypertensive
agents, and conclude that they should still be
favoured. This topic has been reviewed more
recently by Ravid and Rachmani,84 who also
concluded that ACEIs probably had advantages
and, as Harris and colleagues82 point out, the
side-effects of ACEIs (such as cough) are less than
with other anti-hypertensive drugs. They do note
in an addendum that the ALLHAT trial, published
in 2002,85 showed no advantage of ACEIs over
calcium channel blockers.
Another potential consequence of being diagnosed
with diabetes would be that the vascular risk score
would be raised, and this could mean the
difference between being treated with a statin and
not, using the current consensus on levels of risk
[National Institute for Health and Clinical
Excellence (NICE) guidance recommend that
people with a 10-year risk of 20% of CVD should
be treated with a statin].86
The same could apply to aspirin prophylaxis,
which reduces the risk of heart disease in diabetes.
Hence one result of screening for diabetes might
be the benefits from reduction of CVD by non-
diabetic treatment, as a consequence of crossing
the threshold of risk at which these treatments are
recommended.
Harris and colleagues82 also review the harms of
treatment. They are unconvinced that ‘labelling’ is
a significant problem, at least in terms of quality
of life (although noting possible problems with life
insurance costs) and they consider that the side-
effects of drugs such as statins and ACEIs are not
a great problem. They comment on the
hypoglycaemic side-effects of diabetic drugs, but
base that on the UKPDS, where many patients
were on insulin. These results are less likely to
apply to people found by screening, who would, at
least initially, have lower BG levels, controllable by
diet or metformin (which would be the drug of
choice when a drug was needed, assuming that
screening was selective and that a key selection
criterion was BMI).
This review also considers cost-effectiveness, not in
monetary terms, but through estimation of
numbers needed to screen to prevent one event.
They use various assumptions (in the absence of
good evidence) to show that to prevent one case of
blindness from retinopathy, by screen detection
then tight glycaemic control, would have numbers-
needed-to-screen (NNS) ranging from 4300 to
61,400. However, they note that since
macrovascular is much commoner than
microvascular disease, the NNS for that are much
lower, with a range in hypertensive people of 500 to
7200 (which does not include the effect of statins).
Harris and colleagues82 came to no firm
conclusions, perhaps because the purpose of their
review was to provide a basis for the US Preventive
Task Force to do so, but the thrust of their review
is that there are clear arguments in favour of
screening, but also remaining doubts about cost-
effectiveness.
The CDC Working Group87
The Primary Prevention Working Group of the
Centers for Disease Control and Prevention
(2004)87 carried out a review of primary
prevention of T2DM. They summarise the three
recent trials aimed at preventing IGT progressing
to diabetes, as follows.
Da Qing Study88
This was an RCT over 6 years, with four groups –
controls; diet; exercise; and diet plus exercise –
with the incidence of diabetes reduced in the three
intervention groups by 31, 46 and 42%, respectively.
Finnish Diabetes Prevention Study
(DPS)89
An RCT was performed over 3 years with two
groups – control versus lifestyle intervention
(physical activity, weight loss, diet) – with
incidence of diabetes reduced by 58% compared
with controls.
Diabetes Prevention Program (DPP)90
This was an RCT of control versus metformin
versus intensive lifestyle; incidence of diabetes was
reduced by 31% in the metformin group and 58%
in the lifestyle group.
Fuller details of the trials are given in Appendix 3.
The CDC review has some useful thoughts on
policy implications or challenges. These were as
follows:
1. Identification of subjects for preventive
interventions
The Working Group87 notes that there remains
uncertainty over best screening test, because of
the inconvenience of the OGTT. They note
that there have been no trials of prevention of
progression from IFG to diabetes, but that 24%
of those with pre-diabetes have IFG.
They then pose the question as to whether “the
blood glucose criterion should be eliminated”.
They note that many (61%) Americans are
overweight or obese, and that the lifestyle
interventions of the DPP would be beneficial to
all. They wonder if the target should be not
just those with abnormal glucose levels, but all
the 47 million with the metabolic syndrome.
However, they then wonder if intervening with
such large numbers might dilute the
intervention too much. 
No definite conclusion is reached.
2. The delivery of lifestyle interventions
The Working Group87 note that lifestyle
interventions are effective, but that physicians
may not be the best people to deliver them,
because they are more accustomed to the
medical role of disease management and drug
prescribing. While physicians may have a role
in helping motivate people, the lifestyle
interventions might be better provided by non-
medical staff such as dietitians, nurses or
undefined “community health workers”. But
perhaps the key question is whether a more
public health-based approach is required.
Instead of trying to provide lifestyle
interventions as part of medical care, should
the aim be to reduce diabetes by “changing the
underlying environmental factors that
contribute to obesity and sedentary behaviour
in the general population”?
3. Are lifestyle interventions cost-effective?
The review comments on the scarcity of
economic evaluations of preventing diabetes,
but cites a 1998 reference in support of this
statement, and may therefore have missed
some of the more recent economic studies (see
Chapter 4 of this report). It notes that the
incremental costs of the intervention arms of
the DPP were modest at US$2191 and $2269
for metformin and lifestyle interventions,
respectively.
4. The ethical implications
Two main issues are considered by the Working
Group. The first is what strength of evidence is
needed for lifestyle interventions. For any
campaign aimed at the general public, or at a
high-risk subset of it – but in either case at
people who are not actually ill – should the
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strength of evidence required be as good as or
greater than that required for conventional
medical care?
The second is about the ethics of extrapolation.
If there is good evidence that lifestyle
interventions benefit those with IGT, can this be
extrapolated to those with lesser risks of
progression to diabetes or cardiovascular
disease, or are RCTs needed? As the review says:
Is it ethical to await results of a new, extensive
series of randomised controlled trials to evaluate
intervention efficacy in groups at lower risk of
diabetes? Or is it acceptable to infer intervention
efficacy in groups other than those defined by the
eligibility criteria of the Diabetes Prevention
Program?
However the review makes no firm
recommendations but only summarises some of
the evidence.
Other reviews
One of the advocates of screening for diabetes has
been Maureen Harris, who has also been first
author of several studies on the prevalence of
undiagnosed diabetes in the USA. Her reviews are
editorials or commentaries rather than systematic
reviews, but they deserve comment. In 1994, with
Michaela Modan,91 she argued that there should
be a national programme in the USA, basing this
assertion on what was known about the prevalence
of undiagnosed diabetes and the presymptomatic
phase, on the presence of complications in some
at diagnosis, and the availability of effective
treatments. They did not consider cost-
effectiveness or the possible harms of treatment.
They recommended the OGTT, although
simplified to a 2-hour glucose, as the best test,
while accepting its drawbacks. They noted that if
cost and efficiency were to be considered, then
there could be selection of people for screening on
the basis of obesity and hypertension. 
In a later (non-systematic) review, Harris and
Eastman92 make similar points about the health
burden of diabetes, the latent phase and the
damage which can accrue during it, the natural
history and the effectiveness of treatments,
updating the previous editorial with data on the
benefits of statins, and the lowered blood pressure
goal in those with diabetes. Another update
concerns the new criteria of the ADA93 and the
recommendations on which test to use. Harris and
Eastman make the point that although the 2-hour
PG test is still better in theory (because it is more
sensitive), the FPG test may in practice detect a
greater proportion because the simplicity makes it
more likely to be used. They do not consider
HbA1c in this review.
Another recent review is by Borch-Johnsen and
colleagues.94 This was a short but good-quality
review, with a clear search strategy and with the
WHO screening criteria used for assessing the case
for screening. It focused mainly on the criteria, on
a suitable test, on treatment and the indications
for that and on the ethical and psychological
consequences of screening.
They concluded that suitable tests were available,
but that:
● FPG should not be used as the only test because
one out of three cases of diabetes will be missed.
● Random blood glucose was of limited value, as
was urine testing.
● HbA1c would be useful when used as part of a
stepwise process, for example combined with
FPG; they envisaged selecting individuals for
OGTT testing.
● Questionnaires would help select high-risk
people, but might need to be validated in other
countries.
Borch-Johnsen and colleagues94 had more
reservations about treatment aspects. They noted
the beneficial results from trials in newly
diagnosed diabetes (UKPDS) and in the treatment
of hyperlipidaemia and hypertension. However,
they identified a major gap in that there were no
trials, then, of non-pharmacological intervention
in the early stages of the disease, but that the
ADDITION (an Anglo–Danish–Dutch trial of
intervention in those with T2DM detected by
screening)95 had started. They concluded that:
Until such data are available, any recommendation
regarding screening and early intervention will
depend on speculative interpretation of secondary
intervention studies.
As regards the ethical and psychological
consequences, they considered that there was a
need for further research. They also noted that
there were shortfalls in care for many individuals
with existing diabetes, which needed correction
before adding to the number by screening. Their
final conclusions were that T2DM met many of the
criteria but not all, that mass screening could not
be recommended, but that testing for diabetes
should be offered to those with hypertension,





Diabetes UK issued a position statement on “Early
identification of people with type 2 diabetes” in
November 2002.96 In brief, it advocated a
screening programme for both undiagnosed
diabetes, and also for IGT, with a view to reducing
progression to diabetes. It did not support general
population screening, but recommended targeted
case finding, with screening for those with two or
more risk factors, such as:
1. White people aged over 40 years and people
from black, Asian and minority ethnic groups
aged over 25 years, with:
(a) a first degree family history of diabetes
and/or
(b) who are overweight (BMI 25–20 and above)
and who have a sedentary lifestyle and/or
(c) who have IHD, CVD, PVD or hypertension.
2. Women who have had gestational diabetes.
3. Women with polycystic ovary syndrome who are
obese.
4. Those known to have IGT or IFG.
Diabetes UK noted that there was a lack of
evidence on the best method of screening, but 
as regards tests, they favoured the 2-hour 
post-load glucose test (noting that a full OGTT
would be the best possible test but was impractical)
followed by fasting PG measurement. Glycosuria
was also listed as having some value. HbA1c was
not included in their list of recommended tests.
The American Diabetes
Association
The ADA publishes clinical practice
recommendations each year, in a supplement to
Diabetes Care. The 2005 edition97 has the following
statement on screening for diabetes in
asymptomatic adults:
1. Testing for diabetes should be considered in all
individuals at age 45 years and above, particularly in
those with a BMI of 25 or over, and if normal should
be repeated at 3-year intervals.
2. Testing should be considered at a younger age or
be carried out more frequently in individuals who are
overweight (BMI 25) and have additional risk
factors, as follows:
● are habitually physically inactive
● have a first degree relative with diabetes
● are members of a high-risk ethnic population
● have delivered a baby weighing >9 lb or have been
diagnosed with GDM
● are hypertensive (140/90)
● on previous testing, had IGT or IFG
● have history of vascular disease.
(ADA, 2005; abbreviated)97
The ADA said that either an FPG or a 2-hour
OGTT (75 g) was appropriate, but that the FPG
was the preferred test for screening for pre-
diabetes:
The FPG is more convenient to patients, more
reproducible, and easier to administer than the 2-h
OGTT. Therefore the recommended screening test
for non-pregnant adults is the FPG.
Exercise
A very useful collation of the evidence on physical
activity and health was published as a book by
Hardman and Stensel.98 They examined the
evidence for the benefits of exercise for various
conditions:
● CHD – exercise protects. It need not be
vigorous (although vigorous exercise protects
more) and so walking is sufficient to give some
protection. However, protection is lost shortly
after exercise is stopped. The RR of heart
disease amongst the inactive is at least 2.
● Hypertension – the risk of developing
hypertension amongst the inactive is about 1.5.
Exercise is an effective way of reducing blood
pressure, although the reductions are modest
compared with pharmacological treatment –
about 3.4 mmHg systolic and 2.4 mmHg
diastolic.
● Lipid levels – exercise increases HDL and
lowers triglycerides.
● Coagulation of blood – exercise lowers platelet
aggregation and fibrinogen.
● T2DM – cohort studies show a reduction in risk.
Vigorous exercise four times per week cuts the
risk of T2DM by 40% in men (from the
Physicians’ Health Study99). Taking more than
7 hours of exercise a week reduces the risk of
diabetes in women (from the Nurses Health
Study100) by 30%. Having the combination of a
good diet, a BMI under 25 and high physical
activity (over 30 minutes per day of moderate
or more strenuous exercise) in the Nurses
Health Study gave an RR of diabetes of about
0.1; Hu and colleagues100 suggest that 87% of
T2DM in avoidable. In those already having
T2DM, remission was seen after exercise in half
of those recently diagnosed with diabetes after
screening (but numbers were small – only 41 in
total; from the Malmo feasibility study101).
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Hardman and Stensel98 quote the National Audit
Office report on possible reasons for the reduction
in physical activity:
● a reduction in occupational exercise
● greater car ownership and use
● a decline in walking as a mode of transport
● energy-saving devices in public places, such as
escalators, lifts and automatic doors
● fewer opportunities for young people to take
exercise
● the substitution of physically active leisure
activities with sedentary ones such as computer
games, television and the Internet.
Previous reviews
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Organised screening would be a two-stageprocess, with the first stage being selection
from the general population (using general
practice registers) of those likely to be more at risk
than average, and the second being testing of
glucose levels, usually in blood. However, some
studies have used urinary glucose testing as the
second screen, followed by BG testing.
There is already some ad hoc screening on offer,
such as by pharmacies, or urine testing at new
patient registration in general practice.
Stage 1 – selection by risk 
factors
Testing only people who are at higher than
average risk means that a higher proportion of
those who will be tested for glucose will be
positive, the NNS to detect each true positive will
be lower and the whole programme will be more
cost-effective.
1. Age is always a key factor, because the risk of
T2DM increases steeply with age. The cost-
effectiveness of screening will be lower at
younger ages since the NNS to find each case
will increase, and also because the event rate
from CVD will be lower.
However, although the prevalence of diabetes is
greater in the older ages groups, the excess
mortality may fall. Tan and colleagues102 found
that in men diagnosed with T2DM over the age
of 65 years in Tayside, there was no excess
mortality compared with the general
population. This might represent a survival
selection effect. The situation in women was
different, with an RR of death of 1.29 
(95% CI 1.15 to 1.45). The implication of 
this might be that if the main aim of screening
is to reduce heart disease mortality and
morbidity, screening in men should not include
those aged over 65 years. 
Vijan and colleagues103 also looked at this in
their model of T2DM. Improving glycaemia
control improves life expectancy, but the gains
from a 2% improvement (HbA1c 11–9%) are
very different at different ages of onset
(Table 10).
This modelling is based mainly on
microvascular disease, and is more concerned
with poorly controlled patients with higher
HbA1c levels than those who would be found by
screening. However, it does illustrate a general
principle that because most serious
microvascular disease comes on a decade or two
after the onset of diabetes, those who become
diabetic at older ages have less risk and hence
less to gain from screening. Hence one could
argue that screening at 65 years or over is not
worthwhile. It should be noted that in Table 11
the insulin-treated group are a mixture of
patients with type 1 and type 2 diabetes.
2. BMI is the second factor, reflecting overweight
and obesity. The risk of T2DM is greatly
increased by excess weight. However, there is
also a link with the distribution of body fat, with
abdominal (especially visceral) fat distribution
carrying a higher risk. Waist measurement
could be used as a risk factor, for example,
more than 40 inches (approximately 100 cm) in
men or 35 inches (approximately 90 cm) in
women. However, men tend to know their waist
measurement, by which they buy trousers, more
than women, who use overall size.
3. Co-morbidities. The risk of diabetes is
associated with other aspects of the metabolic
syndrome such as hypertension and
hyperlipidaemia, and with the presence of
vascular disease, such as peripheral vascular
disease or IHD.
4. Family history of diabetes, or of premature
vascular disease or hypertension, is a predictor.
5. Ethnicity is also a predictor, in that some ethnic
groups have a higher risk of T2DM than
others, although this is less if adjustments are
made for BMI and fat distribution. In the
Manchester survey,104 the prevalence of known
diabetes in a poor inner city area was 8 and
3.7% in European men and women,
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respectively. and 14 and 18.2% in Pakistani
men and women, respectively. The Pakistani
women had higher BMI than the Europeans
(29.6 versus 27.2) and a higher waist:hip ratio
(0.88 versus 0.81). Pakistani and European men
had similar BMIs (27.4 and 27.5, respectively),
but the Pakistani waist:hip ratio was higher
(0.96 versus 0.92; 95% CIs 0.94 to 0.97 and
0.92 to 0.94). However, the most striking
differences were in physical activity. The
proportions taking at least 20 minutes of
exercise three times per week were 38 and 29%
for European men and women, respectively,
and 7 and 5% for Pakistani men and women,
respectively. Physical activity reduces insulin
resistance even if there is little or no weight
loss.98
6. Drug treatments such as for hypertension, or
corticosteroids. 
There are two ways in which such selection criteria
could be applied. Questionnaires could be sent
out, albeit perhaps only to those above a certain
age. However, increasingly, computer systems in
general practices will have much of the necessary
data – certainly age, drug treatment, co-
morbidities and usually BMI. They are less likely
to have waist measurements and family history.
However, it means that the first stage of any
screening system could use existing data at little
extra cost. This was demonstrated by Baan and
colleagues105 in the Rotterdam study, where data
from a population screening study were used in
three progressively more complex screening tools:
(a) Level 1 had only data available in general
practice records, age, sex, use of anti-
hypertensive and anti-hyperlipidaemia
medications, previous gestational diabetes,
CVD and obesity.
(b) Level 2 had additional items which could be
obtained from a simple questionnaire, family
history, smoking, cardiovascular symptoms
and exercise (cycling).
(c) Level 3 added data that would need to be
obtained from physical examination, blood
pressure and waist and hip measurements (for
waist:hip ratio).
Baan and colleagues105 found that the addition of
level 3 data did not improve the predictive value
over level 2. Level 2 had little advantage over level
1, despite physical activity having a strong
predictive power. In level 2, not cycling had an OR
of 2.83, which was the highest OR of all the
factors.
Patients at higher risk could then be approached
opportunistically when they consulted for other
reasons. Those who did not consult within, say,
2 years of the threshold age could be invited to
attend for screening.
Hence one option for the first stage could be to
rely only on data already in general practice
records, which would provide an inexpensive
method. However, questionnaires could provide
more data.
Questionnaires
Several systems have been used.
The Hoorn study106 used the Symptom Risk
Questionnaire (SRQ), which, despite the name,
covered more than symptoms, age, height, weight,
pain on walking, shortness of breath, frequent
thirst, family history of diabetes, use of anti-
hypertensive drugs and cycling. They then used a
cut-off of >6 mmol/l for selection for glucose
testing.
Herman and colleagues107 used data from
NHANES 2 to examine different combinations of
risk factors. The combination of age, sex, previous
delivery of large infant, obesity, lack of exercise
and family history identified a high-risk group
which contained 79% of people with newly
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TABLE 11 Prevalence of insulin- and non-insulin-treated diabetes per 1000 population, 1998
Age (years)
Diabetes Sex 16–24 25–34 35–44 45–54 55–64 65–74 75–84 85+
Insulin-treated Males 3.5 4.6 6.2 7.2 10 13.3 10.9 6.8
Females 3.2 4.3 5.2 5.7 9.4 12.1 9.4 5.9
Non-insulin-treated Males 0.2 0.6 3.6 11.8 30.5 47.5 47.4 43.1
Females 0.2 0.6 2.8 7.9 20.3 35.7 37.1 33.8
Source: Office of National Statistics.
diagnosed diabetes. Adding hypertension and a
history of glucose intolerance made little
difference (83% sensitivity). Ethnic difference had
little effect once other factors such as weight had
been allowed for (although in this case the ethnic
groups were black people, Hispanics and
American Indians).
Burden and Burden108 reported that the ADA
questionnaire had low sensitivity (46%) in a study
in Leicestershire for detecting those with raised
casual BG levels.
The Diabetes Risk Score (DRS) is designed to be
self-administered, and so could be sent out by
practices to people at the appropriate age. It has
questions on age, BMI, waist circumference,
medications for hypertension, any history of high
BG, physical activity and daily consumption of
vegetables, fruit or berries. The IGLOO group
(Impaired Glucose Tolerance and Long-term
Outcomes Observational study)109 used the DRS
and compared the findings with the results of
OGTT, in people selected on the basis of having
one or more risk factors for CVD, and being aged
55–74 years. Of 1377 patients, but without known
diabetes, 15.4% had IGT, 11.1% had IFG, 11%
had IGT and IFG and 17.4% had diabetes.
The cost per case detected, irrespective of
method, was low (under €23). However, they
applied their results to scenarios of 1000 people
with different prevalences of undiagnosed T2DM
and IGT. For the 10% prevalence (which is closer
to the UK one), they concluded that using the
DRS would reduce the proportion of patients
needing a fasting blood glucose (FBG) test by
about 43%, and then OGTTs by about 90 people
(from 270 to 180). The total cost would fall by
about one-third, and the cost per case detected
from €87 to €65, but there would be a drop in
sensitivity from 68 to 55%. This is mainly because
a DRS cut-off of 9 gives a sensitivity of 86% for
diabetes but 77% for diabetes + IGT. It is worth
noting that a DRS cut-off of 9 is more sensitive for
diabetes + IGT than an FBG with cut-off of
6.1 mmol/l or more.
Griffin and colleagues110 developed a new risk
score for diabetes, the Cambridge Risk Score
(CRS), based on data available in general practice
records (assuming that family and smoking history
are recorded), and then validated it on another
group of people. Using a low threshold, 30% of
the practice population in Ely would go on to
diagnostic testing and 77% of those with
undiagnosed diabetes would be detected. Using a
higher threshold, 15% would be called for
diagnostic testing but only 41% of the
undiagnosed diabetics would be detected. Hence,
as usual, there is a trade-off between sensitivity
and cost, with cost including not just money but
also the adverse effects of screening amongst the
false positives. Griffin and colleagues110 also note
the danger of normal results in those at high risk
because of unhealthy lifestyles – they may see a
normal result as justifying continuing with such
lifestyles.
A different approach was used by Spijkerman and
colleagues.111 They used a three-step approach,
with step 1 being an SRQ, step 2 being an FPG
and step 3 being an OGTT (unless the FPG was so
high that an OGTT was not considered necessary).
The aim of the study was not to assess the
accuracy of the SRQ (already done in a previous
study), and those with scores <6 were not tested
further. The usefulness for this review is two-fold.
First, the group identified by screening had a
lowish HbA1c of 6.7% [standard deviation (SD)
1.4]. Second, they had high prevalences of
hypertension (70%), high cholesterol levels (73%)
and obesity (40%). Hence many would have been
identified as being at high risk of CVD even
without diabetes screening. If the aim of screening
for diabetes is so that measures to reduce
cardiovascular risk, such as statins, can be started,
then in this case screening may have made little
difference.
Greaves and colleagues112 also based initial
selection on data now available in general practice
computer systems. They tested a simple system
using age and BMI only, with four groups selected
by the combination of age (over 70, over 65, over
60 and over 50 years) and BMI (over 33, 31.29
and 27). Hence the oldest and fattest group
excluded the other three, but the other three
groups could overlap with those above. They then
invited patients to attend for FPG measurement.
Those with FPG over 6.1 mmol/l were invited back
for a repeat FPG. Those with FPG at 7.0 mmol/l or
over on both occasions were classed as diabetic.
Those with one or two levels between 6.1 and
6.9 mmol/l were classed as IFG. The uptake of
screening was 61%.
Greaves and colleagues112 then looked at the
efficiency of screening in terms of the NNS in
each group, and found that for diabetes it ranged
from an NNS of 22 in the age over 70 years/BMI
over 33 group to 38 in the 50+ years/BMI 27
group. For detecting diabetes or IFG, the
respective NNS were 8 and 13. There was little
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difference in the oldest/heaviest three groups.
Screening became slightly less efficient in the over
50 years/BMI over 27 group. However, the three
oldest groups were reported as comprising 6.66%
of the practice populations (which seems low) and
so restricting screening to them would detect fewer
people with hyperglycaemia than screening all
over 50 years with BMI over 27.
The authors do not present data separately for the
group with ages between 50 and 59 years BMI
over 27 and under 29. Hence, the marginal
benefits of applying each age/BMI cut-off could
not be examined. It is possible that most of the
patients found in the most inclusive group (over
50 years/BMI over 27) were actually from the
higher groups.
The Atherosclerosis Risk in Communities (ARIC)
Study113 looked at the marginal advantages of
adding laboratory data to a clinical risk score. In
terms of area under a receiver operating
characteristic (AUROC) curve, the results were as
follows:
● Clinical risk score alone [age, waist measurement,
parental history, ethnic group, systolic blood
pressure (SBP)] gave an AUROC of 0.71.
● FPG alone gave 0.74.
● Clinical plus FPG gave 0.78.
● Adding triglycerides and HDL cholesterol
increased that to 0.80.
● Scores based on the metabolic syndrome gave
AUROCs of 0.75 and 0.78.
Hence adding laboratory results improved the
predictive power, but only slightly.
Schmidt and colleagues113 also tested the San
Antonio clinical score (age, sex, family history, BMI,
HDL cholesterol and hypertension) and found that
that gave an AUROC, for whites only, of 0.80.
Stage 2 – glucose testing
Urine testing has been advocated, but in most
reviews has been discounted because of low
sensitivity.1,76,94 It would in effect be another
preliminary screen, with screen positives going on
to blood testing. Nevertheless, it has been shown
to be of some use, especially as it can be done by
post.114 However, it would be much less useful if
screening were to be for all degrees of elevated
BG. It also retains a place in the investigation of
polyuria, but by definition people with symptoms
are not included in the screening situation.
The tests for blood glucose include;
● casual (non-fasting) BG – more sensitive than
glycosuria but less specific
● FPG or FBG
● glucose tolerance tests, combining fasting and
2-hour levels
● HbA1c, which reflects BG over the previous
3 months (assuming red blood cells of normal




Casual BG is usually discounted because of its
variability and poor sensitivity (at levels which give
acceptable specificity).115
The choice of test depends on what one is
screening for. FPG is reliable, in the sense of
showing less day-to-day variability than OGTTs,
and will identify people with diabetes and IFG.
However, it will miss those with IGT, who have a
higher IHD risk than those with IFG. 
The use of HbA1c
The use of HbA1c as a screening test has been
reviewed by various expert groups.
The WHO Expert Group14 did not recommend
HbA1c for diagnosis, commenting that:
An alternative to the single blood glucose 
estimation or OGTT has long been sought to 
simplify the diagnosis of diabetes. Glycated
haemoglobin, reflecting average glycaemia over a
period of weeks, was thought to provide such a test.
Although in certain cases it gives equal or almost
equal sensitivity and specificity to glucose
measurement, it is not available in many parts of the
world and is not sufficiently well standardised for its
use to be recommended at this time.
However, screening was not addressed in this report.
Its perspective was world-wide; HbA1c is routinely
available in the UK. Systems for standardisation
are available such as the National Glycohemoglobin
Standardization Program (NGSP),116 which aims to
standardise results to make them comparable with
the Diabetes Control and Complications Trial
(DCCT) Trial. Most UK laboratories use this
system to align their results to DCCT.
In a recent report, the ADA Expert Committee117
on the diagnosis and classification of diabetes
mellitus summarised the advantages and
disadvantages of HbA1c for the diagnosis of
diabetes. The Committee listed the advantages as:
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● HbA1c measures average glycaemic levels over a
period of 10 weeks or so, and is therefore more
stable than FPG, and especially than 2-h OGTT.
● Fasting is not required, and the test can be done
at any time of day.
● The precision of HbA1c can be as good as that
of PG (Note the use of the word “can” – is there
an implication that results may not be as good
in routine practice?).
● HbA1c is the test used for monitoring control of
diabetes and correlates well with the
microvascular complications; it may be useful to
use the same test for diagnosis and monitoring.
● It has been shown by meta-analysis that when
using a statistical cut-point of 2 SDs above the
non-diabetic mean value, HbA1c is as good as
FPG and 2-hour PG in terms of sensitivity
(66%) and specificity (98%).
The disadvantages were identified as:
● Internationally, there is a profusion of assay
methods and reference ranges. However, this
can be overcome by standardisation to the
DCCT assay.
● HbA1c may be affected by other conditions
which affect the life of the red blood cell; results
may then be misleading. This could be a
particular problems in ethnic groups in which
haemoglobinopathy is common.
● A chemical preparation for uniform calibration
standards has only recently become available
and is not universally available.
However, with the exception of the other
conditions, these disadvantages need not apply in
a national screening system. There is therefore a
case for using HbA1c as the screening test,
particularly in view of its correlation with
cardiovascular risk across a wide spectrum. In the
Norfolk study, Khaw and colleagues118 noted that
the rise in cardiovascular events with rising HbA1c
started well below the diabetic range. Indeed, they
pointed out that when both diabetes and HbA1c
are included in the statistical analysis, HbA1c
dominates, as Gerstein119 argues in an editorial:
the glycosylated hemoglobin level is an independent
progressive risk factor for cardiovascular events,
regardless of diabetes status.
So, if the aim of screening is to identify people at
high risk of vascular disease, is HbA1c more useful
than diabetes?
Rohlfing and colleagues120 noted that two changes
would affect the performance of HbA1c as a
screening test. The first was the standardisation
system (NGSP) mentioned above. The second was
the change in the definition of diabetes, with the
lowering of the FPG threshold to 7.0 mmol/l.
Using data from NHANES 3, they showed that a
cut-off of 1 SD above the HbA1c mean would give
83% sensitivity and 84% specificity, compared with
FPG. Using a cut-off of 2 SD would give 63%
sensitivity and 97% specificity. The 2 SD cut-off
level would be an HbA1c level of 6.1%. 
One weakness of this study was that most patients
did not have an OGTT. Of those who had HbA1c
6.1%, 96% had non-diabetic FPGs. The 4% with
FPGs under 7.0 mmol/l but HbA1c over 6.1% may
have included people with IGT.
A large-scale trial of HbA1c as a screening test was
carried out in New Zealand, somewhat
serendipitously as an add-on to a large screening
programme for hepatitis B.121 In the North
Island, 50,819 subjects being tested for hepatitis B
also had HbA1c measured. Of these, 300 who lived
close to the testing laboratories were invited to
attend for a standard 75 g OGTT. Most (82%) of
the participants were Maori.
Thirty-two were found to have undiagnosed
diabetes. Of these, 30 had HbA1c over 6.1% – an
apparent sensitivity of 94% and specificity of 77%,
if the OGTT is taken as the gold standard. A total
of 67 (22%) people had FG 6.1–6.9 mmol/l; only
33 of these had HbA1c over 6.1%. To detect those
with IFG, a lower HbA1c cut-off would be required.
A cut-off of 5.6% would give a sensitivity of 98%
but a poor specificity of 30%. A cut-off of 5.9%
would give a more reasonable compromise with
sensitivity 82% and specificity 73%.
McCance and colleagues122 compared FPG, 2-hour
PG and HbA1c as diagnostic tests in Pima Indians,
and found very little difference in the predictive
power for retinopathy of FPG, 2-hour PG and
HbA1c.
Peters and colleagues123 carried out a meta-analysis
of the use of HbA1c (and also HbA1) in the
diagnosis of diabetes. They found that a cut-point
of 7.0% for HbA1c would give a group in whom
89% were diabetic by the OGTT, 7% had IGT and
4% were normal. Of those with diabetes by the
OGTT, only 42% had an HbA1c over 7%, but the
authors argue that this cut-off identifies those who
would be likely to require pharmacological
treatment – although this is an assumption, based
on a position that those with HbA1c under 7% are
rarely treated with drugs. They considered that
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the inconvenience of the OGTT might be one of
the reasons for under-diagnosis of diabetes.
Woerle and colleagues124 reported that the 2-hour
PG explained more of rises in HbA1c than FPG.
They also give data on further testing in those
with HbA1c levels between 6.0 and 7.0%. None
had normal glucose tolerance (NGT); 43% had
IGT, 49% were diabetic and 8% had IFG. However,
numbers were small (23, 26 and four, respectively).
There was a steep rise in the proportion abnormal
between the sixth and seventh deciles of HbA1c:
● Sixth decile: mean HbA1c 5.34 %; 30% had
abnormal glucose tolerance.
● Seventh decile: mean HbA1c 5.48%; 70% had
abnormal glucose tolerance.
Hence an HbA1c of 5.5% might be a suitable cut-
off for screening.
One advantage of HbA1c is that it is used as the
target for glycaemic control. The ADA Position
Statement of 200597 recommends that the aim
should be an HbA1c level under 7% (referenced to
a non-diabetic range of 4.0–6.0%, using a DCCT
aligned assay). However, the relationship between
complications and HbA1c is closer for
microvascular disease than macrovascular disease.
HbA1c has become part of the routine of diabetes
care. However, some concerns remain, and a
useful critical review by Jeffcoate125 summarises
these as follows:
● Analytical variability – which should be reduced
by standardisation methods.
● Biological variability, in particular that due to
differences in the longevity of the red blood
cell, but also uncertainties over the relative
contributions to HbA1c of preprandial (such as
fasting) and postprandial BG elevations. He
notes an ADA conclusion that FPG is a closer
correlate than postprandial.
● Clinical variability – and in particular the
poorer correlation with macrovascular disease. 
If postprandial glucose levels are better predictors
of macrovascular disease than FPG, and if HbA1c
is more influenced by preprandial than
postprandial PG, then using HbA1c as a screening
test might be fine for predicting and preventing
future diabetes, but not so good as a basis for
predicting and preventing future heart disease.
However, the relative contributions of fasting and
preprandial (taking fasting to be before breakfast
and preprandial to be before other meals) and
postprandial to overall glycaemia, as reflected in
HbA1c, varies according to stage of disease.
Monnier and colleagues126 reported that the
higher the HbA1c, the greater is the contribution
of fasting and preprandial – which is logical, 
since most people spend most of the day in 
a non-postprandial state. At low levels of HbA1c,
under 7.3%, postprandial has twice as much 
effect on HbA1c as fasting and preprandial. In 
the lowest quintile (mean HbA1c of 6.45%),
postprandial glucose contributed 70% of the
elevation in HbA1c.
This has implications for using HbA1c as a
screening method, since at the lower levels
expected in those found by screening,
postprandial will have more effect, and therefore
the level may reflect an IGT pattern more than an
IFG pattern, which could be useful.
Do we actually need blood glucose testing?
An interesting paper from the Hoorn study127
looked at those who were first-stage screen positive
by the CRS, but who did not have diabetes on
glucose testing. Spijkerman and colleagues127
found that this group had almost as high a CVD
rate as the true positives. Taking the RR in true
negatives as 1.0, the newly diagnosed diabetics
had an RR of 1.73 and the false positives had an
RR of 1.56. Furthermore, the false positives made
up about half of the population, so their number
of events was much greater than that of the true
positives (175 versus 24 events). As the authors
noted, screening might do harm to this group:
In current screening practice this large group of
people would be sent home feeling reassured about
diabetes but unaware of their increased risk of
mortality.
They might then feel less inclined to improve
their lifestyles. The CRS includes remediable
factors in BMI and smoking. Given that this group
have been identified by the CRS as being at
increased risk, they could be reminded of that
post-screening and given appropriate advice.
Would that lead to lifestyle changes? Perhaps
research is needed.
Since 63% of the total deaths occurred in the
false-positive group, the authors comment that:
It may be of greater public health benefit to intervene
in the screen positive group as a whole rather than
only in the relatively small group who on subsequent
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If so, it could be argued that glucose testing is not
necessary. However, this is based on a
macrovascular focus. Detection of diabetes would
lead to screening for and intervention in the
(admittedly less common) microvascular disease
such as retinopathy.
Conclusions
There is no perfect test. The gold standard test
might be the OGTT (or the modified version with
just FPG and 2-hour PG) but repeated a week
later, because of its imperfect reproducibility.
However, it is impractical and, as Hanson and
colleagues128 pointed out, the emphasis on the
OGTT may be part of the reason why so many
people in the USA are undiagnosed. A slightly less
good test may in practice be more useful by being
applied more frequently. 
As regards evidence on tests, there is little to
change since the last NSC review by Wareham and
Griffin in 2001.1 The FPG and the 2-hour PG are
equally useful for assessing the risk of
microvascular complications such as retinopathy,
but the 2-hour PG level is better for assessing
macrovascular risk, because of the difference in
heart disease risk between IFG and IGT. HbA1c
has advantages in terms of convenience and
reproducibility compared with the OGTT or its
modified form, the 2-hour PG. FPG is also more
reproducible than the OGTT.
In practice, HbA1c may be the best test, but costs
more than FPG, although less than OGTT.
Overview
The aim of this chapter is to identify and appraise
economic studies relevant to the decision of
whether or not to screen for undiagnosed diabetes
and or IGT. The chapter is divided into three
sections based around three principal questions: 
1. Is it a cost-effective use of resources to screen
for and treat people with undiagnosed diabetes?
2. Is it a cost-effective use of resources to screen
for and treat people with IGT?
3. If a screening programme were to be
implemented, what screening tests and cut-off
points should be used?
First, modelling studies that assess the long-term
cost and consequences of screening for T2DM are
reviewed. Second, similar models that assess the
long-term costs and consequences of treating
people with IGT or IFG are reviewed. Finally,
studies that consider the short-terms costs and
outcomes of alternative screening tests (and cut-off
points) for diabetes and IGT/IFG are reviewed. 
Methods
A systematic literature search (up to the end of
June 2005) was undertaken to identify any
economic assessments of screening for diabetes
and/or IGT/IFG. Databases searched were
MEDLINE, EMBASE, NHSEED and Science and
Social Science Citation Index; no time limit was
set but there was little prior to the first model
being published in 1998. Abstracts were reviewed
and any studies that were potentially relevant to
any of the three questions outlined above were
retrieved. Articles cited by other relevant studies
were also retrieved for review. In addition, a
broader search was conducted for any economic
models within the area of T2DM, to ascertain if
any such models had been used to address any of
the questions of interest.
Inclusion and exclusion criteria
To be included, studies generally had to assess the
costs and outcomes (long or short term) of
screening strategies for either undiagnosed
diabetes or IGT/IFG. However, given the lack of
economic evaluations that had assessed screening
for undiagnosed diabetes (question 1), studies that
assessed only the long-term outcomes [life-years or
quality-adjusted life-years (QALYs)] or costs of
screening (where relevant to the UK setting) were
also considered eligible for inclusion. In addition,
no studies explicitly assessed the long-term costs
and outcomes of screening for IGT/IFG, so studies
that assessed the costs and outcomes of treating
patients already identified as having IGT/IFG were
considered eligible for inclusion. Studies reported
in languages other than English were not
included.
Data extraction
Data were extracted from the long-term modelling
studies of screening for diabetes or IGT under the
following headings: 
1. author and year 
2. decision problem (comparators, population,
setting, objectives) 
3. cohort information (characteristics and
numbers)
4. model structure, perspective and scope (basic
structure and assumptions) 
5. modelling of disease progression (details of
structure and assumptions used for modelling
diabetes progression) 
6. modelling of diabetes complications (details of
structure and assumptions used to model
progression of diabetes complications)
7. mortality (details of how mortality was
modelled) 
8. costs (details of costs considered in the
model).
9. outcomes (outcomes reported and methods
for calculating life-years or QALYs)
10. findings (reported results of the base-case
analysis) 
11. sensitivity analysis (details and results of any
sensitivity analysis conducted).
For the studies that assessed only the short-term
costs and outcomes of alternative screening
strategies, data were extracted under the following
headings:
1. author and year
2. setting (country for which analysis was
conducted)
3. objectives (specific questions addressed)
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4. strategies (alternative strategies considered)
5. costs (cost included in the analysis, currency
and year)
6. Outcomes considered
7. time horizon and perspective of study
8. results/authors’ conclusions (details of main
findings and authors’ conclusions).
Quality assessment of included studies
One reviewer critically appraised all the economic
evaluations included using the BMJ guidelines for
reviewers of economic evaluations.129 The
economic models included in the review were
appraised by the same reviewer using a published
checklist for good practice in decision analytic
modelling in health technology assessment.130
Economic models assessing long-
term costs and/or consequences
of screening for type 2 diabetes
Background
Proponents of screening for diabetes argue that
the additional investments needed to implement
screening programmes are justified by the
potential reductions in future diabetic
complications, mortality and associated treatment
costs. However, although there is direct evidence
that various treatments are effective in reducing
complications and mortality in people who have
been clinically diagnosed with diabetes, there is no
direct evidence relating to the magnitude of any
further benefit that might be derived from starting
these treatments earlier, after detection by
screening. In the absence of direct evidence,
economic models have been used to estimate the
long-term costs and outcomes associated with
screening. These models are based on available
evidence relating to the progression of diabetes
and its complications and various assumptions
about the impact of treating diabetes in its early
preclinical phase.
Search results
The search for economic studies that assessed the
long-term costs and consequences of screening for
diabetes identified six potential studies. However,
one of the models only considered the benefits of
screening in terms of reduction in the incidence of
blindness, and another study considered only the
long-term costs of screening for a US population.
This left four studies for inclusion in this section
of the review – three that assessed the long-term
cost-effectiveness of screening and one which
considered only the long-term outcomes of
implementing a screening policy at the population
level. These are discussed and compared with each
other and previous diabetic modelling studies
below.
Statement of the decision problem
The characteristics of the four modelling studies
included in this review are summarised in Table 12.
Three of the studies used similar Markov models
to assess the long-term costs and outcomes of
screening for T2DM.131–133 These models used
similar assumptions to a previously published
model by Eastman and colleagues,134,135 but
incorporated a screening module to assess the
impact of identifying and treating patients earlier
than they otherwise would have been. The Center
for Disease Control Diabetes Cost-Effectiveness
Study Group (CDC) was the first to construct a
model assessing the impact of screening.131 This
model concentrated on the long-term costs and
benefits associated with the provision of glucose-
controlling interventions in the early preclinical
phase of diabetes. Conventional treatments were
assumed to begin after early identification by
screening and were compared with the current
clinical practice in the USA at the time
(conventional treatment commencing after clinical
diagnosis). The authors assumed that screening,
followed by early treatment for hyperglycaemia,
would only impact upon the incidence of
microvascular complications and have no effect 
on CVD. 
Chen and colleagues132 later used the same basic
model structure as the CDC to investigate the
impact of repeated universal screening as opposed
to once-off opportunistic screening. This study
also addressed the question of how frequently
screening should be carried out. 
More recently, Hoerger and colleagues133 updated
the original CDC model to incorporate wider
benefits of screening. They used new data for
various model parameters and incorporated the
finding that, for people with diabetes, tighter
blood pressure control provides substantial benefit
(relative to standard control) in terms of reducing
CVD morbidity and mortality. The model assessed
the cost-effectiveness of targeting screening at
patients with hypertension compared with once-off
opportunistic screening for all adults and the
practice of relying on clinical diagnosis. 
The fourth study identified used a different
approach to model the QALY gains associated
with screening. Goyder and Irwig136 used a
decision tree to weigh the potential benefits
against the potential harms of screening. The
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baseline characteristics of the cohort were varied
to ascertain in which populations the benefits of
screening would be likely to outweigh the harm.
They assumed that an early diagnosis with
screening would lead to improved treatment of
other CVD risk factors in addition to BG-
controlling measures. Therefore, benefits in the
model (QALY gains) accrued from reductions in
both microvascular and cardiovascular
complications. The potential harms of screening
included in the model were assumed reductions in
quality of life associated with early diagnosis and
adverse effects of the early treatment. None of the
other studies considered potential harms of
screening. 
Cohort information
The characteristics of the cohorts for which these
modelling studies were conducted are summarised
in Table 13. The CDC group131 simulated
screening for a hypothetical population with the
demographic characteristics of the US population
over 25 years of age. The population was assigned
to either screening or current clinical practice. 
For 10,000 people with diabetes within this
population, the disease progression model
simulated the development of complications from
onset of diabetes under each of the alternative
options (screening and current practice). Different
screening cohorts defined by age (10-year age
groups), race and ethnicity are also considered
separately in the model. 
The cohort simulated by Hoerger and colleagues133
was based on 1997 population estimates projected
from the 1990 US Census and data on the
distribution of people with diabetes by
hypertension, cholesterol level and smoking status.
Different cohorts defined by age, sex, race and
hypertension status were simulated through the
model using cohort simulation (all at once) rather
than Monte Carlo simulation methods (one
patient at a time). 
The cohort used by Chen and colleagues132
consisted of 30,000 individuals with demographic
characteristics reflecting the population of Taiwan. 
The decision tree analysis by Goyder and Irwig136
was conducted for a predominantly Caucasian UK
cohort aged between 45 and 60 years. The
prevalence of diabetes in this cohort was based on
a prevalence survey of the population of the 
Isle of Ely. 
Model structure, scope and perspective
The CDC131 developed a semi-Markov model and
used Monte Carlo simulation to model disease
progression, treatment costs, life-years and QALYs
for the two alternative options considered –
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TABLE 12 Summary of screening models reviewed
Study Comparators Model type Economic Complications Benefits of 
outcomes modelled early treatment 
modelled
CDC, 1998131 1. Clinical diagnosis (case Markov Cost per Retinopathy, Reduced 
finding) (Monte Carlo life-year and nephropathy, microvascular 
2. Once-off opportunistic simulation) cost per QALY neuropathy, complications
screening all CVD
Chen et al., 1. Clinical diagnosis (case Markov Cost per Retinopathy, Reduced 
2001132 finding) (Monte Carlo life-year and nephropathy, microvascular 
2. Universal repeat simulation cost per QALY neuropathy, complications
screening assumed) all CVD
Hoerger et al., 1. Clinical diagnosis (case Markov Cost per QALY Retinopathy, Reduced 
2004133 finding) (cohort analysis) nephropathy, microvascular 
2. Once-off opportunistic neuropathy, and 
screening CHD (angina and cardiovascular 
3. Targeted screening to MI), stroke complications
people with hypertension
Goyder and 1. Clinical diagnosis (case Decision tree QALYs gained All microvascular Reduced 
Irwig, 2000136 finding) (cohort analysis) complications microvascular 
2. Screening for all (not distinguished), and 
45–50-year-olds all CVD (including cardiovascular 
angina, MI, chronic complications
heart failure and 
stroke)
opportunistic screening of all adults versus
reliance on clinical diagnosis. The disease
progression module consisted of a series of
Markov processes, which were used to
simultaneously model disease progression on three
diabetes complication pathways starting at onset of
diabetes. The complication pathways modelled
were retinopathy, nephropathy and neuropathy.
Individuals from the hypothetical cohort were
simulated one at a time through the screening
module, where they were first assigned various
characteristics weighted on the demographic
characteristics of the US population. They were
also assigned a diabetes status (undiagnosed)
based on the prevalence of undiagnosed diabetes
in the US population (adjusted for age, race,
ethnicity, obesity and hypertension status).
Individuals with diabetes in the screening arm of
the model could either be identified by screening
(true positives) or missed (false negatives) based
on the sensitivity/specificity of the test (FPG test
with a cut-off value 6 mmol/l). A total of 10,000
patients with diabetes, as assigned by the model,
were then simulated one at a time through the
disease progression submodels. Patients who
received a diagnosis of diabetes as a result of
screening were assumed to begin conventional
glucose-controlling treatment (diet and exercise)
immediately, whereas those given a false-negative
test result began treatment at clinical diagnosis.
All those with diabetes in the no-screening arm
were assumed to begin treatment at clinical
diagnosis. It was assumed that on average clinical
diagnosis would occur 10.5 years after diabetes
onset. This estimate was based on a study which
looked at the relationship between the prevalence
of retinopathy and time from clinical diagnosis
and used extrapolation to estimate the time at
which the prevalence would be zero (9–12 years
before clinical diagnosis).54 Diagnosis by screening
was assumed to occur 5 years earlier at 5.5 years
after onset (Figure 1). Those identified through
screening were simulated to receive an extra 
5 years of treatment compared with those
diagnosed clinically and, thus, have a slower rate of
progression in the disease progression submodels. 
The model used by Chen and colleagues132 has
the same basic structure as the CDC model,
although it is unclear if cohort simulation or
Monte Carlo simulation was used for the analysis.
Very little information was provided in the
published paper regarding the structure of the
model and the methods for estimation of
parameter values and transition probabilities. This
lack of transparency makes it very difficult to
assess the quality of the model. The authors used
an estimate of 1.1% for the annual incidence of
diabetes, which does not seem to have been varied
as a function of age, sex or any other patient
characteristics. A hypothetical cohort of 30,000
subjects was randomly allocated to one of two
screening arms (screen every 2 years or screen
every 5 years) or a control arm (no screening).
The screening test used was FBG but it is unclear
from the paper what cut-off point was used and
what sensitivity/specificity values were assumed.
Presumably, screening was assumed to result in
diagnosis of the incident diabetes cases at a time
from onset consistent with the screening intervals.
However, it was unclear whether or not the
analysts considered the impact that introducing
mass screening would have on the undiagnosed
prevalent cases in the population. Furthermore,
the time from onset at which clinical diagnosis was
assumed to occur in the absence of screening was
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TABLE 13 Cohort information used in the published screening models
Study Cohort demographic Source of cohort Cohort age range No. of patients 
characteristics based on information (years) in cohort
CDC, 1998131 US population National Health and 25 and over 10,000
Nutrition Examination 
Survey II
Chen et al., 2001132 Taiwanese population Not stated 30 and over 30,000
Hoerger et al., 2004133 US population 1997 population Separate cohort Not stated
estimates projected analyses for 
from the 1990 US screening at 35, 45, 
Census and data on 55, 65 and 75
distribution of people 
with diabetes in the USA
Goyder and Irwig, Caucasian UK population Isle of Ely Diabetes 45–60 10,000
2000136 Project
not stated. However, it was assumed that screening
would result in early treatment that would slow the
development of microvascular complications. 
The model conducted by Hoerger and colleagues133
followed the same basic structure as that of the
CDC but differed in number of important ways.
First, cohort simulation was used to evaluate the
model as opposed to Monte Carlo simulation.
This means that whole cohorts were passed
through the model simultaneously, as opposed to
one individual at a time. The model was evaluated
for different screening cohorts defined by age,
hypertension status and race/ethnicity separately.
As shown in Figure 1, there were also slight
differences in the assumptions about when
diagnosis would occur in the presence (average of
5 years after onset as opposed to 5.5 years) and
absence of screening (average of 10 years after
onset as opposed to 10.5 years). Hoerger and
colleagues133 also made the assumption that upon
diagnosis individuals would immediately receive
intensive glycaemic control, as defined in the
UKPDS trial,8 as opposed to the conventional
treatment assumed in the CDC model.
Furthermore, all hypertensive individuals that
received a diagnosis of diabetes were assumed to
change from standard treatment for hypertension
to more intensive therapy [target diastolic blood
pressure (DBP) of 80 mmHg as opposed to
90 mmHg].83 The disease progression module of
the model used by Hoerger and colleagues133
differed from that of the CDC model with respect
to added complication pathways for CHD and
stroke. 
The three Markov models all took the perspective
of a single healthcare payer and incorporated
inputs consistent with this perspective. The inputs
included were sensitivity/specificity of screening
tests, costs of the screening tests, transition
probabilities relating to the progression of
diabetes and its complications, diabetes- and non-
diabetes-related mortality risks, utilities and data
relating to the effectiveness of glucose- and
hypertension-controlling treatments. The models
all adopted a lifetime horizon and assessed the
lifetime incidence of diabetes-related
complications, and also life-years and QALYs, for
age- and race-specific cohorts under the different
screening and no-screening scenarios.
The decision tree model developed by Goyder and
Irwig136 was used to assess the short-term harms
and long-term benefits of once-off screening for
people aged between 45 and 60 years. The cohort
was assigned to screening or no screening. Those
assigned to screening were modelled to receive a
single FBG test (using a cut-off giving sensitivity
90%), followed by a gold standard diagnostic test
for those screening positive. A prevalence of
diagnosed diabetes of 4% was assigned to the
cohort based on the findings of a prevalence study
conducted on the Isle of Ely.137 For every prevalent
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FIGURE 1 Screening module summaries (indicates time after onset at which diagnosis is assumed to occur in the presence and
absence of screening for each of the models)
case of diagnosed diabetes, it was assumed that
there would be an undiagnosed case, based on a
meeting of an expert committee on diagnosis and
classification of diabetes. Therefore, the
probability of diabetes being undiagnosed at the
time of screening was estimated to be 50%. The
model assumed that treatment for diabetes and
other cardiovascular risk factors (e.g. hypertension
or hyperlipidaemia) would be implemented upon
diagnosis, thus reducing morbidity and mortality
from microvascular and cardiovascular
complications. The authors made the assumption
that early treatment for cardiovascular risk factors
would only reduce the incidence of cardiovascular
events within the time from screening to the time
clinical diagnoses would occur in the absence of
screening. After the time of clinical diagnosis, it
was assumed that the incidence of cardiovascular
events would be the same regardless of whether or
not early treatment of risk factors was received.
This may be an inappropriate assumption if the
incidence of CVD is a function of the duration
that risk factors have been present. 
Goyder and Irwig136 made two assumptions
regarding the impact that screening would have
on the time from onset at which diagnosis would
occur. First, they assumed that 50% of those who
are undiagnosed in the population would never
receive a clinical diagnosis in the absence of
screening – that is, they would die of mainly
cardiovascular causes before receiving a diagnosis
and before any end-stage microvascular
complications would occur. Hence, screening in
this first group of patients would not result in
gains from reductions in the incidence in
microvascular complications, only gains due to
reductions in CVD risks. This differs somewhat
from the assumptions made in the Markov
models, that all the undiagnosed patients in the
population would receive a diagnosis 10 years
after onset unless they died before this time. If
Goyder and Irwig’s136 assumption is correct, it
may be that the CDC model overestimates the
impact that screening would have on reducing
microvascular complications. It adds weight to the
argument that more benefit can be derived from
screening by treating risk factors for CVD in those
screening positive, rather than from reducing
microvascular complications. However, this
assumes that it is more cost-effective to diagnose
diabetes and then treat risk factors rather than just
treat risk factors in those who have them without
first screening for diabetes. The second
assumption made by Goyder and Irwig136 is that
for the 50% of undiagnosed patients who would
receive a clinical diagnosis in the absence of
screening, this would occur on average 6 years
after onset. This is shorter than the 10/10.5 years
assumed in the other models. The effect is that
screening results in a shorter window of
opportunity (3 years as opposed to 5 years) to
provide extra treatment from which patients can
gain extra benefit (Figure 1). 
Modelling of disease progression
In the three Markov models,131–133 all patients are
assumed to have no complications at onset of
diabetes. In the CDC model, progression of
complications in the early prediagnosis phase is
modelled as a function of the prevalence of
complications observed at clinical diagnosis in
various epidemiological studies.54,91,138 Hoerger
and co-workers133 only state that they made
assumptions about transition probabilities between
disease states in the period before usual clinical
diagnosis based on knowledge that progression is
relatively slow during this phase. After the time
when clinical diagnosis would usually occur,
disease progression is modelled in relation to the
time from normal clinical diagnosis based on the
findings of various epidemiological studies (see
below). Some transition probabilities in the
original CDC model are also adjusted for
race/ethnicity to permit the estimation of cost-
effectiveness of screening in different racial/ethnic
groups. Transition probabilities for race/ethnicity
were adjusted using multipliers derived by
Eastman and colleagues134,135 to reflect the higher
incidence rates of complications observed in
African Americans, American Indians and
Hispanic Americans. In the analysis by Hoerger
and colleagues,133 the cost-effectiveness of
screening by different racial/ethnic groups was not
explored. Little detail was given on how
progression was modelled before the time of
normal clinical diagnosis in the model by Chen
and Colleagues,132 but the transition probabilities
are reported to vary by time. 
In the models by the CDC and Hoerger and
colleagues, the transition probabilities for
progression of microvascular complications were
also adjusted for glycaemic control – as measured
by HbA1c levels. Initiation of treatment after
screening or clinical diagnosis reduces the HbA1c
level and thus reduces the transition probabilities
for disease progression. Adjustments for HbA1c
levels were made using a power function derived
by Eastman and colleagues.134 As evidence relating
to the benefits of reducing HbA1c in T2DM
patients was lacking at the time of the CDC
analysis, the relative benefits (reduced incidence)
per unit difference in HbA1c levels were derived
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from a trial of treatments in patients with type 1
diabetes.139 Hoerger and colleagues133 updated
this using more recent data on the effects of
intensive glycaemic control on disease progression
in patients enrolled in the UKPDS trial of T2DM.8
This reportedly results in smaller reductions in the
incidence of complications per unit difference in
HbA1c level, compared with the original CDC
model. 
Figure 2 gives an indication of how the HbA1c
levels were modelled over time in the studies by
the CDC131 and Hoerger and colleagues.133 The
figure is based on our own calculations using data
provided in the papers. In the original CDC
model,131 the HbA1c levels were assumed to be
6.8% at onset of diabetes with an annual increase
of 0.2% points resulting in a level of 8.9% at
clinical diagnosis (consistent with data reported in
the UKPDS)140 and 7.8% at diagnosis by screening.
From the authors’ report, it appears that the
HbA1c level was assumed to drop by 2.1% points
on initiation of treatment and then increase slowly
again by 0.156% points per year – again based on
an earlier report of the UKPDS.141 The HbA1c
levels were not allowed to go above 11% or below
6% with treatment. Patients were modelled to
receive one of four treatment modalities: diet and
exercise, oral hypoglycaemic agents, oral
hypoglycaemic agents with insulin or insulin alone.
The proportion using each treatment modality
varied by duration of diabetes, but exactly how
each treatment affected HbA1c levels and how
HbA1c levels were used to adjust transition
probabilities for disease progression were unclear
from the report. 
In the updated model by Hoerger and
colleagues,133 the same approach was used to
model the HbA1c levels, except that more intensive
treatment upon diagnosis resulted in a greater fall
of 2.9% points in HbA1c levels.
8 In addition, after
the initiation of treatment in the model by
Hoerger and colleagues,133 the HbA1c level is
increased by 0.2% points per year (as opposed to
0.156% points) but is never allowed to rise above
9%. Transition probabilities for the development
of CHD and stroke were also adjusted for the
presence of hypertension and intensity of
hypertensive treatment in the model by Hoerger
and colleagues (see below). 
It was not possible to ascertain the approach used
to model the beneficial effects of implementing
treatment early in the model by Chen and
colleagues.132 The authors only stated that
treatment efficacy parameters were based on those
used in Eastman and colleagues’ model and
findings from the UKPDS. 
Goyder and Irwig136 populated their decision tree
model with probabilities derived from literature
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FIGURE 2 HbA1c levels over time for the screening and no screening strategies in the models by the CDC
131 and Hoerger and
colleagues133
sources and various assumptions. Although little
information was given in the published journal
paper as to how these probabilities were derived, a
technical report was obtained from the authors
providing more detail. The shorter duration of
undiagnosed diabetes (6 years) used in the model
was estimated by dividing estimates of the
prevalence of undiagnosed diabetes (cases per
1000 individuals) by the incidence (cases per 1000
per year) as estimated from various population
surveys.142–145 However, the authors point out that
the incidence estimates were based on clinically
diagnosed cases, which will not accurately reflect
the true incidence of diabetes, since many cases
will never receive a clinical diagnosis. In order to
reflect the uncertainty surrounding this parameter,
the authors examined the impact of a wide range
of estimates in sensitivity analysis. 
In terms of the risks of microvascular complications,
Goyder and Irwig136 assumed a lifetime risk of
13% for any complication in intensively treated,
clinically diagnosed individuals. This was taken
from Eastman and colleagues’ model134 based on
the results from the DCCT trial of treatment in
type 1 diabetes. This may be inappropriate given
more recent findings that suggest intensive
glycaemic control is less effective in reducing the
lifetime risks of complications in T2DM as it is in
type 1 diabetes.8 The authors assumed that the
effectiveness of early treatment to reduce HbA1c
would be 50% relative to the effectiveness of
treatment later in the disease course. They also
assumed that the maximum effect of treatment in
the early post-screening phase (before clinical
diagnosis) would be to postpone microvascular
complications by 3 years (the assumed length of
the early treatment window). However, since it was
assumed that treatment during this early period
would only be half as effective as treatment around
the time complications develop, avoidable
microvascular complications were assumed to be
postponed by 1.5 years with early treatment. 
For cardiovascular complications, Goyder and
Irwig136 assumed that the risk of CVD in
undiagnosed and diagnosed cases would be the
same. In the base case this was assumed to be 2%
per year. This was varied in sensitivity analysis to
assess the impact that screening might have in
groups at higher risk of CVD. It was assumed that
an RR reduction of 33% could be achieved during
the early treatment period by implementing
tighter treatment for hypertension and or
hyperlipidaemia. This assumption is based on the
findings from several trials showing the
effectiveness of these treatments in clinically
diagnosed patients.146–150 The applicability of
these findings to patients detected by screening is
uncertain. The authors also assumed that the CVD
events avoided as a result of early treatment would
have been survived by 15 years on average and
that the RR of CVD due to early treatment would
last only for the period before clinical diagnosis
would normally be made. After the time of normal
clinical diagnosis, the CVD risk is modelled as
being the same, regardless of whether or not early
treatment had been received. 
In terms of the time horizon of the model, the
authors assumed a mean survival time of 17 years
from the time of clinical diagnosis based on the
model of Eastman and colleagues.134
Implementation of early treatment is assumed to
impact upon morbidity only, and has no effect on
life expectancy in the model. The authors
estimated that the impact of screening and early
treatment on the development of microvascular
complications would occur after 15 years.
Cardiovascular complications avoided due to early
treatment were also assumed to last for 15 years. 
Structure of complication submodels
(Markov models only)
Nephropathy
The three studies using Markov models adopted
the same structure for their nephropathy
submodels. Patients follow a path through a
Markov process with four consecutive states: no
nephropathy, microalbuminuria, proteinuria and
end-stage renal disease (ESRD). In the CDC
model, Monte Carlo simulation is used to
determine whether patients progress from one
state to the next or not. Hoerger and colleagues133
use a cohort simulation where the whole cohort
progresses at once. The simulation method used
by Chen and colleagues132 is unclear. In the early
preclinical phase, the models by the CDC131 and
Hoerger and colleagues133 use transition
probabilities that yield the prevalence of
complications observed at clinical diagnosis in
several epidemiological studies.54,91,138 It is
unclear in the model by Chen and colleagues132
how transition probabilities were modelled during
this period. After the time of normal clinical
diagnosis (10 years after onset), the CDC model
uses the same transition probabilities for
developing nephropathy complications as those
used by Eastman and colleagues.135 Chen and
colleagues132 also use these same transition
probabilities, although it is not possible to tell if
these have been used appropriately, that is, after
the time clinical diagnosis would normally occur.
Eastman and colleagues134,135 give details in their
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papers on how transition probabilities for
progression to each state in the pathway were
calculated by duration since clinical diagnosis, and
made conditional on the patient being in the
immediately prior state. Transition probabilities
are also adjusted for race, ethnicity and glycaemic
control, as discussed above. 
In Hoerger and colleagues’ updated version of the
model,133 some of the transition probabilities in
the nephropathy module are the same (e.g.
proteinuria to end-stage renal disease), but others
have been changed without explanation. For
example, the transition probability for
microalbuminuria to proteinuria is substantially
lower. The transition probabilities for
microalbuminuria and proteinuria also vary
depending on hypertension status and the
intensity of hypertensive treatment received
(standard before diabetes diagnosis, intensive
after) based on data from the UKPDS.151
Neuropathy
The neuropathy submodel adopted by all three
Markov models again follows the same structure as
that used in the study by Eastman and
colleagues.135 The states included are no
neuropathy, symptomatic neuropathy, history of
lower extremity amputation (LEA) and death from
LEA. An individual with neuropathy can
experience an LEA during any 1-year cycle, from
which they either die (transit to death from LEA)
or survive (transit to history of LEA). Patients with
a history of LEA can also experience a second LEA
from which they can again die or survive.
Transitions between these states, after time when
normal clinical diagnosis would have occurred, are
again based on the transition probabilities
calculated by Eastman and colleagues.134 They
calculated these from data on the incidence of
neuropathy and LEAs reported in the Rochester
Diabetic Neuropathy Study.152–154 The prevalence
of neuropathy at clinical diagnosis was assumed to
be 3.5% based on data from the NHANES II
survey.155 An annual hazard rate was then assigned
which would result in a cumulative incidence at
8 years after diagnosis that was consistent with the
Rochester study.152,153 Transition probabilities for
progression from symptomatic neuropathy to first
LEA were again based on the cumulative incidence
of this event observed in the Rochester study and
made conditional on the presence of neuropathy.
The neuropathy module in the updated study by
Hoerger and colleagues133 is essentially the same
but the transition probability for peripheral
neuropathy is slightly higher as calculated from
data reported in the UKPDS study.151
Hypertension and its control are assumed to have
no effect on the development of neuropathy. 
Retinopathy
The CDC group based their retinopathy submodel
on the model by Eastman and colleagues.134 The
states included are no retinopathy, non-
proliferative retinopathy, proliferative retinopathy,
significant macular oedema and blindness. The
transition probabilities used for these events are
those reported by Eastman and colleagues.135
These were calculated appropriately using data
from the Wisconsin Epidemiologic Study of
Diabetic Retinopathy156 and were again made
dependent on duration of diabetes since clinical
diagnosis. In the model, people who develop
proliferative retinopathy and receive eye
examinations are assumed to be treated with
appropriate photocoagulation, thus reducing their
risk of progression to blindness. However, it is not
clear what the probability of being identified by an
eye examination is. 
The retinopathy submodel used by Chen and
colleagues132 follows the same basic structure as
that of the CDC model, but the transition
probabilities used appear to be different. No
details were provided by Chen and colleagues132
on how these were calculated. 
The retinopathy module in the model by 
Hoerger and colleagues133 differs from the other
two models in that only three states are included.
These are normal, photocoagulation and
blindness. Transition probabilities are updated
with data from the UKPDS trial and also vary
according to hypertension status and treatment. 
Cardiovascular disease
Specific cardiovascular complications of diabetes
are not modelled in the original CDC analysis.
However, cumulative incidence of all CVD and
CVD mortality is modelled. It is not entirely clear
from the paper how this is done, but presumably
the same approach as by Eastman and colleagues
is used.134,135 In the latter model, each person is
assigned CVD risk factors (smoking status and
mean SBP, total cholesterol and HDL cholesterol),
based on their age, race and sex by sampling 
from probability distributions. A previously
published multivariate model based on the
Framingham Heart Study is then used to 
calculate the incidence of all CVD.157 For 
patients who develop ESRD, 50% are assumed to
have CVD based on the observation that 50% of
deaths in patients with diabetes-related ESRD are
due to CVD. The model assumes that glycaemic
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levels have no impact on CVD. This may be an
inappropriate assumption and more recently
published risk equations for CVD in patients with
diabetes include HbA1c levels as a predictor
variable.158
The model by Chen and colleagues132 also 
follows this same structure and makes the same
assumptions about CVD in patients with ESRD. 
The model described by Hoerger and
colleagues133 (see http://www.annals.org/cgi/
content/figsonly/140/9/689 for additional details)
includes a fairly complex submodel for CHD and
stroke. It is based on previous published models of
CHD.159,160 States in the CHD model include
normal, angina, history of CHD/MI and death
from CHD. Within a 1-year cycle, individuals in
the normal state can experience a CHD event,
which could be angina, or a fatal or non-fatal MI
(MI modelled as state). The Framingham risk
equations are used to calculate the probabilities
for these events based on the demographic and
epidemiological characteristics of the cohort 
being analysed.157 Following an initial MI, 
patients can either die within 30 days, in which
case they transit to the state death from CHD, 
or they can survive over 30 days. Patients who
survive over 30 days can either die from chronic
conditions related to MI within the year,
experience a second MI within the year (from
which they have probabilities of dying or
surviving), or continue on with no further events
for the remainder of the year. Those who survive
move to the state history of MI. Patients whose
first CHD event is angina can either survive with
angina for the remainder of the year, or
experience a MI within the year. Those surviving
with angina transit to the angina state, whereas
those who have subsequent MI within the year 
can either survive (transit to history of MI) 
or die within the year (death from CHD). In the
subsequent cycle of the model, patients in each 
of the states have further chances of staying 
where they are, experiencing an initial or
subsequent MI, or dying. The probabilities 
for all the events in this model are based on
published multivariate equations, which
incorporate age, various CVD risk factors and
CHD history.157,159,160
The effects on blood pressure control are
modelled as reductions in the risks of CHD events.
The efficacy of intensive hypertension control in
preventing CHD comes from the HOT trial, which
found that relative to standard control, it reduces
the risk of CHD by 51%.83
The stroke module included in the model by
Hoerger and colleagues133 includes three states:
normal, history of stroke and death. Within each
1-year cycle individuals can either stay in the
normal state or experience a stroke from which
they die or transit to having a history of stroke.
Again, no details are provided for how risks of
these events are calculated in the published paper
of the screening model. The technical report
describes how the Framingham equation is used to
calculate the transition probability from normal to
stroke. The other transition probabilities were
calculated appropriately from another published
source.161 In the base-case analysis, it was assumed
that intensive hypertension control has no effect
on the incidence of stroke relative to standard
control, but a 30% RR reduction was explored in
sensitivity analysis, based on the findings of
studies showing such benefits for intensive
hypertension control.151,162
Mortality
Mortality in the CDC screening study is modelled
as a competing risk for each of the major
complications of diabetes. Increased mortality
rates among people with diabetes are attributed to
increased mortality due to CVD, ESRD, LEA and
other causes. A mortality rate is assigned to
individuals in a sequential fashion. If, for example,
a patient undergoes an LEA during the year, the
model will assign that person a mortality rate
based on the anatomical level of amputation. If a
patient does not have an LEA or survives the
operation, the model assigns that person either
the mortality rate for ESRD, if it is present, or a
mortality rate determined from the increased risk
of CVD mortality plus non-CVD morality. Data
sources used for the mortality risks for ESRD and
LEA are given in the report, but no details are
given for any calculations required. The
cardiovascular mortality rate is estimated using
equations from the Framingham Heart Study83 as
a function of age, sex, SBP, total cholesterol level,
HDL levels and left ventricular hypertrophy. It is
not clear how these characteristics are assigned
and modelled over time for individuals in the
cohort, but presumably the same approach as by
Eastman and colleagues is taken whereby patient
characteristics are sampled from probability
distributions. The authors of the CDC model131
also assume that diabetic patients have an
increased risk of non-CDV mortality 2.75 times
that of non-diabetic individuals, which is
presumably used to adjust age- and sex-specific
mortality rates published in life tables. Eastman
and colleagues135 originally introduced this factor
to achieve consistency with a reported 5–10-year
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reduction in life expectancy observed for middle-
aged people with diabetes. 
Chen and colleagues132 provide too little detail in
their paper to ascertain how mortality from
competing causes was modelled.
Hoerger and colleagues133 model mortality from
LEA, ESRD, CHD, stroke and other causes.
Details of how these events were modelled were
provided in the technical report only. Mortality
estimates for CVD/CHD are based on equations
originally published by Weinstein and
colleagues159 and updated by Hunink and
colleagues.160 These equations predict
probabilities of CHD-related deaths based on age,
sex and history of CHD events. It is not clear if
these risks are directly relevant to patients with
diabetes, as diabetic patients may have greater
risks of death following CHD events than non-
diabetic patients. Diabetic patients in the cohort
who experience a stroke, LEA or ESRD also have
a higher mortality risk than patients without these
complications. The death rates for LEA were
obtained from published literature154 and
appropriately transformed for incorporation into
the model. Mortality rates from ESRD are specific
for the cohort’s age, sex and race/ethnicity.
Finally, patients in the cohort can experience
death from other causes from any state in the
model. These rates are taken from life tables and
do not appear to be adjusted in the same way as
in the original CDC study.131
Costs
The costs included in the original CDC model are
those for screening, glucose-controlling treatment
(including drugs, self-monitoring costs, outpatient
visits), costs associated with microvascular
complications, costs associated with CVD and
other routine medical costs not specific to
diabetes. Costs are presented in 1995 US dollars
and are discounted at a rate of 3%. Assumptions
regarding extra resources required for screening
and treatment are described and justified in the
model, and the unit costs used are presented and
referenced. However, it is very difficult to
comment on the appropriateness of these unit
costs given the lack of detail on how they were
calculated. 
Chen and colleagues132 use exactly the same cost
data (1995 US dollars) as used in the CDC
model131 and also discount at a rate of 3%.
However, they do not provide any information on
how treatment regimens are assumed to change
over time. 
In addition to the costs considered in the CDC
model, Hoerger and colleagues133 also include the
costs of standard and intensive hypertension
control for patients with hypertension. Also, the
updated study assumes that intensive glycaemic
control would be implemented upon diagnosis of
diabetes, thus increasing resource use and costs
associated with treatment. Costs in the updated
study are provided in 1997 US dollars and unit
costs are derived from various sources in the
literature. In some cases the sources are the same
as in the original CDC study,131 but in other cases
different sources have been used. It is not clear
why such choices have been made, but a number
of costs in the earlier study were derived from
studies of patients with type 1 diabetes, so the
more recent estimates in the updated model may
be more appropriate. Costs in the updated study
by Hoerger and colleagues133 are also discounted
at 3%. 
Outcomes
The primary outcomes in the CDC model131 were
additional life-years and QALYs measured from
onset of diabetes. Outcomes were discounted at
3%. The scarcity of data available for utility scores
at the time this model was constructed meant that
certain assumptions had to be made. Utility scores
were assumed to be 1 for each year of life lived
without a major end-stage complication. Utility
adjustments were only made for years lived with
blindness (0.69),163 ESRD (0.61)164 and LEA
(0.8).165 No details are given in the paper as to
how these utility scores were calculated, so it is not
possible to comment on their suitability for
estimating QALYs. The assumption was also made
that when a patient develops more than one major
complication, the lower utility score applies. These
assumptions are unrealistic. First, reductions in
utility are likely in the earlier phases of diabetes
and its complications (possibly due to having the
diagnosis or side-effects of treatments), and
second, if two major complications are
experienced, it is not likely that a patient would
value this the same as having only one
complication. The model is therefore likely to
underestimate the quality of life impact of
diabetes. 
Chen and colleagues132 use the same utility
adjustments and discount QALYs at 3%. They do
not provide any detail as to how they deal with
patients who experience multiple complications. 
Hoerger and colleagues133 consider the same
outcomes as the earlier model and use the same
utility values for blindness, LEA and ESRD. They
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also add utility adjustment values for angina
(0.947),135 history of MI (0.880)166 and history of
stroke (0.50).167 QALYs were also discounted at a
rate of 3%. The approach used for adjusting utility
values in patients with multiple complications is
not given in the paper. 
A simplifying assumption of the decision tree
model by Goyder and Irwig136 is that no
distinction is made between different types of
microvascular complications and different types of
macrovascular complications. It assumes that early
intervention reduces the incidence of all of them.
A utility weight for all microvascular complications
was estimated by taking the average of the weights
for blindness, LEA and ESRD as estimated in the
Global Burden of Disease study.168 This was a
weighted average based on the relative prevalence
of these complications as estimated by Eastman
and colleagues.135 For the macrovascular utility
weight the same method was used, taking the
average of weights for angina, acute MI, chronic
heart failure and stroke. For the disutility assumed
to be associated with early diagnosis and
treatment, a value of 0.01 was used. This was taken
from a study assessing the impact of treatment for
hypertension given a lack of direct evidence
relating to the impact of diabetes. Benefits, in
terms of QALY gains, associated with avoidance of
micro- and macrovascular complications, were
discounted at 3%. 
Findings/conclusions
The results for the four studies are as follows (costs
in US dollars).
CDC Diabetes Cost-Effectiveness Group131
The incremental cost-effectiveness ratio (ICER)
reported in the CDC study was $236,449 per life-
year gained (LYG) and $56,649 per QALY for
screening of all adults over 25 years of age.
Screening was found to be more cost-effective in
younger cohorts – $35,768 per LYG ($13,376 per
QALY) for a 25–34-year-old age cohort compared
with $64,878 per LYG ($18,707 per QALY) in
35–44-year-olds and $681,989 per LYG ($116908
per QALY) for those aged 55–64 years. This result
is explained by the fact that the CDC model
assumes that early treatment after screening only
benefits patients by postponing occurrence of
microvascular complications. Screening, therefore,
has little impact on mortality/life expectancy but
does improve quality of life. More favourable
ICERs are observed in younger cohorts because
they have more expected life-years in which to
remain complication free. More favourable ICERs
were also observed in African Americans due to
the increased prevalence of diabetes and increased
risks of developing complications in this group. 
Chen and colleagues132
Compared with control, both the screening
regimens are reported to reduce the incidence of
microvascular complications. The reported
reduction in incidence was particularly high for
ESRD (65%). This is much higher than the
reduction reported in the CDC model (35%),
despite the fact that a very similar modelling
approach was reportedly used. No clear
explanation is given for this anomaly. The ICERs
reported for biennial and 5-yearly screening,
compared with no screening, are $17,883 and
$10,531 per QALY, respectively. Chen and
colleagues132 also found that screening younger
cohorts was more cost-effective than screening
older cohorts. 
Hoerger and colleagues133
The authors found that in cohorts of all ages, the
ICERs were more favourable for screening
targeted to people with hypertension than
universal screening – ICERs ranging from $87,096
per QALY (35-year-old cohort) to $32,106 per
QALY (75-year-old cohort) compared with no
screening. The equivalent ICERs for universal
screening were $126,238 and $48,146 per QALY.
The ICERs for universal screening versus targeted
screening range from $143,839 per QALY 
(35-year-old cohort) to $443,433 per QALY 
(75-year-old cohort). Screening in general
(targeted and universal) was found to be more
cost-effective in older cohorts, a very different
finding to that reported in the CDC study. The
main reason for this is that in the new model,
most of the benefits of screening come from
reducing CHD events with intensive hypertension
control as opposed to reducing microvascular
complications with glycaemic control. Younger
people have lower risk for CHD and so benefit
less. A second reason for the difference is that in
the new model, glycaemic control results in
smaller reductions in the incidence of
microvascular complications. This is based on
more appropriate data from the UKPDS trial,
which was not available at the time of the previous
analysis. 
Goyder and Irwig136
The base-case analysis found that for every 10,000
individuals screened, a net of 10 QALYs would be
gained: four from postponed microvascular
complications and 17 from avoided cardiovascular
complications balanced against a loss of 11 from
early diagnosis due to screening. This seems to be
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consistent with the findings of Hoerger and
colleagues,133 that the main benefits of screening
will be obtained from reducing cardiovascular
events as opposed to microvascular complications. 
Sensitivity analysis
The authors of the CDC study report that the cost-
effectiveness of screening was sensitive to several
parameters including the screening test used, the
sensitivity/specificity of the test and particularly
the length of prediagnosis interval and the
intensity of treatment received after screening
(more intensive treatments increasing the cost per
QALY). This is an important finding since the
standard of care for T2DM patients should now be
intensive treatment in the light of the results from
the UKPDS study. A weakness of the CDC model
is the limited sensitivity analysis carried out. Only
univariate sensitivity analysis was conducted on a
small number of parameters, which does not
adequately characterise the uncertainty inherent in
the modelling approach. 
Chen and colleagues132 reported no sensitivity
analysis. 
Hoerger and colleagues133 provided a much more
thorough sensitivity analysis. In addition to
performing univariate analysis, they performed
probabilistic sensitivity analysis by simultaneously
varying 129 parameters over probability
distributions estimated from published 95% CIs.
However, it is not clear if they took into account
interdependence between parameters. From
univariate sensitivity analysis, it was found that the
cost-effectiveness of targeted screening was
moderately sensitive to the duration of the
prediagnosis phase, and highly sensitive to the
intensity of glycaemic treatment individuals
receive after diagnosis (ICERs halved if
conventional treatment was assumed). It is not
entirely clear why this assumption had such a
great effect on the ICER. Results were also very
sensitive to the risk reduction associated with
intensive hypertension control. This is an
important finding given that the reduction used in
the model was taken from a single trial and that
adherence to drugs may be lower in general
populations. Based on 1000 iterations of second-
order Monte Carlo simulation, the median ICER
for targeted screening of 55-year-olds was $34,229
(95% of ICERs falling between $21,594 and
$76,099 per QALY). 
Goyder and Irwig136 conducted one-way sensitivity
analysis on most of the parameters included in
their model and found that with all else remaining
constant (at baseline values), the benefits of
screening would no longer outweigh the harms if
the annual risk of CVD fell below 0.8%, the RR of
CVD could not be reduced by 13% or more with
early treatment, the disutility of early diagnosis is
more than 2% or the annual discount rate applied
to QALY gains was greater than 7%. From this, the
authors concluded that the decision on who to
screen should be based on the baseline risk of
CVD, the presence of other treatable CVD risk
factors and the disutility that is assigned to
diagnosis. In addition to their main analysis,
Goyder and Irwig used these threshold values to
calculate the interval at which the benefits of
repeat screening would be likely to outweigh the
harms. 
Conclusions of critical appraisals
This section summarises the critical appraisals of
the four modelling studies reviewed in this chapter
in terms of a checklist provided for assessing the
quality of decision analytic models.130
CDC Diabetes Cost-Effectiveness Group131
The authors provide a reasonable overview of the
decision problem and the structure and
assumptions of their model, which are consistent
with the underlying theory of diabetes disease
progression. However, there is a lack of
transparency regarding the details of how specific
components of the model work. For example, it is
not clear how mortality risks are calculated or how
the glycaemic levels are used to adjust the
progression of complications. 
Another problem is a lack of transparency
regarding the data incorporation process.
Although sources are generally referenced well,
values used in the model are not presented in
many cases and it is not always clear how/whether
data from original epidemiological, clinical or
costing studies have been synthesised for
incorporation into the model. The generalisability
of US cost data to the UK is also questionable,
especially since it is unclear how costs were
calculated. The limited sensitivity analysis is also a
weakness, making it difficult to express confidence
in the results presented. 
Although there is no evidence presented that
directly assessed the internal and external
consistency of the model, the model does not
produce any counterintuitive results and certain
components of the model were calibrated to be
consistent with data reported in epidemiological
studies (e.g. glycaemic levels and mortality). In
summary, due to the study weaknesses mentioned
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above and the exclusion of any benefits in terms of
reduced risk of CVD (as a direct consequence of
glycaemic control or by initiation of treatments
aimed at other CVD risk factors), the conclusions
of this model cannot be taken as authoritative.
The model is somewhat outdated by the more up-
to-date analysis which incorporates more recent
and relevant data. 
Chen and colleagues132
The model clearly outlines the decision problem
of whether mass screening should be introduced,
how often it should take place and who should be
screened. The objectives of the model are also
clearly laid out. However, the main problem with
this model is the lack of transparency in the paper
reporting it. Many assumptions have not been
made explicit, making it impossible to ascertain
the appropriateness of the results. In general, 
the structure is the same as in the original CDC
model, but there are differences in the screening
component with regard to repeat screening. It is
unclear if the authors have used the same
assumptions regarding the time after onset that
clinical diagnosis occurs in the absence of
screening. It is also unclear whether they have
considered the impact that screening would have
on prevalent undiagnosed cases already present in
the population or only considered its impact on
incident cases in a cohort, which starts with no
diabetes. 
The data incorporation process is not recorded in
sufficient detail, with no information on the
calculation of transition probabilities, although
many of these were taken directly from a previous
model. Another weakness is the fact that no
sensitivity analysis was conducted, which is
particularly important given that assumptions
about the uptake for screening and adherence to
subsequent treatment are likely to impact upon
the cost-effectiveness of mass screening for the
whole population. 
The model also appears to deliver some surprising
results, which seem inconsistent with the CDC
model, despite the apparent similarities between
the two models. First, the model predicts a
proportionally much larger reduction in the
incidence of ESRD. Second, the ICERs reported
for mass repeat screening are substantially lower
than those reported by the CDC for once-off
opportunistic screening. The opposite might be
expected if one considers that the cost of mass
repeat screening is likely to be much higher, and
might not detect very many more cases.
Furthermore, with repeated screening, the cost per
case detected is likely to increase with time, as
there will be fewer undiagnosed cases in the
population. Without knowing what the
assumptions were regarding the prevalence of
undiagnosed diabetes in the cohort, the costs of
implementing mass screening and the uptake for
it, it is impossible to tell if these findings are
credible. With regard to the finding that mass
screening was more cost-effective in younger
cohorts, the same criticisms that applied to the
CDC model also apply here. 
Hoerger and colleagues133
This analysis is more comprehensive than the
original CDC model due to the inclusion of
submodels for CHD and stroke and the
incorporation of benefits accruing from tight
blood pressure control. However, there is a lack of
justification given for excluding other potentially
cost-effective screening strategies from the
analysis. For example, screening for diabetes could
be targeted at other high/higher risk groups using
risk scores that take into account obesity, smoking
status, cholesterol level, etc. Screening could be
potentially more cost-effective in such groups who
have a higher risk for diabetes and CVD than
people who have hypertension alone. The cost-
effectiveness of repeated screening or organised
mass screening have not been explored either. In
addition, the assumption in the screening module
seems to be that implementing opportunistic
screening will result in 100% of those eligible for it
being offered it, and 100% agreeing to uptake,
which may be unrealistic. However, people already
attending their GP for other reasons are likely to
be a fairly accessible population.
Access to a technical report on the model
provided a better understanding of the finer
detail. There is more transparency regarding the
data incorporation process in this analysis, with
point estimates, distributions and sources being
presented in tables. However, there was little detail
given in the published paper about how certain
parameters were derived from the literature. The
technical report gave a better account of the
derivation of model parameters. However, some of
the parameters used in the screening model
appear to be different to those published in the
technical report, so it is still unclear how some
parameter values used in the model were derived.
A further advantage of the updated model is the
incorporation of many parameter values as
distributions, which appear to have been
appropriately estimated from published 95% CIs
where available. This allowed second-order
probabilistic sensitivity analysis to be conducted,
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giving a better indication of the uncertainty
surrounding the cost-effectiveness estimate. 
In terms of internal consistency, the model
appears to work in a predictable manner but does
produce one slightly counterintuitive result. There
is no clear explanation as to why the ICER for
screening is so much lower when conventional
glucose-controlling treatment, as opposed to
intensive treatment, is assumed. However, this is
consistent with the findings of sensitivity analysis
reported in the original CDC model. The results
that do differ from the previous version of the
model are adequately explained in terms of the
inclusion of benefits relating to the intensive
treatment of blood pressure. So, given the findings
from the model, the authors conclude that
screening of people with hypertension between the
ages of 55 and 75 years is likely to be a more
efficient strategy than universal screening. This
conclusion seems reasonably valid given the data
presented in the model. However, the conclusion
is based on an assumption that intensive
hypertension control provides as much added
benefit to people with preclinical diabetes as it
does to people with clinical diabetes. There is also
the same problem of the generalisability of US
cost data to the UK. 
Goyder and Irwig136
The authors of this model use a simpler model
structure than the other analyses. This means that
more simplifying assumptions were required and
these are not transparent and appropriately
justified in all cases. For example, the basis for the
assumption that 50% of undiagnosed cases will
never be clinically diagnosed in the absence of
screening is not clear. Furthermore, it is not clear
how long this group would be expected to live in
the absence of screening. It is difficult to assess the
appropriateness of some of the assumptions given
this lack of transparency and justification.
For parameters based on evidence from the
literature, details of sources and calculations
required for incorporation in the model were
provided in the technical report. Appropriate
methods appear to have been used to identify
sources and the data sources used are perhaps
more applicable to the UK setting than those used
in the other models. However, the prevalence
estimates are based on a sample that is not
representative of the UK population as a whole.
Another problem is that where numerous data
sources exist for one parameter, the choice of
estimate used in the model is not always justified.
Although the impact of using a full range of
plausible values has been considered for most
parameters, only one-way sensitivity analysis was
used. 
In terms of consistency, there is no evidence that
the authors have tested the model prior to
conducting their analysis. In general, the decision
tree approach used by Goyder and Irwig136
provides a less comprehensive and realistic way of
modelling the impact of diabetes screening than
the model by Hoerger and colleagues. Given the
larger number of simplifying assumptions, it is
difficult to assess the validity of the results.
However, it is based on data that are perhaps more
relevant to the UK setting and it does produce
findings that are broadly consistent with the
findings of Hoerger and colleagues. 
Summary and recommendations
Of the four studies reviewed in this chapter, the
model of Hoerger and colleagues is the strongest
and most comprehensive. However, it is difficult to
assess the applicability of the results to the UK
setting given that the model was designed to
reflect the epidemiology of, and the resource use
patterns for, diabetes in the USA. There are
various reasons why the cost estimates used for
long-term complications in Hoerger and
colleagues’ model may not apply to the UK. First,
the treatment protocols for various complications
of diabetes may differ in the UK (i.e. be less or
more resource intensive). Second, the methods
used to estimate the costs to attach to resources
used may be based on inappropriate methods for
transferral to the UK setting (i.e. user charges).
Third, different price structures exist in the USA
compared with the UK. Although Hoerger and
colleagues conducted probabilistic sensitivity
analysis and showed that their findings were fairly
robust to simultaneous variation in 192
parameters (including all cost parameters), a
definitive conclusion on whether or not screening
for diabetes would be cost-effective in the UK is
not possible from this review. On the other hand,
the conclusion that selective screening is likely to
be more cost-effective than universal screening is
likely to be applicable to the UK. However, exactly
how screening should be targeted is still unclear,
as the model by Hoerger and colleagues only
considered one targeted screening strategy. It
would be possible to target treatment at
individuals with cardiovascular risk factors other
than hypertension (e.g. obese patients or those
with elevated lipids). 
Given the shortcomings of the models included in
this review and the difficulties surrounding the
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generalisability of the results, it would be advisable
to conduct a new modelling study to assess the
cost-effectiveness of screening in the UK setting
before drawing any conclusions on cost-
effectiveness. This analysis should include all
possible screening options and in particular should
look at the cost-effectiveness of screening targeted
at other groups at high risk of CVD (not just
hypertensive patients). Modelling such strategies
will require some assumptions about the added
benefit of providing a diabetes diagnosis on top of
the other known cardiovascular risk factors. If it is
assumed that diabetes diagnosis would result in
better treatment, or better adherence to treatment
for other CVD risk factors present (e.g. obesity or
hyperlipidaemia), then targeted screening could
potentially be cost-effective in these groups. On
the other hand, the question remains as to
whether or not it would be more cost-effective to
try and improve treatment for CVD risk factors in
all patients who have them, without screening for
diabetes. Thus a relevant comparator in models of
targeted diabetes screening could be no screening
but improved treatment of all CVD risk factors in
those who have them. 
Another potential screening option that has not
been included in any of the screening models to
date is the possibility of widening screening to
identify those with IFG or IGT. Several clinical
studies have demonstrated the effectiveness of
lifestyle interventions or pharmacological
treatments for reducing the incidence of T2DM in
those who are known to have IFG or IGT.89,90
Cost-effectiveness modelling studies have also
been conducted and estimate favourable cost per
QALY and cost per LYG ratios for such
programmes.169–172 These models are reviewed in
detail in the next section. It would be relatively
straightforward to adapt one of the existing
screening models, or another diabetes model, to
estimate the extra costs and the added benefits of
detecting and treating individuals with IGT or IFG.
Such models would require data on the prevalence
of these conditions, the sensitivity/specificity of
tests to detect them and the prevalence of
cardiovascular risk factors in these groups. Finally,
a future analysis could also investigate the effects
of repeat screening as opposed to once-off
screening. 
The main gap in the evidence relating to the 
cost-effectiveness of screening for diabetes is the
uncertainty surrounding the effects of implementing
or improving treatment for hyperglycaemia,
hypertension and hyperlipidaemia in the
preclinical phase of diabetes. 
Economic models assessing the
cost-effectiveness of identifying
and treating people with impaired
glucose tolerance
Background
Several RCTs have demonstrated the effectiveness
of lifestyle interventions or pharmacological
treatments for reducing the incidence of diabetes
over the short to medium term.89,90,169 Thus, a
potential benefit that could be gained from
screening for hyperglycaemia would be to prevent
progression to diabetes in those found to have
IGT or IFG. A within-trial cost-effectiveness
analysis, carried out alongside the largest diabetes
prevention trial to date,170 estimated the cost per
diabetes case prevented and the cost per QALY
gained for the lifestyle and metformin
interventions compared with placebo. The
reported ICERs were $34,500 per case prevented
($99,200 per QALY) for the metformin arm and
$24,400 per case prevented ($51,600 per QALY)
for the lifestyle arm. However, this analysis only
considered the costs of treatment and the benefits
accrued over the 3-year follow-up period of the
trial. It did not consider future IGT treatment
costs, future costs avoided from delaying or
preventing the onset of diabetes or gains in
quantity and/or quality of life associated with the
avoidance of future complications of IGT or
diabetes. This section appraises and discusses the
findings of several modelling studies that have
been carried out to assess the long-term costs and
consequences of preventing or delaying the onset
of diabetes. 
Search results
Five modelling studies were identified by 
literature searches for inclusion in this section.
The characteristics of the five modelling studies
included in this section are summarised in Table 14.
The studies all used modelling approaches broadly
similar to those used in the studies assessing the
long-term costs and health impact of screening for
diabetes. The main difference is that the models
reviewed in this section assessed the progression of
disease from a time prior to the onset of diabetes,
when subjects would have IGT or IFG. Three of
the studies assessed the long-term costs and
benefits that would be expected with the use of
lifestyle or pharmacological interventions for the
prevention of diabetes,171–173 one study considered
lifestyle interventions and surgery174 and one only
assessed the impact that delaying the onset of
diabetes would have175 – without actually
incorporating in the model the interventions that
































TABLE 14 Summary of prevention models reviewed
Study Comparators Model type Economic Complications Benefits of early 
outcomes modelled treatment modelled
Segal et al., 1998174 1. Intensive diet and behaviour modification Markov model Cost per life-year None Reduced mortality due 
(seriously obese individuals with and without (cohort analysis) to prevention of diabetes
IGT)
2. Intensive diet and behaviour modification 
(women with previous gestational diabetes)
3. Surgery for severely obese individuals 
4. Group behavioural modification for overweight 
and obese men 
5. GP advice 
6. Media campaign with community support 
(general population)
Caro et al., 2004173 1. Lifestyle intervention (DPS trial) Markov model Cost per life-year Retinopathy, neuropathy, Reduced mortality due 
2. Metformin intervention (DPP trial) (Monte Carlo nephropathy, foot ulcers, to prevention of diabetes
3. Acarbose intervention (STOP-NIDDM trial) simulation) hypoglycaemia, stroke, 
4. Control (no intervention) transient ischaemic attacks, 
MI and angina (only the costs of 
these events were considered)
Palmer et al., 2004172 1. Lifestyle intervention (DPP trial) Markov model Cost per life-year None Reduced mortality due 
2. Metformin intervention (DPP trial) to prevention of diabetes
3. Placebo (DPP trial)
Herman et al., 2005171 1. Lifestyle intervention (DPP trial) Markov model Cost per QALY Retinopathy, nephropathy, Reduced mortality due 
2. Metformin intervention (DPP trial) (cohort analysis) neuropathy, CHD (angina and to prevention of diabetes 
3. Placebo (DPP trial) CA/MI), stroke and QALY gains from
reduced diabetes
complications
McEwan et al., 2005175 No interventions but four delay scenarios Semi-Markov Cost per QALY Retinopathy, nephropathy, Reduced mortality due 
assessed: microsimulation neuropathy, MI and stroke to prevention of diabetes 
1. no delay model and QALY gains from 
2. 2-year delay reduced diabetes 
3. 5-year delay complications
4. 10-year delay 
would be required to do this. The models used in
these studies are discussed in detail below. 
Statement of decision problem
Segal and colleagues174 conducted the first cost-
effectiveness modelling study in the area of diabetes
prevention. They developed their model to assess
the cost-effectiveness of several different types of
diabetes prevention programme relative to a
control. The objective was to ascertain which types
of programme were likely to be most cost-effective.
The interventions considered in the model were
intensive diet and behaviour modification (targeted
at all seriously obese individuals with and without
IGT), intensive diet and behaviour modification
(targeted at women with previous gestational
diabetes), surgery for severely obese individuals
(BMI >40), group behavioural modification for
overweight and obese men (mixed and with IGT
only), GP advice (targeted at high-risk adults) and a
media campaign with community support (general
population). The study did not consider any
pharmacological interventions for the prevention of
diabetes. 
A subsequent modelling study, conducted by Caro
and colleagues,173 assessed the cost-effectiveness of
a lifestyle intervention, a metformin intervention
and an acarbose intervention relative to no
intervention. The lifestyle intervention was based
on that used in the DPS trial.89 This intervention
involved seven dietician visits in the first year and
four visits per year thereafter, in addition to
individualised exercise programmes. For the
acarbose and metformin interventions, it was
assumed that patients would be prescribed the
daily doses reported in various diabetes
preventions trials.89,90,169 An additional analysis
carried out by the authors also assessed the costs
of screening that would be required to identify
people with IGT for treatment. This model
concentrated on the benefits that could be gained
from preventing patients progressing from IGT to
diabetes.
Palmer and colleagues172 used a similar approach
to Caro and colleagues173 to extrapolate the
findings from the DPP trial over the lifetime of
patients. They assessed the long-term costs and
outcomes of the lifestyle and metformin
interventions, as reported in the DPP trial,90
relative to the control arm. The analysis was
conducted separately for an Australian, French,
German, Swiss and UK population/setting. It
should be noted that the lifestyle intervention
used in the DPP trial was more resource intensive
than that used in the DPS trial (see below). The
metformin intervention consisted of a target dose
of 850 mg twice per day and also included
standard advice on diet and exercise. The control
arm of the trial was the same as the metformin
arm but a placebo was given instead of metformin. 
In a more recent study, Herman and colleagues171
also assessed the benefits that could be gained
from preventing progression to diabetes using the
lifestyle and metformin interventions reported in
the DPP trial. They used the same model
(Research Triangle International/CDC diabetes
model) as that used by Hoerger and colleagues133
to assess the cost-effectiveness of screening for
diabetes. However, in this analysis the model was
modified to predict disease progression prior to
the onset of diabetes. 
In the most recent study reviewed here, McEwan
and colleagues175 used their model to assess the
impact that delaying diabetes would have on costs
and outcomes over a 20-year period. The report
was only available as a poster presentation at time
of writing, so limited detail was available regarding
the model’s structure and assumptions. Their
analysis was not an economic evaluation in the
sense it did not assess the cost-effectiveness of
different interventions relative to each other.
However, it did assess the costs, clinical outcomes
and QALYs that would accrue for four different
scenarios relating to the timing of diabetes onset.
The four scenarios were no delay in diabetes onset
(control), a 2-year delay in onset, a 5-year delay in
onset and a 10-year delay in onset.
Cohort information
The characteristics of the cohorts synthesised in
the modelling studies of diabetes prevention
programmes are summarised in Table 15. The
cohorts modelled by Segal and colleagues174
varied for the different types of interventions
modelled, which were targeted at different groups
(see above). The authors did state that a single age
group was assumed for all the different target
populations, but it was unclear what this was. 
Caro and colleagues173 conducted their analysis
for a cohort of 1000 patients with the
characteristics of those enrolled in a recent
randomised trial of interventions to prevent
diabetes, the Study To Prevent Non-insulin
Dependent Diabetes Mellitus (STOP-NIDDM).169
Participants were predominantly Caucasians from
Canada, Germany, Austria, Norway, Denmark,
Sweden, Finland, Israel and Spain, with a mean
age of 54.5 years and a BMI between 25 and
40 kg/m2. All participants had IGT defined as 
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2-hour plasma glucose concentration of 7.8 mmol/l
or greater, and less than 11.1 mmol/l after a 75-g
glucose load. Patients also had to have a fasting
plasma glucose concentration of 5.6–7.7 mmol/l.
For their screening analysis, the authors assumed
that the prevalence of IGT was 11% of the
population based on an epidemiological study
conducted in the USA.176
The cohort modelled by Palmer and colleagues172
was constructed to resemble the study population
of the DPP: 3234 patients over the age of 25 years
with IGT and fasting glucose levels between 5.27
and 6.94 mmol/l.90 The mean age of the cohort
was 50.6 years, the mean body weight 92 kg and
the mean BMI 34 kg/m2; 32% of the cohort were
men and 45% were from minority groups. Hence
the cohort modelled by Palmer and colleagues is
substantially different from that modelled by Caro
and colleagues.173
Herman and associates171 also conducted their
analysis for a cohort based on the characteristics of
patients enrolled in the DPP trial. The
demographic characteristics and modifiable risk
factors of the cohort modelled by McEwan and
colleagues175 were not reported in the available
poster but the model cohort consisted of 1000
patients. 
Model structure, perspective and scope
Segal and colleagues174 used a Markov model,
with cohort analysis, to explore diabetic status and
survival in an intervention and control group for
each programme type they considered. Limited
details were provided in the published paper but it
appears that their model had four main states:
NGT, IGT, diabetes and death. Obesity and weight
loss/gain also seem to have been modelled but
there is no detail provided of how this was done.
Progression between the states was modelled to
occur on 5-yearly cycles over a period of 25 years.
This does not seem an appropriate cycle length
and no explanation or justification was provided
for this choice. However, the cohort was subject to
an annual mortality risk so as to yield an annual
tally of the number of survivors in each group, in
addition to expected life-years. The intervention
group was divided into two streams in the model:
those who would complete/adhere to treatment
and those who would fail to complete/adhere to
treatment. The authors conservatively assumed
that those failing to complete treatment would
experience the same outcomes as the control
group. Beyond the 25-year period for which the
model was run, the remaining life expectancy of
survivors was calculated by adjusting the age-
specific life expectancy of the general population
for diabetic state and whether or not weight loss
had occurred. The assumptions made regarding
the time horizon and continued effectiveness of
treatments, beyond the follow-up periods of the
clinical studies on which effectiveness estimates
were based, were not made clear in the paper by
Segal and colleagues.174 Although not explicitly
stated, the model seems to have been conducted
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TABLE 15 Cohort information used in the published prevention models
Study Cohort demographic Source of cohort Cohort age range No. of patients 
characteristics information (years) in cohort
Segal et al., 1998174 Varied by intervention being Not reported Not reported Not reported
assessed (see text)
Caro et al., 2004173 Predominantly Caucasians Patients enrolled in the 40–70 1000
from Canada, Germany, STOP-NIDDM trial
Austria, Norway, Denmark, 
Sweden, Finland, Israel and 
Spain. Mean age 54.5 years 
and BMI between 25 and 
40 kg/m2
Palmer et al., 2004172 Mean age 50.6 years, mean Patients enrolled in the 25 and older Not reported
body weight 92 kg and mean DPP trial
BMI 34 kg/m2; 32% men and 
45% from minority groups
Herman et al., 2005171 Mean age 50.6 years, mean Patients enrolled in the 25 and older Not reported
body weight 92 kg and mean DPP trial
BMI 34 kg/m2; 32% men and 
45% from minority groups
McEwan et al., 2005175 Not reported Not reported Not reported Not reported
from the perspective of the health service,
including only direct medical costs (apart from the
media campaign programme).
Caro and co-workers173 used Monte Carlo
simulation to evaluate a Markov process with four
main states that simulated patients could move
amongst on an annual basis. The four states were
IGT, NGT, diabetes and death. Individuals in the
cohort began in the IGT state, from where they
could either transit to diabetes or regress back to
NGT. Patients who regressed from IGT back to
NGT could also revert back to IGT again. For
patients who progressed to diabetes, it was
assumed to be irreversible and they were assigned
the corresponding lifetime costs and clinical
outcomes associated with diabetes. The estimated
costs and outcomes associated with diabetes were
based on a previous diabetes model developed by
the authors.177,178 The diabetes submodel
consisted of several Markov processes that were
used to model disease progression on several
complication pathways including retinopathy,
nephropathy, neuropathy and CVD (stroke,
transient ischaemic attacks, MI and angina).
Individuals progressed through the model based
on their starting characteristics (age, sex, HbA1c)
and were tracked until death. All patients who
progressed to diabetes were assumed to be
diagnosed at time of onset, as their BG would be
regularly monitored if they were being treated for
IGT. For the screening analysis, the authors
considered the cost of identifying individuals in a
starting population with undiagnosed IGT. The
prevalence in the population was set at 11% based
on a prevalence survey.176 A once-off screen was
assumed and those testing positive were entered
into the model to commence treatment. This was
compared with a scenario with no screening where
individuals with IGT progressed to diabetes at the
base rate observed in the placebo arm of the
STOP-NIDDM trial. However, assumptions about
the time after diabetes onset when this
undiagnosed group would receive a diagnosis were
not made clear. If these patients were not
diagnosed with IGT, it is unlikely they would
receive a diagnosis of diabetes at onset, as do
those with diagnosed IGT. Therefore, individuals
with undiagnosed IGT might not have their
diabetes treated as early as those progressing to
diabetes from diagnosed IGT. The effect might be
that complications would develop at a higher rate
in this group. It is unclear whether this has been
considered in the model. If not, the model could
underestimate the benefits associated with
screening for IGT. The interventions to prevent
progression to diabetes were modelled to continue
for 5 years and then stop. It is not clear whether
or not this is an appropriate assumption and little
justification is given for it in the paper. The model
followed up individuals in the cohort over a
period of 10 years but if they progressed to the
diabetes module, they accumulated lifetime costs
and outcomes associated with diabetes. It is
unclear why this 10-year period was chosen for
follow-up in the IGT model.
Palmer and co-workers172 also adopted a Markov
model structure to explore the long-term costs and
outcomes that could be expected from the DPP
interventions. Three states, IGT, T2DM and
deceased, were included in the model. Simulated
patients started in the IGT state and progressed to
diabetes at different rates depending on the
treatment received. Transitions between states
were modelled to occur on an annual basis though
it is unclear whether cohort analysis or Monte
Carlo simulation was used to model progression.
State-specific annual mortality rates were applied
to patients with IGT and diabetes. In the first 8
years after transition to diabetes, patients were
simulated to have a mortality risk higher than that
for IGT, but lower than that for clinically
diagnosed diabetes. This period reflects the
estimated preclinical phase of diabetes.54,179 In the
base-case analysis, the DPP interventions were
assumed to continue for only 3 years (the trial
period). Thereafter, patients were simulated to
progress from IGT to diabetes at the baseline rate
and accrue no intervention costs. The model took
the perspective of a single healthcare payer, and
considered the direct medical costs and benefits
(LYGs) over the lifetime of patients. The costs
included were the costs of the DPP interventions,
costs associated with side-effects of the interventions
(gastrointestinal and musculoskeletal), the average
annual costs associated with diabetes and the
average annual costs associated with IGT. 
The study by Herman and colleagues171 used a
modified version of the model used by Hoerger
and colleagues133 to evaluate screening for
diabetes. A prediabetes module was added based
on data from the DPP on disease progression,
costs and quality of life associated with IGT.
Several parameters relating to the progression of
diabetes and the quality of life associated with
diabetes were also updated using recently
published findings. In the prediabetes module
patients were followed from IGT to diabetes or
death, whichever came first. Unlike in the model
by Caro and colleagues,173 patients in this model
could not revert to NGT. Patients were modelled
to receive either the lifestyle, metformin or
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placebo intervention of the DPP trial during the
prediabetes phase. The interventions were
assumed to continue until onset of diabetes or
death. This is perhaps a more realistic assumption
than those of Caro and colleagues.173 and Palmer
and colleagues.172 It was assumed by the authors
that the microvascular and neuropathic
complications would not progress during the
prediabetes phase. However, hypertension and
dyslipidaemia were modelled to progress at the
rates observed in the DPP and patients could
develop CHD and CVD. At onset of diabetes,
patients move to the early diabetes module of the
model, where complications progress slowly for a
period of 10 years (preclinical phase). After the
early preclinical phase, patients enter the normal
diabetes progression module, where progression of
complications occurs at the rate observed in
epidemiological studies of clinically diagnosed
diabetes patients.
McEwan and colleagues175 used a modified
version of their model, which was originally used
to simulate the impact of treatments on the
occurrence of diabetes-related complications in
patients with clinically diagnosed diabetes. 
This model was based on the diabetes model
developed by Eastman and colleagues.134,135
The complications included in the model were
stroke, MI, PVD, peripheral neuropathy,
nephropathy and retinopathy. The model was
modified to assess the impact of delaying diabetes
by allowing CVD events to occur before the onset
of diabetes. It was presumably assumed by the
authors that microvascular complications would
not progress during this period. The study
assessing the impact of delaying diabetes was
conducted from the perspective of the UK NHS
over a 20-year time horizon and assumed the
existing pattern of care for people with diabetes.
The costs that would be incurred in delaying the
onset of diabetes do not appear to have been
included in the model. These would include the
costs of identifying those at risk and treating them
appropriately with lifestyle and/or
pharmacological treatments. Thus, this study does
not address the question of whether or not it
would be cost-effective to screen for IGT and treat
people found to be positive.
Modelling disease progression
Segal and colleagues174 conducted their analysis
before results were available from any of the large
diabetes prevention trials. Therefore, the transition
probabilities between the NGT, IGT and diabetes
states were based on smaller trials and
epidemiological studies. The authors provided very
little information on how transition probabilities
between these states were calculated for each of the
programmes considered. Only one example was
provided in the paper of how transition
probabilities were calculated for the behavioural
modification programme aimed at overweight and
obese men. A Swedish study, of an intensive weight
loss and fitness programme for overweight persons
with IGT, relative to a standard care group, was
used.101 The finding from the Swedish study was
that at 5–6 years’ follow-up, persons in the
intensive intervention group had a significantly
reduced rate of progression to T2DM compared
with the control group (10.6% compared with
21.4%). These figures were used directly as the 
5-yearly probabilities of progressing from IGT to
T2DM in the intervention and control groups of
the model. No detail was provided on the quality
of the study or the precise characteristics of the
participants, so it is unclear if these findings 
would be generalisable to the cohort considered in
the model. Furthermore, it is unclear how
transition probabilities were calculated for the
other possible transitions in the model (IGT to
NGT and NGT to IGT). 
In the model by Caro and colleagues,173 the
baseline risk of developing diabetes, from a state
of IGT, was modelled based on the placebo arm of
the STOP-NIDDM trial.169 Based on the results 
of this trial, the annual probability of progressing
from IGT to diabetes was calculated at 0.063.
Diabetes was defined in the model as two
consecutive positive OGTTs. The annual
probability of transiting from IGT to NGT was
estimated to be 0.162 and back from NGT to IGT
0.163. It is unclear exactly how these estimates
were derived. The impact of interventions was
incorporated in the model as relative
reductions/increases in the risks of transition
between IGT, NGT and diabetes. The RR
reductions were taken from the DPP, DPS and
STOP-NIDDM trials89,90,169 using the results for
Caucasian subgroups where available. The
acarbose, metformin and lifestyle interventions
reduced the probability of transiting from IGT to
diabetes by 36%,169 24%90 and 58%,89 respectively.
In addition to reducing the risk of transiting to
diabetes, acarbose, metformin and lifestyle
interventions were all modelled to increase the
transition from IGT to NGT by 9% and reduce
reversion back to IGT by 7%.169 On transition to
diabetes, the progression of complications was
modelled based on the patient’s HbA1c level 
and other characteristics at time of diagnosis.
However, it is unclear from the paper how these
characteristics were assigned to simulated patients
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and modelled to progress over time. From review
of a previous version of the diabetes model used in
this analysis,177,178 it appears that patient
characteristics were assigned by sampling from
probability distributions. However, there is no
mention in the current analysis of the distributions
used for the IGT cohort. Going by the previous
version of the diabetes model, HbA1c was
modelled to increase by 0.15% points per year
regardless of treatment, but it is unclear what
HbA1c level was assumed at transition to diabetes
from the IGT state. There was also a lack of clarity
regarding assumptions about the standard of care
that individuals would receive for hyperglycaemia
and other CVD risk factors after the onset of
diabetes. Regarding the time horizon and the
continued effectiveness of treatment, the relative
effects of the interventions were modelled to be
the same over their entire course (assumed to be
5 years). However, the underlying risk of
progressing to diabetes was assumed to increase
over time, reaching 20% by 10 years of follow-up. 
The probability of transit from IGT to diabetes in
the model by Palmer and colleagues172 was based
on the rates per 100 patient years reported in the
DPP.90 These were 10.8, 7.8 and 4.8 in the
placebo, metformin and lifestyle groups,
respectively. The authors state that these rates
were converted into annual transition probabilities
using the ratetoprob function in DATA (the software
used for the analysis). The side-effects of the
interventions were modelled using the rates of
adverse events reported in the DPP trial for the
lifestyle, metformin and control group. For
gastrointestinal side-effects the rates were 30.7,
77.8 and 12.9 events per 100 patient years for the
control, metformin and lifestyle interventions,
respectively. The corresponding rates for
musculoskeletal side-effects were 21.1, 20 and 14.1
per 100 patient-years. 
In the analysis by Herman and colleagues,171 the
DPP was used to estimate an annual baseline
hazard of diabetes onset of 10.8%.90 This is higher
than the hazard rate calculated by Caro and
colleagues,173 using data from the STOP-NIDDM
trial.169 The lifestyle and metformin interventions
were modelled to reduce the probability of transit
to diabetes by 58 and 29.9%, respectively.90 In
their analysis, Herman and colleagues171 assumed
that these treatments would continue until the
onset of diabetes, and would continue to be as
effective. Patients were modelled already to have
some complications at diagnosis of IGT –
microalbuminuria (6%), nephropathy (0.4%)
neuropathy (8.5%), hypertension 28%,
dyslipidaemia (45%), history of CVD (1.1%) and
history of MI (2%) – based on the participants in
the DPP at baseline.90 Microvascular complications
and neuropathy were assumed not to progress
during the prediabetes phase, whereas CVD risk
factors and CHD and CVD were allowed to
progress to be consistent with the rates observed
in the DPP. The authors estimated that the
incidence of CHD and CVD in patients with IGT
would be 58 and 56%, respectively, of the rates
observed in patients with diabetes. These
estimates were based on two large epidemiological
studies.180,181 It was assumed that the non-
diabetes-related mortality rate would be the same
for persons with IGT and diabetes. On entry to
the diabetes module, patients in Herman and
colleagues’ model were assumed to have an HbA1c
level of 6.4%, the level observed at diagnosis of
diabetes in patients enrolled in the DPP.90 Patients
were assumed to be treated for diabetes during the
early preclinical phase (estimated to be 10 years)
and their HbA1c levels were modelled to rise at a
rate resulting in the HbA1c level observed at
randomisation in the UKPDS, after the dietary
run-in period (7.1%). Thus the annual rate of
increase in HbA1c was estimated to be 0.07% per
year in the early preclinical phase of diabetes.
During this 10-year period, microvascular and
neuropathic complications were modelled to
progress slowly, to yield the prevalence observed at
randomisation in the UKPDS.8,182,183 Hypertension
and hyperlipidaemia were assumed to progress at
the same rates as observed in the DPP trial.183 The
risks of CHD and stroke were modelled using the
UKPDS risk equations.184,185 These equations
estimate absolute risk of CHD and stroke based on
race, sex, age, smoking status, HbA1c levels, SBP
and lipid ratios. However, they were derived using
data for people diagnosed with clinical diabetes so
it is unclear how appropriate they are for
modelling risk in the period immediately after
onset of diabetes. It is possible that they
overestimate the risk of CVD for patients with
preclinical diabetes. If this is the case, the cost-
effectiveness of delaying the onset of diabetes
might decrease. This was not an assumption that
the authors explicitly tested through sensitivity
analysis. McEwan and colleagues175 made the
same assumptions (see below). After the 10-year
preclinical phase of diabetes, patients were assumed
to receive intensive management of their diabetes,
with changes in treatment and HbA1c levels
modelled to reflect those observed in the UKPDS.8
An initial drop in HbA1c of 2.9% was observed in
the UKPDS, followed by increases of 0.2% per
year. Complications were also modelled to develop
at the rates observed in the UKPDS.8,151,183–185
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The factors that have a direct effect on the events
simulated in the model by McEwan and
colleagues175 include HbA1c, HDL cholesterol,
total cholesterol, SBP, race or ethnicity, age,
gender and tobacco use. The modifiable risk
factors were also programmed to increase/decrease
over the simulation period, depending on
treatments received. However, the assumptions
and methods used to model change over time
were not described in the available poster.
Originally the model used the UKPDS risk
equations to estimate the risk of stroke185 and
CHD184 after onset of diabetes – based on the
characteristics and modifiable risk factors of
simulated diabetes patients. The authors adapted
the model so that they could assess the impact that
delaying diabetes would have on lifetime costs and
outcomes. They did this by incorporating the
Framingham risk equations157 into the model, so
that cardiovascular events could be modelled prior
to the onset of diabetes. This is an appropriate use
of these equations since they were derived for a
non-diabetic population. In order to account for
the increased risk of CVD that would be expected
with the development of metabolic syndrome,
prior to the onset of diabetes, the authors assumed
a linear increase in the risk of CVD over the delay
period – culminating in the risks predicted by the
UKPDS equations184,185 at diabetes onset. The
authors also addressed a methodological
uncertainty in their model by assessing the impact
that a different set of risk equations for CHD and
stroke would have on predicted costs and
outcomes.158 The UKPDS outcomes model is a
further development of the UKPDS risk engine.184
It predicts the occurrence and timing of diabetes
complications and death, and also life expectancy
and quality-adjusted life expectancy. It was unclear
from the available report how progression of
microvascular complications was modelled
(perhaps using the transition probabilities
estimated by Eastman and colleagues134,135) but it
was reported to be consistent between both
versions of the model assessed. 
Diabetes complication submodels
The diabetes complication submodels, of the
prevention models that include them, are very
similar to those used in the diabetes screening
models reviewed in the pervious section.
Therefore, less detailed discussion is given to the
individual complication pathways here. 
The model by Caro and colleagues173 included
complication pathways for retinopathy, neuropathy,
nephropathy, foot ulcers, hypoglycaemia and
macrovascular complications (stroke, transient
ischaemic attacks, MI and angina). Little detail
was provided on the structure and assumptions of
these submodels but the transition probabilities
for the various complications were based on
observed outcomes in various trials and
epidemiological studies.139,141,156 The transition
probabilities for the microvascular complications
were made dependent on HbA1c levels using the
risk gradients observed in the DCCT trial of type 1
diabetes.139 The precise method of adjustment is
not reported, but the problems associated with
applying this risk gradient to patients with T2DM
were discussed in the previous section. Another
possible problem with the complication risks used
in this model is that they are based on studies of
clinically diagnosed patients. It is unclear whether
or not the transition probabilities were
appropriately adjusted to reflect the lower risks
that would be observed in the preclinical phase of
diabetes. The risks of macrovascular complications
were reportedly based on the Framingham
equations,157 but again too little detail is provided
to assess if these have been used appropriately.
The main problem with using the Framingham
equations to estimate CVD risks in people with
diabetes is that the equations only include diabetes
as a dichotomous variable, and the risks for
people with diabetes are based on only 337 people
with diabetes included in the study. More
appropriate CVD risk equations for people with
diabetes are now available, as discussed
above.158,184,185
The model by Palmer and colleagues172 did not
incorporate a diabetes submodel and so the
incidence of complications associated with
diabetes was not assessed. However, the costs of
diabetes and its associated complications were
captured (see below). 
Herman and colleagues171 used exactly the same
diabetes complication submodels as used in their
previous analysis of screening for diabetes.133
However, some were populated with more recent
data from the UKPDS. For example, the
progression of nephropathy was based on data
from the UKPDS 64183 as opposed to data from
the DCCT139 and UKPDS 38.151 The risks of CHD
and stroke were based on the UKPDS 56184 and
60185 as opposed to risk equations developed for
people without diabetes.157,159,160
No details were available regarding the structure
of the complication submodels used by McEwan
and colleagues,175 but they are likely to have been
similar to those used in other models described in
the previous section.
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Mortality
In the study by Segal and colleagues,174 mortality
was modelled by deriving annual age-specific
mortality risks for each of the three states (NGT,
IGT and T2DM). Two sets of mortality risks were
estimated for each intervention programme, one
for people who successfully achieve and maintain
the intervention targets and the other for the
control and those for whom the intervention is
unsuccessful (i.e. do not reach or maintain target
weight). The mortality risks were calculated by
adjusting age/sex-specific mortality rates for the
Australian population with the relative risks
associated with IGT, T2DM and obesity (weight
loss). The relative risks were obtained from
published epidemiological studies.186–190
The mortality risk associated with IGT in the
model by Caro and colleagues173 was obtained by
adjusting age- and sex-dependent mortality
estimates from Canadian life tables. Mortality risks
from the life tables were increased by 45% based
on the findings of an epidemiological study.191
This increased risk was assumed to be lost in
patients that reverted back to NGT. For those who
developed diabetes, mortality was presumably
modelled using the diabetes submodels and
mortality risks appropriate to individual
complications, but no detail was provided on this.
Mortality in the model by Palmer and colleagues172
was modelled in the same way. The average
annual probability of dying with IGT or diabetes
was calculated by adjusting age-, sex- and country-
specific all-cause mortality (taken from appropriate
life tables) with published RRs for all-cause
mortality reported for patients with IGT or diabetes
relative to the normoglycaemic population.191
During the first 8 years after onset of diabetes,
patients were assigned the RR of mortality
reported for people with undiagnosed diabetes in
the NHANES II survey (1.76). After the assumed
8-year preclinical phase, patients were assigned
the RR associated with clinically diagnosed
diabetes (2.26). The RR of mortality for IGT was
estimated to be 1.37. 
Herman and colleagues171 used a more
sophisticated approach to model mortality. Their
approach enabled them to keep track of different
causes of death. In their model, patients could die
from ESRD, LEA, CHD, stroke and other causes.
For patients who developed diabetes, the CVD
mortality risks were modelled using the UKPDS
risk equations.184,185 For the prediabetes submodel,
CVD mortality risks were estimated by applying
RR reductions180,181 to the CVD mortality risks
predicted by the UKPDS risk equations. The
mortality risks associated with LEA and ESRD
were obtained from published epidemiological
studies.154,192
The model of McEwan and colleagues175 uses the
same approach as that of Herman and colleagues
to model the CVD mortality associated with
diabetes. The Framingham equations157 and the
assumptions about increasing risk with metabolic
syndrome (discussed earlier) were presumably
used to predict mortality in the period before
diabetes onset.
Costs
Segal and co-workers174 used descriptions of
programmes reported in the literature to estimate
resource use and then attached unit costs to reflect
the cost of implementing such programmes in an
Australian setting. Costs included in their analysis
were the intervention costs and average annual
diabetes management costs for those that transit
to diabetes. Screening costs were also included for
the programmes targeted at obese and overweight
men with IGT and the GP advice programme.
Potential cost savings from reducing the incidence
of CVD in patients with IGT were not included in
the analysis. Reducing CVD in patients with IGT is
a potential benefit of such programmes, aside
from preventing progression to diabetes. All costs
in the model by Segal and colleagues were
expressed in Australian dollars, but no cost year
was specified. Future costs were reportedly
discounted at 5% per annum.
The costs included in the model by Caro and
colleagues173 were treatment costs for the IGT
interventions, test costs to monitor progression of
hyperglycaemia, screening costs to identify
individuals with IGT and lifetime diabetes
management costs for those who transit to
diabetes. The costs of the pharmacological
interventions were based on the daily doses
reported in the diabetes prevention trials89,90,169
and the unit costs for these drugs in Canada. The
cost of the lifestyle intervention was modelled on
the resource use reported for the lifestyle
intervention used in the DPS trial.90 This included
seven dietician visits in the first year of treatment
and four per year thereafter. Costs of two exercise
classes per week were also incorporated using the
cost of monthly gym membership in Canada. The
cost of an OGTT was based on the test cost and
the estimated physician time and all patients were
assumed to undergo one such test a year, and to
undergo a subsequent OGTT if the first one was
positive. The unit costs for tests were based on
Canadian fee schedules. For those who developed
diabetes, the cost estimates for its management
were based on previously developed cost profiles
for each of the complication pathways considered
in the diabetes submodel.193,194 For each
complication, the average direct cost of managing
such an event from the acute phase until death
was estimated. Costs included in these calculations
included hospitalisation costs, home healthcare
services, outpatient services, nursing home care,
laboratory tests, drugs, emergency room visits and
diagnostic and therapeutic procedures. The main
source of cost data was physician and laboratory
fee schedules. Use of such fees to estimate cost
makes it difficult to assess generalisability. It is also
unclear what cost assumptions, if any, were made
for treatment of uncomplicated diabetes (e.g.
intensive control of hyperglycaemia, treatment of
other CDV risk factors). All costs in the analysis by
Caro and colleagues173 were reported in 2000
Canadian dollars and discounted at a rate of 5%
per annum.
Palmer and co-workers172 estimated the cost of
implementing the DPP interventions in a primary
care setting in Australia, France, Germany,
Switzerland and the UK. However, the costs of
identifying people with IGT through screening did
not appear to have been incorporated in the
model. All costs were reported in 2002 euros, and
only the direct medical costs were considered. The
assumptions were that the lifestyle intervention
would require six review sessions with the GP in
year one, 16 lessons on diet and exercise with a
practice nurse, and monthly reviews with the GP in
subsequent years. The resource use for the
metformin intervention was assumed to include
850 mg of metformin twice per day per patient,
one titration visit with the GP in year one, three
subsequent follow-up visits with the GP in year one
and four follow-up consultations with the GP in
subsequent years. The resource use in the control
arm was assumed to be one annual visit with the
GP for standard advice. It was assumed that
patients who experienced side-effects would have
additional consultations with their GPs and incur
the corresponding costs. Patients who progressed
to diabetes in the model by Palmer and colleagues
incurred an annual cost that reflects the average
annual medical costs for people with diabetes.195
The annual direct medical costs associated with
IGT were taken to be 46% of those for patients
with T2DM. This estimate was based on a single
study that found that medical costs 8 years prior to
diabetes diagnosis, at the time patients would have
IGT, were 46% of the annual costs of a patient with
T2DM.196 In this study, costs increased over the
8 years and peaked at the time of diabetes
diagnosis. Palmer and colleagues172 used these
findings to model annual increases in costs
throughout the preclinical diabetes phase. The
costs of the DPP interventions and diabetes
management in each of the country settings
considered in the model were estimated from a
variety of sources appropriate to the country for
which the analysis was being conducted. Sources
included the Cost of Diabetes in Europe Study
(CODE-2),195 which examined resource use in
people with T2DM using population-based registers
in eight European countries including the UK. 
The costs included in the model by Herman and
colleagues171 were the costs of identifying and
treating individuals with IGT, costs of
complications (hypertension and CVD) associated
with IGT and costs associated with T2DM. The
authors also considered direct patient costs for a
separate analysis adopting a societal perspective.
The costs of identifying people with diabetes were
based on screening a large and diverse population
with OGTTs.170 The direct medical costs of
identifying one person with IGT were calculated
by multiplying the number of OGTTs required to
identify one DPP participant by the unit cost of an
OGTT. The OGTT unit cost was based on
Medicare reimbursement rates. The costs of
interventions were calculated based on the
resources use profiles reported in the DPP trial.
The costs of the metformin intervention included
drug costs, costs of ensuring adherence and costs
of monitoring and treating side-effects.170 The
cost of the lifestyle intervention was based on a
core curriculum consisting of 16 one-on-one
lessons covering diet, exercise and behaviour
modification.170 Monthly individual and group
sessions with case managers followed this. The
future costs of IGT associated complications were
calculated using a multiplicative cost model
developed by the authors. Multipliers were
estimated and applied to the baseline costs of the
DPP interventions to account for the costs
associated with incident hypertension and CVD. A
similar, previously developed, cost model was used
for the diabetes module.197 A multiplicative
prediction model was used to estimate annual
direct medical costs according to demographic
characteristics, diabetes treatment (as per UKPDS
intensive group), cardiovascular risk factors and
microvascular and macrovascular complications.
This a more comprehensive cost model than that
used by Caro and colleagues as it includes the
costs treating CVD associated with IGT. All costs
are presented in 2000 US dollars and are
discounted at a rate of 3%. 
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The only detail available on the costs included in
the model by McEwan and colleagues175 was 
that only direct healthcare costs were considered.
The total costs avoided under each delay 
scenario were presented in 2005 UK pounds. 
As mentioned earlier, the costs that would need 
to be incurred in order to delay the onset of
diabetes do not seem to have been incorporated 
in the model. Costs were discounted at 3.5% 
per annum, the current recommended rate for 
the UK.
Outcomes
In terms of outcomes, Segal and colleagues174
modelled the number of diabetic years avoided
and the LYGs for each intervention programme
compared with its control. Outcomes were
discounted at 5% per annum.
The outcomes considered in the model by Caro
and colleagues173 were the number of cases of
T2DM prevented over a 10-year period, life-years
and years free of diabetes. However, it was unclear
what assumptions were made about life expectancy
in the absence of diabetes in order to calculate
life-years gained by preventing it. Life-years are
reportedly discounted at 5% per annum. 
Palmer and colleagues172 used their model to
estimate the number of years free of diabetes, the
percentage of patients developing diabetes over
their lifetime and life expectancy for each of the
comparators. The ICER of the interventions
versus the control arm was reported as cost per
life-year.
Herman and colleagues171 reported outcomes in
QALYs. The utilities associated with IGT were
based on the Quality of Wellbeing Index (QWBI),
which was administered to patients enrolled on
the DPP trial.170 The utility scores associated with
diabetes were based on another study that used
the QWBI to assess utility in patients with both
type 1 and type 2 diabetes recruited from a
medical centre.198 The authors constructed an
additive health utility model to predict health
utility scores associated with IGT beyond the 
3-year follow-up period of the trial. For each
complication that a patient experienced in the
model, a utility decrement was applied to their
utility score. The decrements were estimated by
fitting a regression model of the QWBI4-derived
health utility scores to indicator variables for
diabetes and each demographic variable, treatment
and complication. The same process was used for
assigning utility scores to diabetes and its
complications. 
McEwan and colleagues’175 model predicted the
absolute number of CHD, stroke, CVD deaths,
retinopathy, nephropathy and neuropathy events
for each delay scenario considered. The model
also predicted the number of QALYs gained for
each delay scenario versus the control. The source
of utility scores for IGT and diabetes was not
provided in the available poster. In addition, the
assumptions used for estimating utility scores for
multiple complications were also not made
explicit. The QALYs were discounted at 3.5% per
annum. 
Findings
The programmes considered by Segal and
colleagues174 were estimated to yield between 43
(GP advice for those with IGT) and 423 (surgery
for seriously obese) life-years per 100 patients
treated. Relative to the control groups, the
incremental cost per LYG varied from
interventions that both increased life expectancy
and led to net savings (intensive diet and
behaviour change for seriously obese with IGT,
group behaviour change intervention for
overweight men and the media campaign) to
$12,300 per life-year (surgery for seriously obese). 
Caro and colleagues173 predicted from their model
that over the 10-year period considered, 70 of the
1000 IGT patients in the cohort would be
expected to die in the absence of treatment and
543 would develop diabetes. Intensive lifestyle
modification was estimated to prevent 117 of these
cases and metformin and acarbose were estimated
to prevent 52 and 74 cases, respectively. The
lifestyle modification intervention was found to be
the most expensive in addition to being the most
effective (ICER $749 per LYG compared with no
treatment). The metformin and acarbose
interventions were found to be cost saving
compared with the no-treatment option. The
ICERs reported for lifestyle modification versus
metformin and acarbose were $7725 and $9988
per life-year, respectively. 
Palmer and colleagues172 estimated that the
lifestyle and metformin interventions would
increase both the number of years free from
diabetes and life expectancy. The mean number of
years free from diabetes was 8.14, 9.94 and 9.02
for the control, lifestyle and metformin group,
respectively. The corresponding improvements in
non-discounted life expectancy for the lifestyle
and metformin interventions were 0.22 and 0.11,
respectively. They also estimated that in many
countries the interventions would be cost saving.
However, for the UK setting they predicted that
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the interventions would lead to small increases in
net costs of €1021 and €378 for the lifestyle and
metformin interventions versus control,
respectively. This translates to a net ICER of
€6381 and €5400 per life-year for the lifestyle and
metformin interventions, respectively, in the UK
setting. 
Herman and colleagues171 found that
approximately 50% of their cohort would be
expected to develop diabetes within 7 years if
treated with placebo. In contrast, they estimated it
would take 18 years for 50% of lifestyle-treated
patients to develop diabetes and 10 years for 50%
of the metformin-treated participants to develop
diabetes. These findings are broadly similar to
those of Caro and colleagues,173 despite the
differences between the models and the
populations for which they were conducted. Over
a lifetime, Herman and colleagues171 estimated
that 83% of participants treated with placebo
would develop diabetes compared with 63% of
those treated with lifestyle intervention and 75%
of those treated with metformin. They also
estimated that the lifestyle intervention would
increase life expectancy by 0.5 years and reduce
the cumulative incidence of blindness by 38%,
ESRD by 38%, LEA by 35%, stroke by 9% and
CHD by 8%. The metformin intervention was
found to increase life expectancy by 0.2 years and
reduce the cumulative incidence of blindness by
16%, ESRD by 17%, LEA by 16%, stroke by 3%
and CHD by 2%. Compared with the placebo
intervention, the lifestyle intervention was found
to cost $635 more over a lifetime and produce a
gain of 0.57 QALYs ($1100 per QALY). The
metformin intervention cost $3922 more over a
lifetime and resulted in a gain of 0.13 QALYs
($31,300 per QALY). The lifestyle intervention
dominated the metformin intervention. 
As mentioned earlier, McEwan and colleagues175
evaluated their model using the original UKPDS
risk equations for CHD and stroke184,185 and also
using the newer equations from the UKPDS
outcomes model.158 Using the original equations,
the no-delay scenario resulted in discounted costs
of £13,076 and 7.6 discounted QALYs over the 
20-year time horizon. The total costs were found
to decrease to £11,291 per subject with a 2-year
delay in diabetes, £9998 with a 5-year delay and
£8395 with a 10-year delay. This translates to
discounted cost savings of £1785, £3078 and
£4681 for the three delay scenarios, respectively. 
It should be noted that the cost savings would
decrease or disappear if the costs required to 
delay diabetes were to be included in the analysis.
The predicted QALYs for the three delay 
scenarios were 8.3 for the 2-year delay, 9.1 for the
5-year delay and 10.1 for the 10-year delay,
representing gains relative to the no-delay
scenario of 0.7, 1.5 and 2.5, respectively. When the
equations from the UKPDS outcomes model158
were used, fewer cardiovascular and microvascular
events were predicted over the 20-year time
period. The cost savings associated with the three
delay scenarios were subsequently less using these
equations. However, the QALY gains were similar
using the equations from the UKPDS outcomes
model. 
Sensitivity analysis
Segal and colleagues174 assessed the sensitivity of
their findings to variations in several model
parameters using one-way sensitivity analysis. The
results were found to be sensitive to the assumed
success rates of the programmes. However, even
when it was assumed that only 20% of patients
would achieve the weight loss/exercise targets for
the behaviour modification programmes, the cost
per life-year stayed within the range considered
favourable.198 This was presumably due to the
avoidance of high costs associated with diabetes
management. 
Caro and colleagues173 conducted one-way
sensitivity analysis on many of the parameters in
their model. They also found that the ICERs of all
the interventions remained in acceptable bounds
relative to no treatment. However, the intervention
of choice changed when effectiveness results were
varied within the upper and lower bounds of their
CIs. For example, at the lower bound of the CI for
the lifestyle intervention, all else remaining
constant, the acarbose intervention would be
dominant. However, no multivariate or
probabilistic sensitivity analysis was conducted to
characterise better the uncertainty in the decision
between the options.
Palmer and colleagues172 conducted their analysis
for different subgroups to characterise the impact
that the heterogeneity in outcomes, observed in
the DPP trial,90 would have on their findings.
They assessed the cost-effectiveness of the
interventions for cohorts of different age and BMI
groups using the findings reported for these
different subgroups in the DPP trial. They found
that the metformin intervention had a better
impact on costs and life expectancy than the
lifestyle intervention in younger more obese
patients but led to less benefit and higher costs
than the lifestyle intervention in the older cohort
(aged 65 years at baseline). In a cohort with a BMI
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<30 kg/m2, the metformin intervention led to
minimal improvements in life expectancy and
increased costs, whereas the lifestyle intervention
had a greater impact on life expectancy and was
cost saving. However, even in this group the ICER
of metformin still remained attractive (€47,200 per
life-year) compared with other interventions for
diabetes.199 In a group with BMI >30 kg/m2, the
metformin intervention led to a greater
improvement in life expectancy and greater cost
savings than the lifestyle intervention. Palmer and
colleagues also conducted extensive one-way
sensitivity analysis on many of the individual cost
and probability parameters included in their
model. They found that the findings were most
sensitive to the probabilities of developing
diabetes, the RRs of mortality associated with IGT
and diabetes, the annual costs of managing
diabetes and the costs of implementing the DPP
interventions. However, they found that when
these parameters were varied within plausible
ranges, the ICERs of the DPP interventions
remained in the range considered cost-effective by
international standards.199 They also showed that
greater improvements would be seen in diabetes-
free years and life expectancy if the DPP
interventions were to continue, and continue to be
effective, for longer than the 3-year follow-up
period of the DPP trial. They also found that the
total lifetime net costs associated with the lifestyle
intervention decreased as the assumed duration of
the effect of the intervention increased. This was
due to the higher number of diabetes cases being
prevented offsetting the costs of ongoing delivery
of the intervention. 
Herman and colleagues171 conducted fairly
extensive univariate and bivariate sensitivity
analysis. First they ran the model for different age
groups and then they assessed the impact of
altering various treatment effectiveness and cost
assumptions. They found that the lifestyle
intervention would be cost saving in participants
younger than 45 years and that metformin would
not be cost-effective in patients aged over 65 years
(>$100,000 per QALY). The authors also reported
that the cost-effectiveness of the interventions
improved if they were modelled as they might be
implemented in routine clinical practice – group
sessions as opposed to one-on-one lessons for the
lifestyle intervention and generic metformin for
those on pharmacological treatment. Even if
effectiveness was assumed to be 50% less than
reported in the DPP trial, they estimated that both
interventions would remain in the cost-effective
range.198 The authors also conducted probabilistic
sensitivity analysis where 81 parameters were
simultaneously varied over probability distributions
for 500 iterations of the model. They found that
95% of the cost per QALY ratios fell between $587
and $9456 for the lifestyle intervention and
between $16,509 and $84,583 for the metformin
intervention. 
Apart from assessing the methodological
uncertainty surrounding the use of different risk
equations in their model, McEwan and
colleagues175 reported no details of any further
sensitivity analysis conducted. 
Conclusions of the critical appraisals
The five modelling studies reviewed in this
chapter were appraised using a quality assessment
checklist for decision analytic models.130 The
results of this process are summarised below.
Of the five models reviewed, four clearly
highlighted the decision problem that they were
addressing, and had objectives consistent with this
problem.171–174 The fifth study, by McEwan and
colleagues,175 was not a decision analytic model in
that it did not consider a choice between
alternative treatment options. In terms of the
structures of the models, most were broadly similar
but some were more comprehensive than others.
Two of the models seemed rather simplistic in that
they did not model individual complications
associated with IGT and diabetes172,174 or did not
incorporate the quality-of-life impacts that these
complications would have.173 The models by
Herman and colleagues171 and McEwan and
colleagues175 are preferred on these grounds. The
model by Segal and colleagues,174 in particular,
seemed over-simplistic, using just one set of 
5-yearly transition probabilities to model
transitions between three states. Furthermore, the
assumptions regarding the probabilities of
transition were not made clear for many of the
interventions considered by Segal and
colleagues.174 There is also a lack of transparency
in the reporting of the model by Caro and
colleagues.173 In this model, some of the
assumptions used to model life expectancy and
LYGs were unclear and not explicitly justified. In
the model by McEwan and colleagues,175 it was
not possible to ascertain the methods used to
model the microvascular complications. This was
because we only had access to a poster
presentation of this modelling study at the time of
writing. The models by Palmer and colleagues172
and Herman and colleagues171 were reported very
transparently, allowing a clearer assessment of
their quality and the appropriateness of the data
they incorporated. 
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In terms of the data incorporation process, none
of the models provided much detail on the
methods used to identify sources for the
parameters included. In addition, the details of
methods used to synthesise data for incorporation
into the models were not provided in many of the
reports. The exceptions were the models by
Herman and colleagues171 and, to a slightly lesser
extent, Palmer and colleagues.172 Herman and
colleagues provided all the details of how model
parameters were estimated in a technical report
published alongside the published paper.133 It was
clear from this report that, as far as possible,
appropriate sources had been used and
incorporated into the model correctly. This is not
to say that there were not some potential problems
with the model as discussed in the previous
sections of this review. Another strength of the
model by Herman and colleagues171 was the
extensive use of sensitivity analysis. A strength of
the model by Palmer and colleagues172 was that
good-quality resource use and cost data were
incorporated, which was more relevant to the UK
setting. Although individual complications were
not included in the model, the costs of treating
these were captured. 
In terms of consistency, most of the models
produced results that made intuitive sense based
on the data that had been incorporated, and they
all produced findings that were broadly consistent
with one another. 
In conclusion, the model by Herman and
colleagues171 was the most comprehensive and
transparent of the models reviewed. The model by
McEwan and colleagues175 was also very
comprehensive but the lack of detail available at
the time of writing made it difficult to assess its
quality and the appropriateness of its assumptions.
The model by Palmer and colleagues,172 although
simple, was presented very transparently and
made assumptions that seemed reasonable in the
light of the decision that the model was designed
to inform. The report on the model by Caro and
colleagues173 lacked transparency and made some
assumptions that were not appropriately justified.
Finally, the model by Segal and colleagues174 was
over-simplistic and lacked transparency. 
Summary and recommendations
The models reviewed all estimated long-term costs
and outcomes associated with the delay or
prevention of diabetes. Four of the studies
modelled the short-term costs and effects of
delivering interventions to prevent/delay the onset
of diabetes, and balanced these additional
treatment costs against expected future health
outcomes and cost savings.171–174 Although these
models were of variable quality, and varied in their
structure and assumptions, all predicted that
diabetes prevention interventions would provide
good value for money. The fifth study included in
the review only assessed the impact that delaying
diabetes would have on future health outcomes
and medical costs.175 However, it also produced
findings that were broadly consistent with those of
the other models – that delaying the onset of
diabetes by even modest periods would
substantially reduce the incidence of vascular
complications (microvascular and cardiovascular),
improve quality of life and avoid future medical
costs. These results certainly seem to suggest that
if a screening programme were implemented for
people at risk of developing diabetes, it would be
a good use of resources to treat those found to
have IGT with lifestyle or pharmacological
interventions. 
Based on the models reviewed, there appears to
be some uncertainty surrounding the preferred
intervention for people identified as having IGT.
First, the characteristics of the cohort seem to have
some bearing on which option is to be preferred,172
and second, the relative effectiveness of the
alternative treatments in routine clinical practice
may also prove important. The evidence from the
diabetes prevention trials and above modelling
studies suggests that lifestyle interventions are
likely to be the best option for most people with
IGT. However, for select groups a pharmacological
treatment might be preferred.172 Furthermore, if
lifestyle interventions prove very difficult to
implement effectively in routine clinical practice,
and pharmacological treatments are well accepted,
then these might prove the better option or be
used in combination with lifestyle change. Another
point worth mentioning is that lifestyle
interventions could have substantial impacts on
other CVD risk factors such as obesity, blood
pressure and lipid ratios. It is not entirely clear if
these potential benefits have been captured in the
models reviewed here. If not, they could
underestimate the benefits of the lifestyle
interventions. 
Some of the models reviewed also included the
costs that would be incurred in identifying people
with IGT (screening costs).171,173,174 Even when
these costs were included, the reported ICERs
remained favourable. However, none of the
models appeared to compare directly an IGT
screening and treatment scenario with a no-
screening scenario. Although the model by
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Herman and colleagues171 included costs of
identifying patients for treatment, the control arm
in the model also assumed that patients would be
identified as having IGT. Therefore, patients in
the control arm also received intensive treatment
for diabetes upon onset. If no screening
programme were in place to identify patients with
IGT, then they would not receive a diagnosis of
diabetes at onset, and would not receive treatment
until they were clinically diagnosed. In this
absence of screening, individuals progressing from
IGT to diabetes would probably develop diabetic
complications at a higher rate than those
progressing to diabetes after having been
diagnosed with IGT. Hence, if screening followed
by treatment for IGT were to be compared with a
no-screening scenario, then the cost-effectiveness
estimates might be more favourable than those
reported in the studies reviewed here. However,
there remains a question over who to screen that
needs further clarification. 
The prevalence of IGT will be highest in groups
who have other CVD risk factors. As the previous
section of the review concluded, screening for
diabetes is more likely to be cost-effective in these
groups. The question is, with the cost-effectiveness
of treating IGT having been demonstrated, should
the target population for screening be wider than
it would otherwise be if it were only those with
undiagnosed diabetes who would benefit? This
question requires a more thorough exploration of
the cost-effectiveness of different screening
strategies, where the benefits of treating those
identified with both IGT and undiagnosed
diabetes are incorporated. 
In conclusion, several modelling studies all
predicted favourable ICERs for the identification
and treatment of people with IGT. Two of the
studies in particular were transparently presented,
allowing a thorough assessment of quality. Both of
these studies appeared to use appropriate data
and assumptions and used fairly extensive
sensitivity analysis to characterise uncertainty.
Both studies reported consistent findings and one
was conducted from the UK NHS perspective.
Based on the findings of these two studies, lifestyle
interventions similar to those reported in the DPP
trial90 would appear to be the best option for
treating people identified with IGT. Their cost-
effectiveness of the metformin intervention
appears less certain, although there may be
particular groups for whom this intervention
would be the preferred option. Based on the
available evidence, it seems reasonable to conclude
that screening and treating people for IGT would
be cost-effective in the UK setting. However,
before proceeding with such a programme, the
question of who to screen requires further
consideration. A modelling approach could be
used to assess the relative cost-effectiveness of
screening targeted at different populations. 
Studies assessing the costs and
short-term outcomes of diabetes
screening tests
Background
If a decision is made to implement a screening
programme for diabetes or IGT/IFG, then there
remains a question of what screening tests and 
cut-off points to use. One way to help inform this
decision is to consider the costs of alternative test
strategies and the associated outcomes in terms of
the numbers of true cases that would be detected,
and also the numbers of false positives, false
negatives and true negatives. In this section,
studies that have assessed these costs and
outcomes for different tests and test cut-off points
are reviewed.200
Search results
The searches identified five studies for inclusion in
this section of the review201–205 These studies are
summarised in Table 16 and discussed in detail
below.
The studies
Shirasaya and colleagues203 conducted an economic
evaluation alongside a study to establish the efficacy
of alternative screening tests for IGT and T2DM.
They established the sensitivity and specificity of
three indicators, which do not require fasting
beforehand, in order to identify the best option
for screening in situations where fasting tests are
not practical. The three indicators compared were
1,5-anhydroglucitol (1,5-AG), glycosylated
haemoglobin (HbA1c) and fructosamine (FRA).
The sensitivity and specificity of the three
indicators were assessed on a sample of 891 men
who had been assigned diabetes status according to
WHO criteria. The optimum cut-off point for each
of the indicators was established by plotting receiver
operating characteristic curves and then
determining the point on the curve that was closest
to the point where sensitivity was 100% and the
false-positive rate 0. The optimum cut-off points for
the three indicators were calculated for detecting
diabetes only and also diabetes and IGT together. 
An economic evolution was then conducted using
the sensitivities and specificities at the optimum
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cut-off points for the three test indicators. The
authors adopted a healthcare payer perspective
and developed a model to estimate the cost-
effectiveness of screening with the three indicators
for a hypothetical cohort of 1000 men with a given
prevalence of undiagnosed diabetes and IGT. The
numbers of true positives, true negatives, false
positives and false negatives were estimated based
on the previously calculated sensitivities and
specificities. For those who screened positive using
each of the indicators, an OGTT was assumed to
follow. Those who screened negative (false and
true negatives) were assumed to undergo the same
screening test in subsequent years (annual
screening assumed) and the model was run until
more than 99% of diabetes cases in the cohort
would be identified. The cost per case detected for
each of the indicators was established for IGT and
diabetes together, and for diabetes alone. For the
analysis using the optimum cut-offs for IGT and
diabetes together, the authors also calculated the
number of cases of IGT detected that would
progress to diabetes (over a 10-year period) to give
the prospective number of diabetes cases that
would be detected. The prospective and present
cases were added together to give the total
number of diabetes cases that would be identified
through each screening alternative. 
The costs included in the analysis were the costs of
each of the screening tests and the costs of the
OGTT for those screening positive. Those who
screened negative were assumed to incur the same
test costs in subsequent years. In the case of false
negatives, individuals were assumed to incur the
screening test costs in subsequent years until they
screened positive, in which case they would also
incur the cost of an OGTT that year. The future
costs were discounted at 5% per annum. 
The results of the study were that, out of the three
indicators, HbA1c and 1,5-AG resulted in the
highest number of diabetes cases identified.
However, when the optimum cut-off points for
IGT and diabetes were used, 1,5-AG identified the
highest number of cases – closely followed by FRA.
The authors concluded that in Japan, FRA would
be the most cost-effective strategy for screening
when fasting was not practical due to the low cost
of the test. However, the study findings were not
clearly presented, making it very difficult to
ascertain the validity of this conclusion. Moreover,
the results would depend on several assumptions.
For example, one assumption was that testing
would be conducted on an annual basis and 
so the negative consequences/costs of false
negatives would be minimised. In addition, the
costs and number of cases that would be detected,
at the different cut-off points for the different
tests, were not presented. The authors did report
some sensitivity analysis and reported that the
choice between indicators depended on the costs
of the tests and the cut-off points chosen, but
again these analyses were poorly reported.
Moreover, other important parameters such as the
screening interval were not addressed in sensitivity
analysis. Given the lack of transparency in the
reporting of this study, it is impossible to comment
on the applicability of the findings to the UK
setting. 
In another similar study, Johnson and colleagues202
set out to assess the efficacy and cost of several
different strategies for identifying diabetes that
would not require fasting. They carried out their
analysis for the US population aged between 45
and 74 years, estimating that 72.6 million people
would be eligible for screening. The prevalence of
undiagnosed diabetes and IGT in the population
was estimated to be 10 and 22%, respectively, at
baseline. Johnson and colleagues202 estimated the
number of true positives, false positives and false
negatives that would be obtained using three
different cut-off points (100, 130 and
160 mg/dl) on a random plasma glucose (RPG)
test, at 1-, 3- and 5-yearly intervals over a period
of 15 years. In addition they also assessed the
screening performance of a multivariate logistic
equation, which incorporated RPG level,
postprandial time, age, sex and BMI. The
sensitivity and specificity of the different cut-offs,
and the logistic equation, were calculated by
applying them to a large dataset, which had all the
appropriate information, including results of
OGTTs performed on consecutive days (gold
standard for diagnosis of diabetes). The total
direct medical costs and patient costs associated
with each strategy were calculated. 
Johnson and colleagues202 found that for each
incremental improvement in sensitivity, using cut-
offs below 130 mg/dl, there were substantial
reductions in specificity. The multivariate equation
was also shown to be more sensitive than RPG
alone at any given level of specificity and vice
versa. The absolute difference in the number of
true positive screening tests between the most
sensitive (RPG 100 mg/dl every year) and least
sensitive strategy (160 mg/dl every 5 years) was
4.5 million over the 15 years. The absolute
difference in the number of false positives between
the most sensitive and least sensitive strategy was
476 million. Hence cut-off points with a higher
specificity were found to decrease minimally the
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number of true-positive screening tests but to
decrease substantially the number of false-positive
tests. Based on these efficacy findings, the authors
concluded that an RPG cut-off point of 130 mg/dl,
or the multivariate equation, applied every 3 years
would be the optimal screening strategy. It was not
entirely clear what criteria the authors used to
arrive at this conclusion. The costs of each of the
strategies were estimated by assessing the direct
medical and patient costs associated with each
strategy. It was estimated that 54.4 million of the
eligible population would seek routine medical
care within any given year, and would therefore be
eligible for opportunistic screening. For this
group, the only direct medical costs were the costs
of the screening test and, when necessary, a
diagnostic test. The remaining population were
assumed to incur the cost of an arranged
outpatient visit, in addition to the test costs. Based
on the baseline prevalence of undiagnosed
diabetes, the prevalence of IGT, an estimated rate
of progression from IGT to diabetes, and the
number of cases detected at each screening
examination, the authors calculated the prevalence
of undiagnosed diabetes in the population for
each screening examination following baseline.
The costs of the different screening strategies were
estimated to vary from US$6.9 to 42.7 billion. A
weakness was that no cost year and no discounting
of future costs were reported. The strategies that
the authors declared optimal based on sensitivity
and specificity data (RPG cut-off point of 
130 mg/dl and the multivariate equation applied
every 3 years) cost US$11.1 and 9.7 billion,
respectively. This translates into $642 and $563
per true positive, respectively. However, it should
be noted that this was not an economic evaluation
designed to identify the most cost-effective
screening strategy. It is not possible to answer that
question without considering the longer term costs
and consequences associated with false negatives
relative to the costs and consequences of true and
false positives. The costs and consequences of false
negatives will depend on the length of the
screening interval, the uptake of screening at
subsequent recalls and the rate of development of
diabetes-related complications in undiagnosed
individuals (relative to those who are diagnosed
and treated). 
Another study, conducted by Icks and colleagues,201
compared several once-off screening strategies in
terms of cost per case of undiagnosed diabetes
detected. A simple decision analytic model was
developed to compare four different strategies
over a time horizon of 1 year. The strategies
considered were a single FPG test (using a cut-off
of 7 mmol/l), an FPG test followed by an OGTT
for those with FPG 6.1 and <7.0 mmol/l
(diabetes assumed if FPG 7.0 or OGTT
11.1 mmol/l), an OGTT alone (11.1 mmol/l)
and an HbA1c test followed by an OGTT for those
with an HbA1c level >5.6%. For each of these four
strategies, two different models for their delivery
were also assessed – screening of everyone in the
population and screening targeted at those at
increased risk (as defined by various risk factors
for diabetes). 
The authors estimated the total cost and the
number of cases that would be detected for each
of the strategies. The characteristics of patients,
the prevalence of the various levels of
hyperglycaemia (defined by each of the indicators)
and the sensitivities/specificities of the various tests
were estimated from a population prevalence
survey of inhabitants (aged between 55 and
74 years) of the German city of Augsburg.206 They
also used data from a UK-based study to reflect
different levels of uptake for the different test
strategies.200 The uptake of HbA1c testing was
estimated to be 100% based on the assumption
that everyone in Germany between the ages of 55
and 74 years would visit their physician at least
once per year and so be accessible to testing. This
may be an over-optimistic assumption. The
authors conducted their analysis from both the
healthcare payer and societal perspectives,
including direct medical costs and indirect
productivity costs associated with each strategy. 
One of the main findings of this study was that the
population screening options dominated all the
targeted options. This was probably due to the
assumption that the patient-level information
required for the targeted options would not be
routinely available, and so its collection would
require additional assessments and incur extra
costs. These costs were estimated to be greater
than the extra costs it would take to screen
everyone in the population. However, the
assumption seemed to be that in order to target
screening, everyone in the population would
require their BMI, blood pressure and
triglycerides to be measured. This would unlikely
be the case in reality, so this finding should not be
taken as authoritative. In terms of the relative cost-
effectiveness of the different strategies for
population-based screening, the strategies
requiring FPG tests were dominated by the single
OGTT from the perspective of the healthcare
payer. The HbA1c test followed by an OGTT was
found to identify more true cases but at greater
cost (€771 per additional case detected). It was
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more effective due to the assumption that uptake
of HbA1c testing would be 100% and that those
with a positive HbA1c test would have a much
higher uptake for the OGTT. Similar results were
also obtained when the cost-effectiveness of the
strategies was considered from the societal
perspective. One of the weaknesses of the study by
Icks and colleagues201 was the lack of detail given
regarding the estimation of the model
effectiveness and cost parameters, making it
difficult to assess the internal and external validity
of the results. A fairly comprehensive sensitivity
analysis was carried out, which showed that the
results were reasonably robust to changes in the
prevalence of disturbed glucose metabolism,
uptake for the various strategies and productivity
costs. However, the strategy considered to be most
cost-effective was sensitive to changes in the
participation rates. The same weakness that
applies to the other studies discussed in this
section also applies here. That is, by failing to
consider the relative long-term costs and
consequences of the different screening outcomes,
it is not possible to answer the question of which
strategy is best. Moreover, given the lack of
transparency regarding the parameter estimates
included in the model, and the use of charges as
opposed to costs, it is not possible to ascertain
with confidence which of the strategies would be
the most efficient in the UK in terms of the cost
per case detected. 
Zhang and colleagues204 addressed a similar
question to that of Icks and colleagues.201
However, they assessed the efficacy, effectiveness
and efficiency of various strategies for detecting
both cases of prediabetes (IGT and/or IFG) and
cases of undiagnosed diabetes. Like Icks and
colleagues they assessed once-off screening for the
US population but assumed that only those who
seek healthcare would be screened. Based on data
from the US 2000 census,207 the third national
health and nutrition examination survey
(NHANES III)208 and other published literature,
they estimated that there would be 54.4 million
adults aged between 45 and 74 years who would
be eligible for screening. They further estimated
that the eligible number would be 37.4 million if
screening were to be restricted to those with a BMI
25 kg/m2. It was also estimated that there would
be 12.1 million cases of prediabetes and
5.4 million cases of undiagnosed diabetes in the
whole population and 9.6 and 4.7 million cases in
the population with BMI 25 kg/m2. The
methods used for calculating these figures were
not clearly reported. 
The screening strategies assessed by Zhang and
colleagues204 were as follows: (1) an OGTT for
everyone in the study population; (2) an FPG test
for everyone followed by an OGTT for those with
fasting glucose levels above the cut-off used
(95 mg/dl) but below the level used to diagnose
impaired fasting glucose (110 mg/dl); (3) an HbA1c
test with an OGTT for those with an HbA1c level
above 5%; (4) a capillary blood glucose (CBG) test
with an OGTT for those with capillary glucose
above 100 mg/dl; and (5) a risk assessment
questionnaire followed by an OGTT for those who
scored above a certain limit. The cut-off points
used for the FPG, HbA1c and CBG tests were
reportedly selected on the basis that they incurred
the lowest cost per case detected out of a range of
cut-off points tested, but the analysis used to
inform this decision was not reported in the paper. 
Zhang and colleagues204 assessed the effectiveness
of the different strategies by estimating the
proportion and number of prediabetes and
undiagnosed diabetes cases that would be detected
using each screening strategy. The sensitivities and
specificities of the various tests were taken from
published sources and it was assumed that the
OGTT was 100% sensitive and specific for
identifying IGT, IFG and undiagnosed diabetes.
Some assumptions were also made about the
sensitivity and specificity of the FPG test, but these
were not entirely clear. The direct medical costs
that would be incurred through each screening
strategy were calculated by using charges for the
different laboratory tests and physician time
requirements. The patient costs were calculated
based on estimates of patient time required for
each strategy and transportation costs. Since the
unit costs for the laboratory tests and physician
time were based on charges, it is difficult to
generalise them to settings outwith the USA. 
It was unclear how patient time and travel costs
were estimated.
The estimated number of cases that would be
detected with each of the screening strategies
applied to the whole population ranged from 12.1
to 17.5 million. The equivalent range for the
targeted screening option was 9.8 to 14.3 million
cases. In both cases the OGTT on its own was
found to be the most effective strategy, followed by
HbA1c, FPG and CBG. The total costs of each of
the strategies from the single payer’s perspective
ranged from $2.16 billion (risk assessment
questionnaire) to $3.44 billion (HbA1c with OGTT)
for the whole population. This translates into costs
per case averted ranging from $176 (CBG with
OGTT) to $236 (HbA1c with OGTT). When
societal costs were included, all the strategies were
more costly and the costs per case averted ranged
from $247 (CBG with OGTT) to $332 (HbA1c with
OGTT). The cost per case identified was lower
when screening was restricted to those with a BMI
25 kg/m2 but the rank order remained the same.
This finding differs from that of Icks and
colleagues,201 who estimated that targeted
screening would be dominated by population
screening. This is probably due to the differing
assumptions about the costs involved in
identifying people for the targeted strategy. 
Based on these findings, the authors concluded
that the OGTT test alone was superior (more
effective and less costly) to a strategy involving
HbA1c followed by OGTT. The choice between the
other options, they concluded, would depend on
the objective of the screening programme because
the less effective strategies were also more efficient
in terms of the cost per case detected. However,
these results were found to be sensitive to
assumptions about uptake of the different tests. In
the base case, 100% uptake was assumed for all
the tests, but when these assumptions were varied
during sensitivity analysis (75% uptake for FPG
and 50% uptake for OGTT), the FPG test became
the more effective and efficient strategy. However,
the authors did not seem to consider the
possibility that uptake of OGTTs would be higher
after positive screening tests than it would be
without. Had this been investigated, the strategy
involving the HbA1c test may have appeared more
favourable. Due to the lack of transparency
surrounding some of the calculations and
assumptions in this analysis, and the limited
sensitivity analysis, it is not possible to say with
confidence which of the strategies would be most
effective and efficient (in terms of cost per case
identified) in the context of a national screening
programme in the UK. 
Zhang and colleagues conducted a subsequent
analysis205 using a very similar approach to their
previous study. However, in this later study they
examined the efficiency of a wider range of cut-off
points for three different screening tests –
presenting the cost per case detected for each 
cut-off point assessed. In addition, they looked at
how the efficiency of the different cut-offs would
change if the goal of the screening programme
were to identify cases of undiagnosed diabetes
alone, as opposed to both prediabetes and
undiagnosed diabetes. The three tests they
assessed were FPG, HbA1c and random CBG. The
most efficient cut-off point on each of these tests
was defined as the point that yielded the lowest
cost per positive case identified. The sensitivities
and specificities for each of the cut-off points
assessed in the analysis were obtained from the
published literature,8,10 but little detail was given
on these studies. As in the previous analysis,
subjects with an FPG above the cut-off, but below
the value used to define prediabetes (or
undiagnosed diabetes), were assumed to undergo
an OGTT. For the other two screening tests, all
subjects above the different cut-offs assessed were
assumed to undergo an OGTT. The numbers of
individuals above the different cut-off points were
presumably modelled based on the reported
sensitivities and specificities for the different cut-
off points on the different tests. As before, the costs
and effects of the three strategies were modelled
for all eligible adults in the US population –
54.4 million adults aged between 45 and 74 years
who seek healthcare at least once per year – from
both single-payer and societal perspectives. The
costs were all reported in 2000 US dollars.
Zhang and colleagues205 found that, if the purpose
of screening was to identify both prediabetes and
undiagnosed diabetes, the cost per case identified
by cut-off value ranged from $125 to $321 for the
CBG test, from $114 to $476 for the FPG test and
from $153 to $536 for the HbA1c test from the
single-payer perspective. If the purpose was to
identify only undiagnosed diabetes, the cost per
case detected from the single-payer perspective
ranged from $392 to $671 for the CBG test, from
$556 to $717 for the FPG test and from $590 to
$817 for the HbA1c test. It was found that for all
three screening tests, the cost per case identified
first decreased and then increased as the cut-off
value of the screening test increased. This was
because, to begin with, the decreased sensitivity
(decreasing number of cases detected) was
outweighed by the decreased costs associated with
fewer diagnostic tests. However, after a certain
limit, the decreased number of cases detected
outweighed the decreased costs, resulting in a rise
in cost per case detected. The optimal cut-off
point based on the cost per case detected, for
detecting both pre- and undiagnosed diabetes, was
100 mg/dl for the FPG test, 5% for the HbA1c test
and 100 mg/dl for the CBG test. For detecting
undiagnosed diabetes only, the most efficient cut-
off points were 110 mg/dl, 5.7% and 120 mg/dl,
respectively. The authors did not present the
number of cases that would be detected at the
different cut-off points or the additional costs of
detecting extra cases by increasing sensitivity.
Again, the decision as to which screening test to
use in a screening programme will depend on the
number of cases that would be identified, and not
































TABLE 16 Summary of studies assessing the short-term costs and outcomes of alternative test strategies for the detection of diabetes or IGT/IFG
Study and Population Objectives/ Strategies Costs Outcomes Time Results/authors’ Comment
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$6.9 to $42.7 billion
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TABLE 16 Summary of studies assessing the short-term costs and outcomes of alternative test strategies for the detection of diabetes or IGT/IFG (cont’d)
Study and Population Objectives/ Strategies Costs Outcomes Time Results/authors’ Comment
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strategy identified more
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TABLE 16 Summary of studies assessing the short-term costs and outcomes of alternative test strategies for the detection of diabetes or IGT/IFG (cont’d)
Study and Population Objectives/ Strategies Costs Outcomes Time Results/authors’ Comment
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just the cost per case identified. It will also be
dependent on the costs and consequences of false
negatives, which will in turn be dependent on the
rate of progression of undiagnosed cases relative
to diagnosed cases, and the screening interval. If a
decision was made to screen every 2 or 3 years,
then the adverse consequences of false negatives
would be less severe than they would be if
screening was to be just once off. 
Summary and conclusions
The studies reviewed in this section201–205 all
assessed the short-term costs and consequences of
different approaches to screening for T2DM, or
IGT and IFG. All considered the costs that would
be incurred and the number of cases that would
be identified using different tests or different cut-
off points on the same test. The studies all had
similar designs although estimates of cost per case
detected varied due to different assumptions about
costs, prevalence of diabetes/pre-diabetes,
sensitivity/specificity of tests and participation
rates. Moreover, the efficiency ranks for the
different tests varied from study to study and were
also found to be sensitive to assumptions within
studies. Due to these uncertainties, it is not
possible to draw any conclusions as to which test
would be most efficient in a screening programme
for detecting diabetes and/or IGT/IFG in the UK.
One thing that is clear is that when considering an
appropriate cut-off point for a test, there is likely
to be a trade-off between the number of cases that
the test can identify and the efficiency of that test.
As the sensitivity of a test is increased beyond a
certain limit, by lowering the cut-off point, the
cost per case identified is also likely to increase
due to the larger number of false positives that
will require a definitive diagnostic test. As Zhang
and colleagues demonstrated,205 the opposite
effect is seen when the specificity of a test is
increased beyond a certain limit. Therefore, the
preferred test and the preferred cut-off points for
tests will vary depending on the precise objectives
and nature of the screening programme. If it is
considered very important to detect as many true
cases of disease as possible and minimise false
negatives, then more sensitive strategies with
higher costs per case detected might be
appropriate. If the false negatives are not
considered to be such an important consequence
of screening, then a more specific and efficient
screening strategy could be used. 
The main problem associated with all the studies
reviewed in this section is that by only considering
the short-term costs and outcomes associated with
the detection process, and failing to consider the
longer-term impact of false negatives relative to
true positives, these types of studies cannot tell us
which screening tests and cut-off point to use in
screening programmes for diabetes/IGT. If false
negatives result in substantial increases in costs or
reductions in life expectancy/quality of life, relative
to true positives, then more sensitive and
expensive test strategies are likely to be the
preferred option. However, if the long-term
impact of false negatives is not particularly severe,
more specific strategies might be preferred. This
might be the case if repeat screening were to be
undertaken every 2 or 3 years.
In order to address these questions, the different
screening tests and cut-off points need to be
assessed in the context of models that consider the
lifetime costs and outcomes of screening for
T2DM. Such models were reviewed earlier in this
report. By incorporating the costs and
sensitivities/specificities of different screening
strategies into such models, it would be possible to
assess the longer term impacts that different test
strategies might have relative to each other. This
would provide a way of balancing the short-term
costs of the different screening strategies against
the long-term costs and health outcomes, giving a
better indication of how to optimally screen for
diabetes.
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Introduction
Context of research
The aim has been to produce a basic screening
model linked to the existing fully developed
treatment model to investigate the order of
magnitudes of effects given different scenarios for
diabetes screening policies.
Background
T2DM increases the risk of cardiovascular events in
addition to causing microvascular complications.
The disease remains asymptomatic for a number of
years during which the disease progresses and
cardiovascular risk is elevated compared with the
normal population. It is estimated that up to one
million people have undiagnosed T2DM in the
UK.209 Screening for diabetes is potentially
beneficial as early treatment may delay progression
of diabetes and reduce short- and long-term
complications. Treatments include statins,
antihypertensive and hypoglycaemic therapy and
lifestyle change (dietary modification and increased
physical activity). 
Although there have been previous assessments of
the cost-effectiveness of screening for diabetes,
these have some limitations such as being
performed before the use of statins.
Objectives
In order to quantify the trade-off between the
costs and benefits of screening and early
treatment, a diabetes screening model was
developed for this study and integrated with an
existing diabetes treatment model. This enabled:
● information derived from the screening literature
review to be integrated with information on the
current and projected prevalence of undiagnosed
diabetes and information on the costs and
effectiveness of diabetes-related treatment
● the key parameters that will influence the cost-
effectiveness of screening for diabetes and the
significance of uncertainty around these key
parameters to be identified
● the characteristics of the screened population
(including the proportion of diabetes
undiagnosed in the absence of systematic
screening), the characteristics and costs of the
screening and diagnostic tests to be varied
● the effectiveness and costs of subsequent
treatment to be varied
● initial estimates of the relative cost-effectiveness
of a range of different screening options that
could be used to inform an option appraisal for
diabetes screening to be produced.
Some existing limitations of previous publications
on screening modelling were also overcome, 
such as:
● modelling macrovascular risk reductions
● incorporating the widespread use of generic
statins
● accounting for existing policies such as diabetes
testing for those with existing CHD, and control
of hypertension in the general population.
Model scenarios
Baseline scenario
The baseline model assesses the cost-effectiveness
of a single screening round of a population with
an age of 40–70 years in order to identify and
treat diabetes before clinical diagnosis would
occur. The modelling covers a period of 40 years
from the decision to screen or otherwise.
Other scenarios
In sensitivity analyses, the cost-effectiveness of
screening different populations was assessed, such
as those in the 40–49-year age band, the
hypertensive subgroup and the obese subgroup.
Sensitivity analyses also tested the impact of
uncertainty in some of the parameters and model




The principal approach to model-based
evaluations of screening interventions is to 
(1) develop a natural history model covering the
preclinical detectable phase (PCDP) and (2) then
Chapter 5
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type 2 diabetes
overlay relevant screening programme
interventions (and also the ‘no screening’ option
in which diabetes is detected clinically).
The link between the screening programme and
the PCDP provides outcome measures including
the proportion of persons detected prior to
clinical presentation and the timing of the screen-
detection. For diabetes, screening outcomes can be
measured in terms of number of new cases
diagnosed, distribution of HbA1c levels at
diagnosis and distribution of ages at diagnosis
compared with ages at which diabetes would
otherwise present (i.e. the reduction in time spent
in the preclinical phase). These inputs feed into
the treatment model so it is possible to compare
overall lifetime costs and outcomes of a screened
cohort and an unscreened cohort. 
Treatment model
This simulates the development of microvascular
and macrovascular complications in patients with
T2DM. Microvascular risk is based on HbA1c and
blood pressure, whereas risk of developing
cardiovascular complications uses a modified
version of the UKPDS CVD Risk Engine (UKPDS
56184 and UKPDS 60185), which is based on
cardiovascular risk and outcomes in the UKPDS
trial cohort (including treated and control arms).
The structure of the model is shown in Figure 3.
Note that the pathway after screening for the
following people is assumed to be the same as if
they had not been screened (regardless of whether
they have diabetes or not):
● patients who test negative at screening test
● patients who test negative at diagnostic test.
Where these pathways are common regardless of
the choice to screen or not, there is no need to
model their long-term pathway because the costs
and benefits cancel out. It is only necessary to
account for the costs of the screening programme
itself.
Key model assumptions
Screening and diagnostic process
A single HbA1c measurement was assumed as the
screening test, followed by a single OGTT if the
HbA1c is above 5.7%. There is much debate about
the optimum test strategy201 and the model can
incorporate more complex strategies, including
the use of a questionnaire, followed by a screening
blood test before diagnostic testing. However,
there is agreement that in the absence of
symptoms (as is the case in screening) a second
glucose measurement is required before anyone is
diagnosed as diabetic.






























FIGURE 3 Model structure.* Matched patients in screening and ‘no screening’ model.
Natural history of HbA1c progression
The potential benefit of earlier diagnosis and
treatment of hyperglycaemia will be closely related
to the distribution of HbA1c results at screening
and its progression up to the point of clinical
diagnosis. 
Overview of method
To obtain the duration between screening and
clinical detection, HbA1c distributions were
sampled at screen and clinical detection, and
estimated rates of HbA1c progression used to
calculate to preclinical duration. This method was
chosen as it provides some degree of variability in
the preclinical duration which was thought to be
an important factor in determining the overall
risk profile of patients during the preclinical
period. Variability in the rate of HbA1c
progression, however, was considered too
uncertain to model given that HbA1c progression
is the most uncertain aspect of the natural history
to estimate (see below).
Although there may be some correlation between
HbA1c at screen detection and the HbA1c at which
a patient would be clinically detected, this was
thought to be low and not significant. Therefore
the screen and clinical HbA1c distributions were
sampled independently.
HbA1c at screen detection
First, a distribution of HbA1c is assumed for
screen-detected patients. Results from screening
programmes are summarised in Table 17.
It was assumed that HbA1c values were reported
on the required DCCT aligned scale (the risk
equations in our model are UKPDS-aligned). Data
suggest that the FPG test yields a higher HbA1c
than an OGTT test – this is expected because
postprandial hyperglycaemia is often the more
dominant defect in early diabetes. Weighting has
been given to studies that used an OGTT test as
this test is the most sensitive, and it is assumed
that the mean HbA1c of the undiagnosed diabetic
population is 6.4%.
The HbA1c test is effectively a ‘hybrid’ of an 
FPG and an OGTT test, resulting in a sensitivity
below 100%. To obtain a sample of HbA1c values
from the undiagnosed population, samples were
taken from the upper region (starting from 
1 – sensitivity), giving a mean HbA1c through
screening of 6.7%.
The 1998 CDC screening evaluation131 used a
similar mean HbA1c of 6.8% at screen detection.
An SD of 1.0 was assumed, as reported from the
KORA survey,206 this is consistent with
assumptions in the CDC screening modelling. 
The reviewers have assumed a skewed distribution,
as the higher the HbA1c the more likely patients
would be symptomatic and be detected clinically,
this assumption is supported by the HbA1c
distribution shown in Figure 3 of Hofer and
colleagues213 based on NHANES III data.
HbA1c at clinical detection
Patients were randomly assigned to an HbA1c level
that would have been found in the absence of
screening, that is, clinical detection using the
HbA1c distribution from the UKPDS (which was on
average 9% but was higher in symptomatic
patients). Another study also found that
symptomatic patients had a slightly higher HbA1c
of 9.9% at diagnosis.214 A higher HbA1c level of
10.8% was observed in the Poole Diabetes Study,215
although the scale used here has not been
confirmed. The assumption of an average HbA1c
of 9% at clinical detection may be slightly
conservative in terms of estimating the duration of
undiagnosed diabetes.
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TABLE 17 HbA1c at screen detection
Study Test Mean HbA1c (%) FPG (mmol/l)
KORA survey201 OGTT 6.2
Hoorn111 Mixed 6.7
NHANES III210 ADA criteria (FPG levels) 7.07
WHO criteria (OGTT results) 6.58
EDIP211 (estimated from Figure 3) FPG + HbA1c 6.5 6.6
UKPDS – low FPG group of which 44% 
asymptomatic184,185 Unknown 6.7
Other UK studies:
Ely,137 Coventry Diabetes Study212 Not available
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Although there is some variation in HbA1 at
diagnosis by age group, as shown in the Poole
Diabetes Study (their Figure 2),215 this is
considered to be of minimal significance, because
there will be little effect on the incremental risk
between the two cohorts. 
HbA1c progression
Having established two HbA1c distributions at
screen and clinical detection, the remaining
parameter required is the HbA1c progression
during the preclinical phase – this will also
determine the additional time duration that 
would pass before clinical detection. Although
indirect estimates of the duration have been made,
these vary greatly from 6 to 11 years and may
involve unjustified assumptions about HbA1c
progression.
We believe that the best way to model this
uncertainty is firstly to consider the HbA1c
trajectory of an average person with diabetes:
● To review evidence on the rates of change in
HbA1c where possible – results of patients
developing diabetes in IGT studies can give an
idea of the rate close to onset of diabetes; the
UKPDS gives an idea of the rate of change at
clinical detection. A modelling paper by 
Bagust and Beale60 using results from the
Belfast Diet Study also suggests a possible
HbA1c trajectory.
● To explore a range of scenarios for the HbA1c
trajectory (for an average patient).
● To identify the scenario which has the best fit
with other sources of evidence on disease
progression.
Average HbA1c in non-diabetics is around 5.4%.
We estimate HbA1c at onset of diabetes to be
around 5.85%. Although the DPP reported 
an HbA1c of 6.4% at onset of diabetes,
90,171
(assumed onset as tested 6-monthly), this could 
be because those that progressed had more severe
beta-cell dysfunction (rather than modifiable
insulin resistance), leading to a rapid rise in
HbA1c.
There is little hard evidence on which to base the
rate of change of HbA1c. Some aspects of the
natural history can be inferred from various
sources – ‘triangulation’ using various sources 
of evidence is considered to be the only 
approach to estimating the natural history as 
there is no existing dataset that demonstrates 
the natural history of untreated diabetes. 
Various results from studies do seem to suggest 
a lower rate of change in the earlier part of the
preclinical phase.
In the US Diabetes Prevention Program,90 38% of
placebo patients became diabetic at 4 years. HbA1c
change in the placebo group during this period
was 0.2%. For the placebo patients, even if it is
assumed that HbA1c rose three times faster in
those who became diabetic, we estimate that
HbA1c would only have risen at an annual rate of
about 0.1%.
In the Finnish Diabetes Prevention Study,89 HbA1c
did not change at least up to the end of year 3 in
the control group even though diabetes incidence
was significant (21, 23 and 42 at 3, 4 and 6 years,
respectively), although the control group did
receive some dietary information making
interpretation more difficult.
Of note is the HbA1c level at screen detection, that
is, between 6.0 and 6.5%. This is much closer to
the HbA1c level at onset (which is estimated to be
about 5.8–5.9%) than the level at clinical detection
(9% per UKPDS). This suggests one or both of the
following could be happening:
● The rate of HbA1c progression increases either
gradually or increases more rapidly at a specific
phase of progression such that patients
generally are less likely to be detected in the
more advanced preclinical phase (because there
would be relatively less time in this phase).
There is a biological study that supports this
hypothesis.216
● Some slower progressors may not be detected in
the latter stages of the preclinical phase because
their raised CHD risk may result in mortality
during this period – this would have the effect
of detecting patients at relatively low HbA1c
levels
The International Diabetes Center, Minneapolis,
MN, produced a diagram217 showing a
hypothesised trajectory for glycaemic progression
– this appears to be frequently referenced 
and is consistent with an up-sloping HbA1c
trajectory.
The rate of change in HbA1c during the first few
years of the UKPDS was around 0.2% p.a., 
despite antiglycaemic therapy.8 The expected 
rate of increase would be greater without
treatment.
Taking account of the limited evidence above, 
it was assumed that, for the baseline analysis, 
the rate of HbA1c change increases exponentially
over time from 0.15 p.a. at diabetes onset to
0.45 p.a. at clinical detection (assumed to be at
9.0% HbA1c on average). This is clearly an area for
further research. The impact of a more rapid
exponential increase (and shorter preclinical
period) was examined in the sensitivity analyses.
Reduction in time to diagnosis through screening
Estimates of the expected lead time between
screen and clinical detection are an indirect 
output of this modelling approach and can be
compared with the findings with other sources of
data using other methods to estimate the
preclinical course. 
The estimated average delay in diagnosis through
not screening is approximately 6–7 years. The
estimated sojourn period between onset and
clinical detection is around 11 years. The
distribution of the delay obtained is shown in
Figure 4.
Changes to other risk factors during the
preclinical period
The assumptions made about baseline
characteristics and changes to these during the
preclinical period of the unscreened cohort are
important.
Systolic blood pressure (SBP)
SBP in the UKPDS at baseline was 136 mmHg. It
was assumed that there is reasonably tight SBP
control in undetected patients given current NHS
incentives for GPs, although not as tight as the
recommended level for people with diabetes. It
was also assumed that SBP is at most 150 mmHg
at baseline.
For annual changes in SBP, data from the Health
Survey for England 200363 (Volume 2, Risk factors
for cardiovascular disease, Figure 7C, p. 186) were
used.
Approximate changes (in the general population)
were calculated as follows:
● Rise p.a. women = 118 to 137 mmHg from age
40 to 60 years, or approximately 1 mmHg p.a.
● Rise p.a. men = 129 to 138 mmHg, from age
40 to 60 years, or approximately 0.5 mmHg p.a.
It was assumed due to the higher prevalence of
hypertension in diabetes, that the SBP rises at
twice the general population rate.
Cholesterol
Total cholesterol was 5.4 mmol/l at baseline in the
UKPDS.8
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FIGURE 4 Distribution of reduction in time to diagnosis through screening
Changes in cholesterol vary by age and gender in
the general population. Further uncertainty arises
from some cholesterol monitoring and the impact
of diabetes, so no changes in cholesterol levels
have been included (this is consistent with
observations in UKPDS218).
No annual changes in cholesterol level are
assumed.
Modelling of treatment and outcomes
Risk equations
Throughout the time horizon of the modelling
(i.e. including the preclinical period), the UKPDS
CHD and stroke risk equations were used to
model the risk of cardiovascular events. The
equations published by Eastman for microvascular
events were also used.134,135
Treatment assumptions from the point of
diagnosis
Modelling the no-screening comparator involves
initially modelling patients without statin or
further antihypertensive therapy or diet/exercise
or antiglycaemic therapy. At a patient’s
determined point of clinical detection, they begin
active treatment in the model. The model assumes
that from diagnosis, both hyperglycaemia and
other CHD risk factors such as hypertension and
dyslipidaemia, are treated according to current
clinical guidelines. The widespread availability,
falling cost and significant cardiovascular risk
reduction (30%) of statins is a key factor in the
effectiveness of screening. 
The model assumes that if proliferative
retinopathy or macular oedema develops, then
this would be treated using photocoagulation,
leading to a 45% reduction in risk of severe vision
loss. For the purposes of costing retinopathy
screening, it was assumed that this takes place
annually. 
An area of uncertainty is whether reductions in
HbA1c lead to reductions in CHD. A recent review
concludes that the evidence suggests that chronic
hyperglycaemia is associated with increased CHD
risk.219 A recent analysis reported from the follow-
up of DCCT participants (type 1 diabetes), the
Epidemiology of Diabetes Interventions and
Complications (EDIC) study, may be highly
significant – tight HbA1c control (7% versus 9% for
conventional control) reduced CVD events by
about 50%.220 For our base-case analysis, the
results reported in UKPDS 35221 were used,
namely that each 1% decrease in the observed
mean updated HbA1c is associated with a 14%
lower incidence of MI. Sensitivity analysis was
undertaken to test the impact of varying this
assumption. 
A detailed description of the Sheffield Treatment
model should appear shortly as an on-line
Discussion Paper222 until the full publication is
available. The modelling of risk factors post-
diagnosis is covered in detail in the ‘Background
to methods’ section at the end of this chapter.
Other assumptions
Pathways following screening
A key assumption is that the only long-term
modelling required involves comparing the
progression of the true positives under screening
with their progression if they had been detected
later clinically. This assumes that a negative
screening test or a positive screening test followed
by a negative diagnostic test does not have any
clinically significant long-term consequences,
although screening itself will potentially have an
impact on both quality of life (by provoking
anxiety or reassurance) and risk behaviour (due to
individuals becomes more or less motivated to
change their diet or lifestyle) depending on the
context of screening (these issues are well
described in papers by Speight223 and Edelman
and colleagues224). It is assumed that these effects
can be modified by providing appropriate
information and support at the time of screening
and have not been included in the modelling. The
main impact of diabetes on health-related quality
of life (HRQoL) is through the development of
complications.
Costs
The model considers costs from an NHS
perspective. The costs of screening tests and costs
of subsequent treatment for both diabetes and
associated complications are included.
Costs borne by patients or society such as costs to
the individual of attending for glucose tests or the
costs to society of supporting an individual with
diabetes-related blindness are not included. 
Key model parameters
Population characteristics
The age, sex and ethnicity structure of the
screened population is based on the PBS 
model developed by the Yorkshire and Humber
Public Health Observatory,225 available at
www.yhpho.org.uk.3 Details on how the population
prevalence figures were calculated for alternative
subgroups are in the ‘Background to methods’
section at the end of this chapter.
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The population size of subgroups based on age
group, diagnosed hypertension and BMI were
calculated using information from the PBS model
and recent data from The Health Survey for
England.
As the PBS prevalence figures are at 2001 levels,
an uplift of 10% was applied to estimate the
prevalence in 2007 based on assumptions
published with the PBS prevalence model.226
The percentage of the diabetic population that is
undiagnosed can be varied. The PBS prevalence
model documentation suggests that the figure lies
between one-third and half based on Wild and
colleagues227 and King and Rewers.228 In
NHANES III,210 35 and 45% of diabetes cases
were undiagnosed by ADA and WHO criteria,
respectively. More recent estimates, based on a
National Diabetes Audit,229 suggest that with
current levels of ad hoc screening activity,
approximately 25% remain undiagnosed in
England. The default figure was set to 35%.
Baseline complication rates
Macrovascular complications
When evaluating the effectiveness of screening
older age groups, the increased prevalence of
CHD at baseline is important given the increased
risk of subsequent MI. However, patients with a
CHD history should be screened for diabetes as an
element of secondary prevention and it was
therefore assumed that the baseline prevalence of
CVD amongst the cohorts for potential screening
would be negligible. 
Similarly, prevalence of prior stroke at diagnosis is
assumed to be nil because these people have a
CVD profile and in theory should be covered by a
broader prevention programme other than a
purely diabetic screening programme.
Undiagnosed CHD would be increasingly
prevalent at baseline as age increases. As both age
at diagnosis and duration since diagnosis are
factors in the UKPDS risk engine, this trend is
accounted for within the model.
Microvascular complications
Microvascular complications are related to
glycaemia and blood pressure. There is debate,
however, about the level of glycaemia needed for
retinopathy to develop. A recent report from the
ADA Conference indicated that retinopathy is
present in some prediabetic patients.230 The
assumption was used that the prevalence of (non-
proliferative) retinopathy increases linearly from
nil at the average HbA1c at onset (5.85%; see end
of paragraph) to 17% (330/1919 with Level 35 or
worse)231 in the UKPDS at an HbA1c of 9%. This is
close to the 15% prevalence recently reported
from the Tayside Diabetes Network232 and the
17% based on the Early Diabetes Intervention
Program (EDIP) study.211 Analyses from NHANES
III and other studies show a marked change in
prevalence above an HbA1c of 5.9%,
17 confirming
that our assumption above is reasonable.
An individual’s presence or otherwise of
retinopathy at entry to the simulation is
determined by their HbA1c at entry.
A similar relationship is assumed for baseline
prevalence of nephropathy, with the prevalence
assumed at diagnosis at an HbA1c level of 9%
being 6.5% for microalbuminuria and 0.7% for
macroalbuminuria.183
At an average HbA1c of 6.7% at screen detection,
estimated prevalence of retinopathy,
microalbuminuria and macroalbuminuria is 4.6,
1.8 and 0.2%, respectively. As the prevalence of
neuropathy at diagnosis was only 1.2%,233 it has
been assumed that this is negligible at screen
detection.
Uptake of screening
This is set to 50% based on uptake rates within the
current UK NSC’s diabetes screening pilots in
England (the DHDS pilots), where patients are
being invited for screening by letter. It has been
assumed there is no uptake bias and therefore that
the screened population is similar to the general
population that would be eligible for screening. 
Screening and diagnostic tests
In the baseline model, the screening test assumed
is an HbA1c test with a cut-off of 5.7%, as
suggested by Zhang and colleagues,205 as the
optimal cut-off. They reported sensitivity and
specificity at different HbA1c cut-off levels, these
were 66 and 83%, respectively, at a cut-off of 5.7%.
An OGTT is assumed to be performed to confirm
(or otherwise) diagnosis in patients who are
initially screen positive using the HbA1c test. 
Costs
Table 18 shows the key costs associated with
screening and early treatment.
It was assumed that no additional costs of case-
finding would be incurred on the grounds that
suitability for testing would be evident at the time
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of a routine GP appointment (i.e. assuming
opportunistic screening rather than a new
dedicated mass screening programme).
The costs for an HbA1c test and OGTT test are
estimated to be approximately £5 and £20,
respectively, including nurse time, transport and
laboratory processing costs. No societal costs
associated with patients’ lost time is included.
Additional GP infrastructure costs are assumed to
be avoided through adoption of opportunistic
screening when patients visit GP practices for
‘routine’ appointments. No costs of monitoring
the screening programme are assumed.
Costs of therapies were obtained from the NHS
Drug Tariff234 (which are generally considerably
lower than BNF prices).
The main additional cost of statins arising from
screening occurs during the period in which they
would otherwise have been undiagnosed (some
further additional costs are attributable to improved
subsequent survival). It was assumed that 40 mg of
(generic) simvastatin is sufficient to manage
cholesterol levels during this period and applied
this cost throughout the model. Average costs of
statins were therefore estimated at £ 0.17 per day.
Insulin cost was based on the average cost of
Monotard (£10.50 per 1000 units) and Lantus
(Insulin Glargine) (£26 per 1000 units).
Costs of treatment of complications are as specified
for the Sheffield Diabetes Treatment Model.
Treatment costs are from an NHS perspective; for
example, no costs are included for carers of
patients who develop blindness.
Costs are expressed in real terms (i.e. no inflation
included).
Discount rates
Costs and benefits were discounted in line with the
new NICE guidance for England and Wales of
3.5% for both.
Screening scenarios
In addition to baseline scenarios for the age bands
40–49, 50–59 and 60–69 years, sensitivity analyses
were undertaken to demonstrate the relationship
between the key parameters and the model
outcomes. One-way sensitivity analyses include the
impact of screening a higher risk population
(hypertensive and obese populations), the impact
of varying treatment regimes (more intensive
glycaemic control), treatment costs (statin costs)
and the impact of varying the assumed natural
history (progression of hyperglycaemia prior to
clinical diagnosis).
Model outputs
For a given population, the model predicts the
number screened, the number of new cases that
would be diagnosed by screening, cardiovascular
events (MI, and unstable angina and stroke) and
mortality in the presence and absence of
screening, microvascular complications and 
the overall costs and QALYs associated with
screening. Cost-effectiveness is presented in 
terms of:
● Marginal net benefit (i.e. the financial value,
above that expected to have to be invested, to
realise the QALY gains using an acceptability
threshold of £ 20,000 per QALY)
● The ICER – the ratio of incremental costs to
incremental QALYs.
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TABLE 18 Key cost inputs relating to screening and early treatment
Resource Unit Cost (£) Note
Case finding Per case 0
Screening test (HbA1c) Test 5.00 This is based on a conversation with laboratory
colleagues, suggesting a range of costs from about
£3.50 to £20 depending on volume and speed of
results; a figure has been taken near the lower end
of that range assuming that screening would involve
large numbers but with no need for speed
Diagnostic test (OGTT) Test 20.00 HTA Review of screening for gestational diabetes2
Cost of statins Per day 0.17 40 mg generic simvastatin234
Non-medication costs of monitoring/managing Per year 97.00 Calculation based on several sources
diabetes (based on two GP visits with HBA1c
tests, and retinopathy screening)
The marginal net benefit is more readily
interpretable, particularly where the ICER
calculation involves negative figures, as is often the
case in our results.
Results
Results from baseline scenario
Screening outcomes
Screening a cohort of patients between 40 and
70 years of age in a Primary Care Trust (PCT)
population of 100,000 individuals would mean
that 33,740 people would be invited for screening,
of whom 16,870 would respond and take a
screening test; 3078 would need diagnostic testing
and 283 (0.3%) would be new cases of diabetes.
Based on our model, they would be detected an
estimated 6–7 years earlier than in the absence of
screening. In practice, only those with BMI over
30 kg/m2 might be invited.
Cost-effectiveness of screening (per person
diagnosed)
Overall £715 would be the cost of additional
treatment and monitoring, largely resulting from
earlier diagnosis, and £880 would be saved from
the reduction in complications and their
treatment. The apportioned total cost of screening
and diagnosis per diagnosed case would be £516.
This represents an overall additional cost of £351
and a gain in QALYs of 0.155 per case detected
and treated, giving an incremental cost per QALY
ratio of £2266.
Sensitivity analyses
Numbers screened and test results are given in
Table 19. The relative proportions with
undiagnosed diabetes and IGT would vary
depending on cut-off level chosen. With lower cut-
offs, IGT would be more common.)
The screening strategy (i.e. choice of test and
HbA1c cut-off) and assumed uptake rate would
leave 575 people in the 40–70-year age band
undetected per 100,000 total population; 428 of
these would not have taken up screening, with the
remainder being those who are screened but
whose HbA1c is below the 5.7% cut-off level for a
positive result.
The numbers to screen are obtained from the PBS
prevalence model by providing weighted averages
of age-specific prevalence within 5- or 10-year age
bands. As the numbers are based on the mix of
the total population of England, they represent
the expected number from a ‘typical’ PCT
population.
The results of one-way sensitivity analyses for the
treatment of diagnosed patients at screen
detection compared with clinical detection 
(i.e. excluding screening costs) are given in 
Table 20.
This modelling suggests that screening is cost-
effective for all populations between 40 and
70 year of age, and for all one-way parameter and
treatment sensitivity analyses around the base
case. It cannot be concluded without further
analysis, however, that this would be the case for
sensitivity analyses around every population. The
same applies if some of the sensitivity analysis
assumptions were combined (e.g. higher
monitoring costs and lower CHD reduction from
HbA1c lowering).
Age groups
Table 20 shows additional treatment costs and
QALY gains per new case detected. All age groups
show a QALY gain of at least 0.12. The 50–59-year
and 60–69-year age groups both show cost savings
from treatment also. After the costs of screening
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TABLE 19 Numbers screened and test results
Screening scenario Undiagnosed Number to screen Detected and Detected and diagnosed 
prevalence (%) (per 100,000 diagnosed diabetic as IGT/IFG 
population)a (approximate estimate)
All 40–70-year olds 2.50 16,869 283 177
40–49 years of age 1.40 6,535 60 37
50–59 years of age 2.20 6,051 88 55
60–69 years of age 4.80 4,283 135 84
Hypertensive (age 40–70 years) 4.40 6,083 176 110
Obese (BMI >30 g/m2) 4.10 4,004 108 67
Higher uptake (70%) 2.50 23,616 396 247
a Assuming 50% uptake of those invited to screening.
are taken into account, cost-effectiveness appears
greatest for the 60–69-year age group (Table 21).
This is partly because more cases are diagnosed in
the 60–69-year age band due to the higher
prevalence (see Table 19), resulting in the effective
screening cost per case detected being much
lower in the 60–69-year age group (£590 and £281
per case detected for 50–59- and 60–69-year age
groups, respectively).
The 40–49-year age group yields additional
treatment costs, lower QALY gains and higher
screening costs per case detected due to lower
baseline risk of complications and lower
prevalence.
High-risk populations
Populations at higher risk of diabetes are also at
higher risk of cardiovascular complications in the
presence of diabetes, for example if older or
hypertensive. The model suggests that QALY
gains will be greater in some higher risk
populations, as shown above for the hypertensive
subgroup.
Prevalence
The degree of uncertainty in the prevalence of
diabetes is unlikely to affect whether screening is
cost-effective or not, unless several of the
‘pessimistic’ assumptions in the sensitivity analyses
apply.
Preclinical HbA1c trajectory
A more rapid rise in HbA1c prior to diagnosis will
influence both the potential benefit and the
potential duration of additional treatment. The
model suggests that this will reduce the additional
costs largely by reducing the duration of additional
treatment (to about 4 years under this assumption)
while impacting on later complication rates.
CHD benefit of HbA1c reductions
The assumption that reducing HbA1c will reduce
CHD rates is one of the reasons for the significant
drop in CHD complications with earlier treatment.
However, even after eliminating this benefit, the
treatment of associated risk factors (statins,
antihypertensives, aspirin) will still produce a
significant benefit.
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TABLE 20 Results of one-way sensitivity analyses for early treatment compared with treatment at clinical detection per case
diagnosed (excludes screening costs)
Screening scenario Incremental costs Incremental QALYs 
compared with compared to 
no screening (£)a no screening






Hypertensive patients –56 0.166
Obese patients –165 0.155
Natural history
Faster HbA1c progression prior to clinical detection (shorter delay from –353 0.175
screen to clinical detection)
Treatment effectiveness
Lower CHD risk reduction achieved from HbA1c reduction 34 0.096
Lower CVD risk reduction from statins 217 0.156
More intensive HbA1c control (adding high-cost drug as third-line 
combination therapy) 432 0.093
33% lower reduction from screening in microvascular complications –24 0.138
Treatment and monitoring costs
Monitoring cost £129 instead of £97 p.a. 0 0.155
Higher statin cost – average 40/80 mg 440 0.155
Insulin cost 1/3 lower (to see effect of fewer patients requiring insulin in 
long-term through screening) –121 0.155































TABLE 21 Results of one-way sensitivity analyses for overall costs and cost-effectiveness of screening versus no screening per 100,000 population
Screening scenario Number Total Number Total incremental Total Marginal net ICER (screening 
screened screening detected and treatment incremental benefit of screening vs no screening)
cost (£) treated cost (£)a QALYs (per screened 
person) (£)b
All 40–70-year olds (baseline) 16,869 145,898 283 –46,697 44 46 2,266
Age (years)
40–49 6,535 55,781 60 18,259 7 11 10,216
50–59 6,051 52,141 88 –17,528 15 44 2,324
60–69 4,283 37,981 135 –10,103 24 106 1,152
Risk factors
Hypertensive patients 6,083 53,708 176 –9,824 29 89 1,505
Obese patients 4,004 35,234 108 –17,791 17 79 1,046
Natural history
Faster HbA1c progression prior to clinical 16,869 145,898 283 –99,861 50 56 929
detection (shorter delay from screen to 
clinical detection)
Treatment effectiveness
Lower CHD risk reduction achieved from 23,616 204,257 396 13,656 38 23 5,706
HbA1c reduction
Lower CVD risk reduction from statins 16,869 145,898 283 61,281 44 40 4,682
More intensive HbA1c control (adding high-cost 16,869 145,898 283 122,247 26 15 10,214
drug as third-line combination therapy)
33% lower reduction from screening in 16,869 145,898 283 –6,837 39 38 3,563
microvascular complications
Screening test costs
Higher HbA1c test cost (£10) 16,869 230,241 283 –46,697 44 41 4,193
Treatment and monitoring costs
Monitoring cost £129 instead of £97 p.a. 16,869 145,898 283 65 44 43 3,334
Higher statin cost – average 40/80 mg 16,869 145,898 283 124,503 44 36 6,177
Insulin cost 1/3 lower 16,869 145,898 283 –34,307 44 45 2,549
a Negative incremental costs denote cost savings.
b Assumes a cost-effectiveness acceptability threshold of £20,000/QALY.
Treatment costs
The additional use of statins is a major driver of
associated costs and benefits associated with early
treatment of patients identified through screening.
The potential for a wider range of generic statins
over the next 5–10 years and associated reductions
in the costs of all statins could potentially further
increase the cost-effectiveness.
The results of the sensitivity analysis of the effect
of adding a high-cost drug as third-line
combination therapy can be explained as follows.
If screening is undertaken, long-term HbA1c
control is improved. This means that more
patients remain below the HbA1c level at which
insulin would be added (8.3% was assumed), but
many could, if recommended by guidelines, be
taking triple combination drugs to control HbA1c
to target HbA1c levels applicable to patients using
oral agents (7.5% in the model).
Detailed analysis of base-case results
The following analysis relates solely to the costs
and benefits of treatment at screen detection
compared with treatment only after clinical
detection.
The QALY gain in the base case can be broken
down as follows:
Survival benefits
Discounted LYGs during the preclinical 0.013
period
Benefit of postclinical detection from 0.030
improved survival during the preclinical 
period
Benefit from being in ‘no CVD’ state versus 0.048











The benefit from reduction in first CHD events is
shown in Figure 5.
Table 22 shows cost and benefits of treating
screened detected diabetics compared with no
treatment until clinical detection. The results are
based on multiple simulations of 10,000 patients.
The incremental costs arising from earlier
treatment (i.e. at screen detection) can be











There is a significant reduction in microvascular
complications as a result of screening attributable
to:
● The long-term improved HbA1c control
predicted resulting from earlier detection and
treatment (see Figure 6) as observed in the
UKPDS.158 Similarly in the DCCT, the
screening HbA1c value was a major predictor of
subsequent HbA1c levels.
235
● The high sensitivity of retinopathy risk to
different levels of HbA1c, even at moderately
elevated levels.
● The microvascular risk equations take account
of historical HbA1c levels by using ‘mean
updated’ HbA1c, that is, the mean of the annual
values. (The HbA1c-based hazard ratios used by
Eastman and colleagues134 are based on the risk
gradients from the DCCT using mean updated
HbA1c values
235). This is important because the
substantial difference in HbA1c levels during the
preclinical period (see Figure 6) has some effect
on long-term risk. The elevated long-term risk
despite improved glycaemic control shown in
the DCCT as pre-DCCT exposure (determined
by screening HbA1c value and diabetes
duration) was a major predictor of subsequent
complications.235
Note that the complications submodels (i.e. CHD,
stroke, etc.) run in parallel to reflect the reality
that these are ‘competing risks’ – this means that
the level of risk in, for example, the CHD model
affects survival, thereby affecting the number of
patients remaining at risk. This can be seen in the
results – although CHD events are lower in the
screened cohort, stroke incidence is very similar
(despite the benefit of statins during the
preclinical period) and other-cause mortality is
higher in the screened cohort.
The initial drop in the screened curve is due to
patients starting diet and exercise and medication
after diagnosis.
































TABLE 22 Total lifetime incidence of events and years spent in health states: costs and QALYs arising through treatment per patient
Per patient
Opening Prevalence at end Incidences of all ‘State years’ Total costs (£) Utility (utility loss): 
prevalence events (non-fatal events) QALYs
Screening Screening No Screening No Screening No Screening No Difference Screening No Difference
screening screening screening screening Screening
Treatment
Utility of those alive 10,000 453 446 10.632 10.549 0.083
(unpenalised for complication):
Of which ‘Complication-free’ – – –
States
No retinopathy 9,276 229 159 178,286 147,445
Non-proliferative retinopathy 641 90 86 1,540 3,122 18,217 30,047 0.000 0.000 0.000
Proliferative retinopathy 84 5 8 61 193 1,869 2,807 2 9 –7 –0.002 –0.003 0.001
Significant macular oedema – 57 85 1,055 2,112 8,647 21,614 51 113 –63 –0.008 –0.022 0.014
Severe vision loss – 73 108 237 601 2,404 5,741 31 82 –50 –0.007 –0.019 0.012
No history of coronary heart 10,000 313 299 190,394 184,206
Non-fatal MI – 140 147 2,032 2,388 19,029 23,448 1,648 1,915 –267 –0.044 –0.056 0.012
Death (from MI only) 3,500 3,558 3,500 3,558 0
No cerebrovascular history 10,000 166 161 189,635 187,118
Stroke or transient ischaemic attack – 287 285 2,752 2,801 19,788 20,535 3,899 4,089 –190 –0.185 –0.194 0.009
Death due to stroke only 708 709 708 709 0
No nephropathy 9,681 261 226 175,296 164,320
Microalbumuria 281 142 135 2,124 2,630 29,417 34,586 –0.018 –0.022 0.004
Gross proteinuria 38 46 71 363 726 4,470 8,281 –0.003 –0.005 0.002
Dialysis – 1 5 32 64 97 207 103 250 –147 –0.000 –0.001 0.000
No nephropathy – post-transplant – 2 9 18 56 143 260 55 98 –43 –0.000 –0.001 0.000
Death due to nephropathy only 5 34 5 34
No previous PVD 10,000 366 352 202,825 197,521
PVD – 85 90 687 915 6,238 9,353 108 179 –70 –0.019 –0.031 0.012
Amputation (A1 or A2) – 2 4 79 145 359 780 44 86 –43 –0.005 –0.010 0.005
Death – multiple co-morbidities 19 20 19 20
Death – involving other causes 5,317 5,234 5,317 5,234
continued
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TABLE 22 Total lifetime incidence of events and years spent in health states: costs and QALYs arising through treatment per patient (cont’d)
Per patient
Opening Prevalence at end Incidences of all ‘State years’ Total costs (£) Utility (utility loss): 
prevalence events (non-fatal events) QALYs
Screening Screening No Screening No Screening No Screening No Difference Screening No Difference
screening screening screening screening Screening




1st line 77 0 77
2nd line 111 45 66
3rd line 95 82 14
4th line 0 227 –227
All other 0 0 0
Antihypertensive 398 364 34
Lipid-related 774 546 228
Total drug costs 1,455 1,263 193
Monitoring 1,348 821 526
Adverse event costs 41 43 316 320 –4
Totals 20,567 25,350 1,047,111 1,038,268 9,060 9,225 –165 10.339 10.184 0.156
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FIGURE 6 HbA1c trends (from time at which decide to screen or otherwise)
The HbA1c curves temporarily cross because of the
significant short-term fall in HbA1c on initiation
therapy at clinical detection in the 
no-screening cohort. This is only a short-term
effect, with HbA1c resuming its upward course
within a year or two. As clinical detection is
occurring at varying times, the curve of average
HbA1c is flattened out over the period during
which most unscreened patients are detected.




In the baseline scenario, offering screening to
everyone aged 40–70 years, screening appears to
represent a cost-effective intervention. This is due
to the cost reductions and QALY gains from
reductions in complications, largely from fewer
cardiovascular events (risk reduced largely by
statin treatment during the preclinical period) and
fewer individuals developing retinopathy and
other microvascular complications (risk reduced by
sustained improved glycaemic control).
The main economic trade-off is between:
1. the costs of the screening and diagnostic tests
2. the net cost of statins, other therapy and
monitoring costs (such as retinopathy
screening) during the period before clinical
detection minus the reduction in treatment
costs of cardiovascular events and retinopathy
3. the higher QALYs that result from earlier
intervention.
In addition to reduced retinopathy during the
preclinical period, the decision to screen or not
creates a modest but clinically significant
difference in HbA1c that leads to sustained
differential retinopathy incidence rates after the
point of clinical detection.
Sensitivity analyses show that whereas a prevalence
has a relatively minor impact on overall cost-
effectiveness, the cost-effectiveness of earlier
treatment is closely dependent on the costs and
effectiveness of subsequent treatment of
cardiovascular risk.
The trade-off between size of CVD risk reduction
and duration of benefit is seen in the results in
Table 20. The most cost-effective age groups to
screen and treat earlier appear to be the 50–59-
year and 60–69-year groups, these have a
sufficiently high CVD risk to obtain a significant
benefit from earlier intervention while having
sufficient remaining life expectancy to realise
medium- to long-term benefits. Although seeming
to be still cost-effective, the 40–49-year age group
is much less so than the other age groups as the
uncertainty in the various parameters could affect
whether this group, in particular, is cost-effective
to screen and treat. 
Comparison with previous models
Overall, the importance of key parameters
identified by previous models has been confirmed
and some additional areas of uncertainty,
particularly around the preclinical course of
diabetes, have been highlighted. As expected, the
cost-effectiveness of screening is strongly related to
the costs of screening/additional treatment and the
effectiveness of the additional treatment. The costs
and usage of statins become key parameters
because of the model assumption that one impact
of earlier diagnosis will mean that individuals at
high risk of CVD are started on statins earlier.
This is consistent with the CDC model, which
predicted that screening would be most cost-
effective in those with pre-existing hypertension
who would receive intensive, and cost-effective,
earlier treatment to reduce their cardiovascular
risk.131
Our modelling of the natural history gives an
estimated total preclinical duration of around
11 years, with 6–7 years being the average delay
between screen detection and symptomatic
detection, this is close to the assumption within
the CDC model. The average delay is probably
greater for younger age groups (the estimate is
about 8 years), assuming some correlation between
age and HbA1c at detection.
Previous models have also assumed linear HbA1c
progression, which could also result in an
underestimate of the potential benefits of earlier
treatment.
The large reduction in cardiovascular events
predicted is due to use of statins from diagnosis.
Some other diabetes screening effectiveness
evaluations were performed either before statins
were in widespread use or before the recent sharp
falls in the price (largely through expiry of
patents), and therefore would include either lower
risk reductions or greater costs.
The population in the present model excludes
those with existing CHD at baseline and has
reflected the move towards tighter blood pressure
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control in the general population. This means that
long-term survival in the modelled population is
higher. As a result, differences in survival arising
through screening (up to the point at which
clinical detection is made) result in a greater long-
term benefit than would otherwise have been
obtained.
Our model incorporates the relationship between
HbA1c at diagnosis and long-term HbA1c control.
Improved long-term HbA1c control arising
through screening is translated into long-term
reductions in microvascular complications.
Other models have also not considered the
potential benefit of reductions in long-term HbA1c
levels on CHD incidence. Although our base case
assumed a 14% CHD risk reduction per 1% fall in
mean updated HbA1c as per UKPDS 35,
221
sensitivity analysis indicates that screening would
still be highly cost-effective if this were 
only 5%.
Our test cost is low compared with other models.
Treatment costs are largely UK based, accounting
for some of the difference with other models. 
A utility of 0.77 was assigned to a person with
diabetes but no complications, whereas other
models tend to use 1.0. The latter does not reflect
either the reduced age-related quality of life of the
general population or the diabetes-specific loss of
quality of life arising from taking medication,
monitoring and so on. This explains why some
models report a utility gain through screening of
similar order to our model, despite much lower
reductions in complications.
Strengths and weaknesses of analysis
Due to the timescale involved, we have not
produced a state of the art model or made use of
more sophisticated modelling methods to
undertake evidence synthesis to structure or
populate the economic model. It has been
necessary to make various assumptions and
exploration of uncertainty has been limited to
simple sensitivity analyses. We have nevertheless
produced a screening model linked to the existing
fully developed treatment model to investigate the
order of magnitude of effects given different
scenarios for diabetes screening policies.
The model results are dependent on the choice of
model parameters and, although more complex
than some previous models, there are a number of
areas where complete data are unavailable. In
particular, the natural history of diabetes before
clinical diagnosis and the clinical characteristics of
cases detected by screening remain uncertain,
despite review of the best available evidence. For
this reason, a number of sources have been used
or different methods triangulated to estimate, for
example, the duration of disease between
screening and clinical detection and the HbA1c
trajectory.
Our modelling suggests that screening is cost-
effective across all populations between 40 and
70 years of age and across most one-way sensitivity
analyses. However, it cannot be concluded without
further analysis that this would be the case for
sensitivity analyses around every population. The
same applies if some of the sensitivity assumptions
were combined (e.g. higher monitoring costs and
lower CHD reduction from HbA1c lowering).
Equally, there is some uncertainty about the
relative cost-effectiveness of the alternative
populations.
A probabilistic sensitivity analysis would be
required to determine adequately the optimum
screening policy (see the subsections ‘Optimum
screening age’ and ‘Rescreening interval’, p. 82),
taking account of the impact of uncertainty and
exploring the most significant parameters.
Probabilistic sensitivity analysis would effectively
be a more comprehensive multivariate extension
of the one-way sensitivity analyses that have been
conducted so far, and would quantify the
likelihood of a screening policy being cost
effective. Methods have recently been developed
that reduce the heavy computational burden of
probabilistic sensitivity analysis for patient-level
models based on the algebra of analysis of
variance and Bayesian statistics,236 making a
rigorous uncertainty analysis feasible in reasonable
time. Our simulations have removed most ‘first-
order variability’ from the results but any
probabilitic sensitivity analysis should be large
enough to ensure that this is effectively
eliminated.
Potential for further modelling
Further development of existing model
parameters
Although this model has used the best available
published evidence on the natural history of
diabetes prior to clinical diagnosis, there is
potential to develop more sophisticated models. 
A gradual upsloping HbA1c curve during the
preclinical period was assumed, but there are some
suggestions that there could be a slow linear phase
followed by a more rapid linear phase (possibly
where beta-cell failure becomes more significant
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than insulin resistance). It would be useful to
incorporate more primary data on aspects of the
natural history of the development and early
progression of diabetes. Potential sources of data
include the Whitehall Study,237 the UKPDS,238 the
ADDITION trial95 and the DARTS Tayside
Regional Diabetes Network.239
Screening for both prevention/delay and earlier
detection of diabetes
This model addresses screening and earlier
treatment for diabetes. However, any screening
programme for diabetes will also identify
individuals who would benefit from interventions
to delay or prevent the development of diabetes.
This issue has been considered separately, but if
both prevention and early detection are deemed
to be cost-effective, it would be useful to model the
overall impact of screening on both prevention
and early treatment. 
Optimum screening age
Our modelling suggests that screening is cost-
effective for all age groups between 40 and
70 years. However, it may be that there is relatively
little incremental benefit from screening patients
in their 40s compared with waiting until they are
around 50 years old (but any future modelling
should also consider possible interactions between
age and rate of diabetes progression as discussed
below in the subsection ‘Patient variability in the
preclinical phase’).
Rescreening interval
Rescreening would not arise as an issue if a single
screening intervention to identify prevalence cases
of undiagnosed diabetes had not been
demonstrated to be cost-effective from a certain
age. However, if a prevalence-round screening
strategy is cost-effective, then clearly whether
rescreening should be done, and if so at what time
interval, should also be modelled. In practice,
once an individual has been given a screening test,
they will expect to be rescreened unless they can
assume they are no longer at a significant risk of
the condition screened for. This is unlikely,
particularly if they have already been offered a
screening blood test on the basis of the presence
of risk factors for diabetes.
Cardiovascular risk reduction
If screening for diabetes is considered in the
context of screening for CVD, then it would be
logical to quantify the additional value of
identifying both individuals at risk of diabetes
and individuals with diabetes within a
cardiovascular screening/risk reduction
programme. The model would still estimate the
overall costs and benefits of screening, but with
the objective of cardiovascular risk reduction. Such
an approach might reduce the potential for those
without diabetes but with other cardiovascular risk
factors to be ‘falsely reassured’ by screening. Our
model could be refined to restrict statin use to a
person diagnosed with diabetes once their CHD
risk exceeds a certain threshold.
Secondary CHD risk
The modelling has shown that the reduction,
through earlier treatment, in the prevalence of
CHD (non-fatal MI), at the time at which clinical
detection would otherwise have occurred, is a
significant driver of cost-effectiveness. It would be
possible to refine the secondary event rates so that
they are dependent on risk factors.
Relationship between nephropathy and CHD
CHD risk increases significantly with progression
from overt nephropathy to ESRD. The very high
costs of dialysis and renal transplantation are
reduced to some extent by screening (through
better long-term glycaemic control), but it would be
useful to model the risk relationship more precisely.
This is especially the case given the relatively high
long-term survival of our modelled population
(having no symptomatic CHD at baseline and tight
blood pressure control), because more patients
could live long enough to develop ESRD. 
Patient variability in the preclinical phase
It would be useful to consider the between-patient
variability in HbA1c changes – this may be
important because slow progressors are more likely
to be detected through screening as they spend
longer in the preclinical phase. Further
information on this variability might be obtained
using data from trials treating patients with IGT
and from UKPDS data.
The literature often refers to younger patients
experiencing a faster beta-cell decline than older
patients – it would be worth investigating this
further to see if this interaction is significant and,
if so, to quantify the impact on cost-effectiveness.
Newer agents
Any future work should include new therapeutic
developments; for example, if glucagon-like
peptide (GLP) analogues or dipeptidyl peptidase
IV (DPPIV) inhibitors can stabilise or reverse 
beta-cell decline, the benefits of early detection
may change. Inhaled insulin may change both the
costs and effectiveness of glycaemic control
(through improved adherence).
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Conclusions
The modelling undertaken has led to the
following conclusions:
1. Screening for diabetes appears to be cost-
effective for the 40–70-year age band subject to
limitations of the evidence available and within
the one-way (parameter and treatment protocol)
sensitivity analyses that we have carried out.
2. Screening for diabetes appears to be most cost-
effective for the 50–59-year and 60–69-year age
bands and less so for the 40–49-year age group.
3. Screening appears to be even more cost
effective for the hypertensive and obese
subgroups.
4. Further analysis should explore whether
screening is cost-effective under some
combined parameters and treatment sensitivity
assumptions, particularly for the 40–49-year
age band.
5. Assumptions about degree of control and
treatment protocols after clinical detection are
as important, if not more so, than assumptions
relating to the screening programme itself in
determining the cost-effectiveness of screening.
6. Although the results suggest that there is a
cost-effective screening programme, the
optimum age and other criteria are not
obtainable from these results and further work
is needed to determine this. The optimum
policy also needs to take account of the
optimum rescreening interval and the benefits
of treating patients detected with IFG or IGT.
7. Further uncertainty analysis (including
probabilistic sensitivity analysis) is required to
explore the robustness of our preliminary
conclusions and to prioritise any areas for
further research or modelling.
8. There appears to be limited quantified
evidence in the public domain describing the
natural history of diabetes before clinical
detection. Further work to understand this
would increase confidence in the estimated
time between potential screen detection and
clinical detection.
9. Further work to refine central estimates for
some parameters (such as CHD risk reduction
resulting from HbA1c reductions) would be
useful, possibly using expert elicitation.
Further work is also needed to establish the overall
cost-effectiveness if diabetes screening is
incorporated into a comprehensive risk reduction
strategy that includes assessment and
management of overall risk of CVD, including
assessment and management of IGT. However, it
seems plausible that including assessment of
glycaemia as an element of a cardiovascular risk
assessment and risk reduction intervention would
prove cost effective:
1. given the additional benefits (from reduction in
long-term complications) from earlier
intervention in individuals at significant risk of
CVD due to IGT and other associated risk
factors and
2. assuming the availability of cost-effective
interventions to offer to those identified as
being at risk.
Background to methods
Modelling of treatment and outcomes
post-diagnosis
We have developed a patient-level Markov
simulation model following the lifetime clinical
pathways of T2DM patients from diagnosis.
Patients’ attributes include age, sex, ethnicity,
smoking and baseline levels of HbA1c, cholesterol
and blood pressure. 
Each period, patients have their metabolic
variables monitored (which can be varied, but
usually 6-monthly or yearly) and if they exceed
thresholds on blood pressure or glucose control,
patients’ therapies are re-examined and switched
to the next therapy in a defined sequence; hence
the model can compare alternative therapy
sequence strategies in addition to alternative
tighter or looser control and monitoring of
metabolic variables. 
The risks of fatal and non-fatal events associated
with the key diabetes co-morbidities are examined
each period using published evidence on risk. The
co-morbidity modules are heart disease, stroke,
diabetic retinopathy, nephropathy and neuropathy.
These work in parallel and independently, so that
any individual patient may have a number of co-
morbidities at the same time. 
Patients’ quality of life is measured based on
published evidence of utility values of all of the
health states concerned. This enables a final result
of overall survival and QALYs to be calculated.
Similarly, costs of drugs, monitoring and related
co-morbid clinical events are included and
tracked, enabling a lifetime cost to be quantified. 
Risk factors and treatment for screening
detected cases in treatment model
Modelling the screening arm involves running the
model in the usual way, with characteristics of
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true-positive patients at screening forming the
baseline characteristics at diagnosis in the
treatment model. 
● Cholesterol: following the results of the Heart
Protection Study showing that statin therapy is
beneficial in diabetics regardless of baseline
cholesterol levels,79 the model assumes that all
patients with diabetes will be prescribed statins
on diagnosis, and benefit from a 30%
cardiovascular risk reduction (Waugh N,
University of Aberdeen; personal
communication).
● BG: it is assumed that patients are initially
treated with diet and exercise followed by
monotherapy, then combination oral agents
followed by the addition of insulin. Patients
progress to the next line of therapy if their
HbA1c exceeds the specified threshold in the
treatment model, namely 7.5%. The annual
HbA1c changes are based around (a) an
equation derived from UKPDS results58 to link
HbA1c falls during 3 months’ diet and exercise
treatment to the level at diagnosis and (b) the
equation provided in UKPDS 68,158 which
relates annual changes to HbA1c levels at
randomisation and levels in the previous year.
● Smoking: smoking status at baseline is included
in the risk calculations. The UKPDS 68
model158 gives a hazard ratio of 1.4 for current
smokers versus non-smokers. We have no
information on which to incorporate any
changes in smoking behaviour resulting from a
diagnosis of diabetes. Adoption of interventions
to increase smoking cessation at diagnosis of
diabetes would enhance the clinical benefits of
screening but entail additional costs.
● Blood pressure: the same threshold is assumed
for starting antihypertensive therapy as for
clinically detected patients, i.e. 135 mmHg. 
● Aspirin efficacy: aspirin is assumed to be 
taken where the 10-year CHD risk exceeds 
15%. The associated risk reduction achieved 
in primary CHD prevention in patients with
diabetes is uncertain, but analyses suggest 
some benefit.240 The present model uses a
modest default 5% CHD risk reduction as there
is no clear evidence that the benefit observed in
non-diabetic people is mirrored in diabetic
patients. If the risk is significantly greater, this
could increase the effectiveness of screening
because it would provide further benefit 
during the preclinical period at negligible
additional cost. 
Use of relative risk reductions
Where multiple RRs are applied to reflect the
effect of statins, HbA1c reductions, aspirin therapy
and so on, these have been applied on a
multiplicative rather than additive basis.
Calculation of diabetes prevalence in
specified population
The total prevalence of T2DM for the population
specified by the age, gender and ethnicity
variables is obtained from a link to the PBS
Prevalence Model3 (Yorkshire and Humber Public
Health Observatory). These calculations have been
adjusted to calculate only T2DM prevalence,
excluding the type 1 diabetes population.
There are options to filter patients further
according to hypertensive status and BMI levels.
Adjustments to the prevalence from the PBS
model are made using the following RRs:
● RR for diabetes if hypertensive = 1.67, which is
estimated from the RRs in the reports in the
KORA survey206 and the Inter99 Study.241
● RR for diabetes per unit BMI = 1.25 (based on
internal review242).
Where both hypertensive and BMI criteria are
specified, these two RRs have been multiplied
together and then multiplied by a factor of 0.67
to make a rough adjustment for the correlation
between hypertension and obesity, which was
estimated from the univariate and multivariate
relative risk reported in the Inter99 study.241
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The aims of screening
As discussed earlier, the aims of screening could
include:
● Detection of undiagnosed diabetes, with a view
to starting treatment aimed at lowering BG
levels and reducing the risk of the microvascular
complications of diabetes. Treatment would
start with diet and exercise, with hypoglycaemic
drugs added if necessary.
● Detection of people at risk of developing
diabetes, with a view to starting measures to
reduce progression to diabetes. Treatment
would be with diet and exercise.
● Identification of a group, comprising both of the
above, who are at increased risk of macrovascular
disease, and then treatment to reduce
subsequent CVD. Treatment would include
reduction of BG as above, but control of
hypertension and reduction of hyperlipidaemia
would probably be more important. A further
benefit would arise from treatment of
hypertension with ACEIs and ARBs, which would
prevent progression to diabetes in some people.
● An additional reason for screening might be
that even in those individuals already identified
as at high cardiovascular risk, knowledge of the
additional risk due to diabetes/hyperglycaemia
may motivate individuals to act to reduce risk
by increasing the perceived benefit (versus
inconvenience/personal cost) of lifestyle change
or taking medication – that is, the value of the
information to the individual rather than the
clinician.
Diabetes and IGT confer an increased risk of
macrovascular disease, but the increase with IFG is
much less. Hence if the main aim is to reduce
future heart disease, detecting IFG is less
important. This has implications for the screening
test. It makes FPG less attractive. The remaining
options are then the OGTT (reduced to a 2-hour
challenge test after 75 g of glucose) or HbA1c.
In favour of HbA1c test is that it is simpler to
perform than the 2-hour OGTT and is more
reproducible, and that we have data from the
Norfolk Study showing that it is associated with
CVD across a wide spectrum. 
As Goyder and Irwig10 pointed out, people with
diabetes detected by screening are at high risk of
macrovascular disease but at comparatively low
risk of microvascular disease. In the UKPDS, those
whose diabetes was asymptomatic had lower FPG
and fewer microvascular complications at
diagnosis and were at lower risk in the years which
followed (admittedly, not all had diabetes – the
entry criterion was FPG over 6 mmol/l).
Could it be argued that in people known to be at
high risk of heart disease, because of factors such
as hypertension, high cholesterol levels and
overweight, that testing BG level would provide
little additional benefit, since they should already
be treated with antihypertensive agents, diet and
statins? (Diet because it helps reduce both
cholesterol and blood pressure.) Many of this
group would be able to control their
hyperglycaemia on diet alone.
Arguments against such a position is that they are
at some risk of microvascular disease at diagnosis,
that the natural history of the disease is that beta-
cell failure appears progressive (UKPDS 16),243
that most require additional antihyperglycaemic
therapy over time (UKPDS 16)243 and that the
marginal cost of adding an FPG or an HbA1c test
is low when fasting blood is being taken for lipid
estimation anyway.
Screening interval
Assuming the first screen is at age 45 years, when
should people be rescreened? Rather than have a
fixed interval for all, the second screen could
depend on the result of the first. If an HbA1c level
of 6% is taken as the threshold for intervention (at
that level, with diet, exercise and monitoring over
time), and if it is assumed that HbA1c rises by 0.2%
per year (in those in whom it does rise), then the
interval in years could be
6.0 – HbA1c at age 45/0.2
Those whose HbA1c had not risen at second screen
could be reassured and not recalled. The recall
interval could be based on rate of rise. If the age
expected to reach an HbA1c of 6% or more was
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Chapter 6
Discussion
over 70 years, then perhaps they could also be
discharged (on the grounds that screening for
diabetes at age over 70 years is not worthwhile).102
However, the above arguments make an
assumption that rise in HbA1c is linear. This is not
known, and given that the rate of rise may vary
amongst patients, and that it may not be linear, it
would probably be safer to recall at a fixed interval
for the first two rounds of screening. The resulting
data should then provide the evidence base for
future recall policy.
At present there are insufficient data on which to
base any screening interval. A pragmatic approach
might be to screen by risk factors at age 45 years,
screen by BG in those who were risk-factor positive
and then re-screen a random sample of BG-negative
people at, say, 5 years as part of a research project.
Research needs
1. Research is needed into ways of reducing the
prevalence of insulin resistance. More research
is also needed into which forms and amounts of
exercise are effective in reducing hyperglycaemia
and the effect on cardiovascular risk. Why do
some people become insulin resistant when
overweight whereas others do not? Is exercise
the key factor?
2. The main need is to find ways of achieving
compliance with diet and other lifestyle
measures in order to reduce overweight and
obesity. How can public health campaigns be
made more effective?
3. In the UKPDS, HbA1c rose in all treatment
groups. However, the groups included those
who gained and those who lost weight.
Research is needed into whether the rise over
time is seen also in those who reduce weight
and take exercise. Would return to normal
weight, or close to it, coupled with regular
exercise to reduce insulin resistance, abort the
beta-cell failure over time?
4. If screening is to be introduced, should it be
one-off; if not, what should the interval be?
Data are needed on the rise in glucose over
time, and whether it is linear.
5. If blood is being taken for glucose
measurement, what other investigations would
be cost-effective at the same time? A lipid
profile for HDL, LDL and triglycerides?
6. Where should screening stop? Should it be for
undiagnosed diabetes, or that plus IGT, or for
the wider metabolic syndrome? What cut-off
should be used, to strike the optimum balance
amongst sensitivity, specificity and what the
NHS can cope with?
7. What is the optimum balance between 
the clinical approach of identifying and
treating individuals and the public health
approach of intervention at population 
level? 
Some of the public health questions will be
addressed by the Public Health appraisal function
now taken over by NICE. The appraisals will
inevitably pose another broad question:
8. Which public health or health promotion
interventions are not cost-effective and should
be stopped? These may include current ad hoc
screening activities that could be stopped or
targeted more efficiently.
Research currently under way includes:
● The ADDITION study – do screening and early
diagnosis and intervention reduce
cardiovascular risk? (Griffin S and Khunti K:
personal communication, 2005).
● The Whitehall Study, which should yield
information on the potential benefits of
screening (Brunner E: personal communication,
2005).
● The Diabetes Heart Disease and Stroke
Prevention Study of screening in a routine
setting, including in less affluent areas, and
those with a high proportion of ethnic
minorities, is already showing differences in
uptake of screening, and in percentages of
people with new diabetes (Goyder E: personal
communication, July 2005).
● The 1958 Birth Cohort Study, which is
examining risk scores and their marginal
benefits over simply using BMI, and also
regional variations in prevalence (Power C:
personal communication, 2005).
Does screening for diabetes and
IGT meet the NSC criteria?
The UK NSC criteria for evaluating screening
programmes were adapted from the WHO 
criteria published in 1968.244 The criteria are
published by the NSC on their website
(http://www.nsc.nhs.uk/pdfs/criteria.pdf).
This section applies the criteria to screening for
diabetes and lesser degrees of glucose intolerance
and summarises the evidence presented in the
previous chapters. Our view on the extent to which
the criteria are satisfied is appended in bold at the
end of the text on each criterion.
Discussion
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The condition
Criterion 1. The condition should be an
important public health problem
Whether the problem is defined as diabetes, all
degrees of glucose intolerance, the metabolic
syndrome or even wider as overweight and obesity,
it is an important public health problem. The level
of individual risk will vary according to the scope
of the definition – in some cases at the margin, the
individual health problem, in terms of excess risk,
will be slight. However, because of the very large
numbers involved, even slight increases in risk
amount to a major public health problem. The
‘Rose principle’ applies here – there is more to be
gained from a leftward shift in the population risk,
even if the individual benefits are small, compared
with only identifying those at the high-risk right
end of the population curve.245 However, both
approaches can be applied.
Criterion met.
Criterion 2. The epidemiology and natural history
of the condition, including development from
latent to declared disease, should be adequately
understood and there should be a detectable risk
factor, or disease marker, and a latent period or
early symptomatic stage
This was discussed at length in Chapter 1. There
are several uncertainties about natural history:
● Is the progression to diabetes linear
throughout, or is there a slow initial phase
followed by a faster decline in beta-cell
function? This would affect screening interval.
● Why do some people with IGT progress to
diabetes, whereas about half return to
normality? What do the half do that ensures
improvement?
● Is the progression always IGT, then IFG, then
diabetes? Or are there two pathways?
● In people diagnosed with T2DM, is progression
inevitable as shown in UKPDS overall – or do
those who lose weight and take exercise have
much slower progression, or indeed regression
to normal, as shown in the Malmo trial?
However, answers to all of these questions are not
needed before screening can start. Enough is
known about natural history on a population basis
(for example, a sizeable minority of those with
IGT will progress to diabetes; many with
undiagnosed diabetes will be developing
retinopathy; many people with diabetes will have
advancing but asymptomatic heart disease, the
first manifestation of which may be a fatal MI).
Criterion met.
Criterion 3. All the cost-effective primary
prevention interventions should have been
implemented as far as practicable
Primary prevention of T2DM involves several
aspects:
● Public health campaigns to encourage the public
to avoid overweight and take exercise. A review
of the evidence on interventions at population
level is outwith the scope of this review. 
● Intervention on a personal basis in those who
can be identified as being at higher risk of
T2DM, such as those with IGT as already
mentioned. There is good trial evidence that this
can be effective, and our review of the economic
evidence shows that intervention is cost-effective,
but that refers to prevention of diabetes alone.
The main problem with public health measures is
not cost-effectiveness (most campaigns would be
inexpensive because they are delivered to large
numbers) but clinical effectiveness. There have
been many campaigns at varying levels, from mass
media campaigns about healthy eating to local
initiatives at health authority level such as trying
to encourage people to ‘walk about a bit’. Yet the
prevalence of overweight and obesity continues to
rise. The research need arising from this has been
mentioned above. We know that lifestyle measures
can work; if they do they would be cost-effective
(measures such as diet and exercise being largely
cost free to the NHS).
Criterion met? For diabetes, yes. For IGT and
IFG, unproven. Prevention certainly possible in
theory.
Criterion 4. If the carriers of a mutation are
identified as a result of screening, the natural
history of people with this status should be
understood, including the psychological implications
Not applicable.
The test
Criterion 5. There should be a simple, safe,
precise and validated screening test
As discussed in Chapter 3, screening would be two
stage – assessment of risk by ‘questionnaire’ but
with most of the necessary data already held on
general practice computer systems; and then BG
measurement in those at higher risk. The decision
on the risk level at which to intervene would be
influenced by the capacity of the service to cope
with those newly diagnosed.
There have been various ways of achieving the
first stage, and the debate is not about validation
but about the marginal benefits of adding or
removing additional items.
For the second stage, there are three acceptable
tests – FPG, OGTT and HbA1c. All are safe,
precise and validated. However, each has its
advantages and disadvantages. OGGT is
inconvenient, poorly reproducible and has to be
repeated, and would probably not qualify as
simple. FPG requires people to fast, compliance
may be imperfect and those with isolated IGT
would be missed. HbA1c is more expensive but can
be done at any time of day and reflects glycaemia
over a period of several months.
But the debate is about which test is best – all are
acceptable.
Criterion met.
Criterion 6. The distribution of test values in the
target population should be known and a suitable
cut-off level defined and agreed
The distribution of test values is known from
population-based research studies. The cut-off level
depends on whether screening is for diabetes,
diabetes plus IGT or wider. The case for screening
for metabolic syndrome is unproven pending
further research. Hence it could be assumed that
screening is only for diabetes and IGT, using HbA1c
or the 2-hour PG. The cut-off would be for debate,
partly influenced by what it was felt the NHS could
cope with, but might be based more towards the
levels shown to increase risk in the EPIC 
Norfolk study, rather than the HbA1c of 7%
suggested on the basis of being the level at which
pharmacological treatment might be necessary.
Criterion met.
Criterion 7. The test should be acceptable to the
population
The evidence is that the test is acceptable to many,
but not all. For example, unpublished data from
the Leicester ADDITION study shows a poor
uptake (Griffin S and Khunti K, ADDITION Study
Group, Cambridge and Leicester: personal
communication, July 2005), although that was in
the context of a trial and may have been affected
by an information overload imposed by ethics
committees. There seems to be a wish on behalf of
Diabetes UK, the key consumer organisation, for
screening to be provided.
In any case, screening would be offered, and those
who did not wish it would not need to accept. 
Criterion met.
Criterion 8. There should be an agreed policy on
the further diagnostic investigation of individuals
with a positive test result and on the choices
available to those individuals
There is agreement on further investigation, 
with the key rule being that one abnormal 
glucose level should always be confirmed. In
asymptomatic people, diabetes should not be
diagnosed on the basis of one result. If the 
initial screening test was HbA1c, the follow-up 
test could be an FPG, for simplicity. If that was
normal, a 2-hour post-load PG could be 
sought.
Criterion met.
Criterion 9. If the test is for mutations, the
criteria used to select the subset of mutations 
to be covered by screening, if all possible




Criterion 10. There should be an effective
treatment or intervention for patients identified
through early detection, with evidence of early
treatment leading to better outcomes than late
treatment
The question of which condition is to be screened
for is less important here, because initial treatment
for T2DM, IGT and the metabolic syndrome
would be the same – diet and exercise. Statins
might be added.
There is a good evidence base for treatment of
diabetes itself. Several trials have shown that the
progression to diabetes from IGT can be reduced
by lifestyle changes or drug treatment (see
Appendix 3). Lifestyle changes can also improve
control of diabetes. A meta-analysis of the effects
of exercise246 showed that it reduced HbA1c
by a clinically significant amount of 0.66% (which
is not far off the difference between the intensive
and control groups in UKPDS). Interestingly, 
the benefit of exercise was achieved without 
weight loss.
Other aspects of management of diabetes include
screening for complications; the case for eye
screening is beyond doubt and has been addressed
by previous NSC policy considerations.
The key issue is whether treatment earlier in the
disease process is better than later treatment once
the condition has become symptomatic. The aim
of treatment is to prevent the complications of
Discussion
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diabetes. Some people have retinopathy at
diagnosis (UKPDS) but rarely to a sight-
threatening stage, so earlier treatment is unlikely
to prevent more visual loss than later. Similarly,
nephropathy takes time to develop. 
However, vascular disease is the main risk in the
group which would be affected by screening. 
IHD is often asymptomatic until an MI occurs,
and the first MI may be fatal. The risk can be
reduced by about one-third by statin therapy.
Hence earlier treatment would have clear
advantages. Many of the people in this metabolic
group will have other risk factors, but the
diagnosis of diabetes or IGT may result in them
crossing the NICE 2% per year threshold, and
being treated with a statin.
In the absence of RCTs of screening versus no
screening, we have to try to obtain evidence on
whether earlier treatment gives better outcomes
from other studies. Data from the UKPDS have
been used for this purpose58 by examining
outcomes according to FPG at diagnosis. Those in
the lowest tertile of initial FPG were more likely to
be asymptomatic and found by screening (such as
insurance or employment medical examinations).
They had less retinopathy at diagnosis and had
fewer complications during the study. However,
this may just mean that they were at an earlier
stage of the disease – lead time bias. It could also
be because they had a milder form of the disease,
but their rise in PG over time was similar to that
in the other groups, so that seems unlikely.
Nevertheless, they were diagnosed with fewer
complications, and there is scope to reduce the
future development of complications by
intervention.
Criterion met.
Criterion 11. There should be agreed evidence-
based policies covering which individuals should
be offered treatment and the appropriate
treatment to be offered
Initial treatment would be diet and exercise, and
monitoring for progression to levels at which
pharmacological treatments would be given. For
statins, this might be at a risk level of 2% or more
per annum, aiming at a total cholesterol of
5 mmol/l or less. For HbA1c, the aim might be to
keep it under 7% (ADA) or 7.5% (NICE), with
metformin the first-line drug. The meglitinide
analogues might be considered if the problem is
mainly post-prandial hyperglycaemia.
Criterion met.
Criterion 12. Clinical management of the
condition and patient outcomes should be
optimised in all healthcare providers prior to
participation in a screening programme
Many patients with T2DM are not well 
controlled, and many may not be on, for example,
statin therapy. Only 43% of people with 
diabetes in Scotland for whom an HbA1c result was
available for the Scottish Diabetes Survey, 
had an HbA1c under 7.5%, the NICE 
guidelines target. These data also include people
with type 1 diabetes, but are numerically
dominated by T2DM. However, guidelines for
management of diabetes have been issued by
NICE, as has guidance on statin use.86 It may
take some time for these to work through the
system.
Hence there is more to be done to optimise care
and outcomes thereof for existing patients, and it
could be argued that they should take first priority.
Adding an additional load of new patients would
make it more difficult to achieve this.
Criterion not met.
The screening programme
Criterion 13. There should be evidence from high-
quality randomised controlled trials that the
screening programme is effective in reducing
mortality or morbidity
As yet, no RCTs of screening for diabetes have
been reported. However, one is under way. The
ADDITION Study is an RCT of systematic
screening and targeted cardiovascular risk
reduction in primary care, being carried out in
Cambridge, Denmark and the Netherlands.95
However, the screening phase was not due to be 
completed until late 2006, after which there will 
be a 5-year follow-up period. Hence results 
will not be available for the next review of 
NSC policy.
Criterion not met.
Criterion 14. There should be evidence that the
complete screening programme (test, diagnostic
procedures, treatment/intervention) is clinically,
socially and ethically acceptable to health
professionals and the public
Screening would only be offered, not imposed,
and details of follow-up investigations and
treatments would be included with the invitation.
Hence only those who found the complete
programme acceptable would attend for screening.
Criterion met.
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Criterion 15. The benefit from the screening
programme should outweigh the physical and
psychological harm (caused by the test,
diagnostic procedures and treatment)
Any screening programme has the potential to
convert a healthy person into ‘a patient’. Being
labelled as diabetic could cause anxiety, in addition
to possibly having adverse effects on some forms of
employment (although that is more of a problem
with insulin-treated diabetes). The anxiety would
depend on the perceived seriousness of diabetes to
the newly diagnosed person.
In the Hoorn study,106 the psychological impact of
screening was assessed by qualitative methods (semi-
structured interviews) in 20 patients newly
diagnosed (mean age 62 years) and 20 at increased
risk of diabetes but who tested negative. The main
limitation of the study was the small numbers
involved. The results indicate that the fact of the
diagnosis caused little alarm. This may have been, as
the authors report, because only one of the new
diabetic patients regarded the disease as serious,
and because about half felt that they had control, in
the sense that they believed they could take effective
action to deal with it, such as dieting. Their mean
BMI was 28.6 kg/m2, so their belief seems justified.
More harm might ensue in the group who were at
risk but who tested negative. Adriaanse and
colleagues106 note that this group may have been
so reassured by the result that they saw no reason
to adjust their lifestyles.
Criterion met? Uncertain.
Criterion 16. The opportunity cost of the
screening programme (including testing, diagnosis
and treatment, administration, training and
quality assurance) should be economically
balanced in relation to expenditure on medical
care as a whole (i.e. value for money)
The economic analysis suggests that screening for
IGT and prevention of diabetes would be cost-
effective, although not all costs have been
identified. If screening was, as assumed, based in
primary care, there would presumably be a form
of target or points-based systems to remunerate
practices. The cost of the programme would
depend on the number of people invited for
screening and the response rate. Screening might
only be offered to those with BMI 30 kg/m2 or
over, although any such cut-off would be an
arbitrary line in a continuum of risk. The
modelling exercise in Chapter 5 shows that
screening would be more cost-effective in the
obese or the hypertensive, but not dramatically so.
Criterion met. 
Criterion 17. There should be a plan for
managing and monitoring the screening
programme and an agreed set of quality
assurance standards
Not applicable until a decision is made in
principle to provide screening. A quality
assessment system for HbA1c exists.
Not applicable.
Criterion 18. Adequate staffing and facilities for
testing, diagnosis, treatment and programme
management should be available prior to the
commencement of the screening programme
Primary care services and diabetes clinics are
already under pressure. It is unlikely that they
could cope with a large extra load at present.
Screening could be brought in slowly, and a high
threshold for positivity used, at least in the early
stages.
Criterion not met.
Criterion 19. All other options for managing the
condition should have been considered (e.g.
improving treatment, providing other services), to
ensure that no more cost-effective intervention
could be introduced or current interventions
increased within the resources available
The main option other than screening would be a
public health programme to encourage people to
keep weight down and take exercise. The rise in
overweight and obesity implies that past and
present public health campaigns have failed. Is it
worth trying harder, or trying new options such as
‘exercise prescriptions’? Is there a danger of
‘medicalising’ unhealthy life style and reducing the
emphasis on personal responsibility for health?
It was noted that the best way to identify people
for screening would be to identify them from
general practice records. Instead of inviting them
for screening, the data could be used for targeted
health promotion interventions such as for weight
loss or exercise.
Criterion met? Uncertain.
20. Evidence-based information, explaining the
consequences of testing, investigation and
treatment, should be made available to potential
participants to assist them in making an informed
choice.
The evidence exists and would be supplied when




Criterion 21. Public pressure for widening the
eligibility criteria for reducing the screening
interval, and for increasing the sensitivity of the
testing process, should be anticipated. Decisions
about these parameters should be scientifically
justifiable to the public
The problem here might be that the decisions of
screening policy, such as whom to invite, would
depend partly on cost-effectiveness aspects, which
may not be understood by the public.
Criterion met? Uncertain
Criterion 22. If screening is for a mutation the
programme should be acceptable to people




Of the 22 criteria:
● 12 are met.
● Three are not met.
● In three there is uncertainty.
● Four are not applicable.
Conclusions
Targeted screening for T2DM meets most but not
all of the NSC criteria. The main failure is that
there is no RCT of screening. Screening also
appears to be cost-effective.
However, several issues need to be resolved. The
main aim of screening would be to reduce CVD,
and that is increased not only in diabetes but also
in IGT, and to a lesser extent in IFG. Depending
on which test for BG was used and what cut-off
was used to define ‘positives’, many more people
with IGT would be found than with diabetes. A
decision is needed on what to do for them.
The first national policy decision might therefore
be whether to screen for diabetes, or to have a
broader, integrated approach to reduction of CVD.
The next decision might be the balance of
investment in public health/health promotion
measures, versus individual screening and care. 
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1. exp *Diabetes Mellitus, Type 2/ 
2. exp Mass Screening/ 
3. (diabetes and screening).m_titl. 
4. 1 and 2 
5. 1 and 3 
6. 4 or 5 
7. limit 6 to (english language and yr="2000 –
June 2005") 
EMBASE
1. exp *Non Insulin Dependent Diabetes Mellitus/ 
2. exp Mass Screening/ 
3. (diabetes and screening).m_titl. 
4. 1 and 2 
5. 1 and 3 
6. 4 or 5 
7. limit 6 to (english language and yr="2000 –
June 2005")
The Cochrane Library 2005, 
Issue 2 – all sections 
#1 MeSH descriptor Diabetes Mellitus, Type 2
explode all trees in MeSH products 
#2 MeSH descriptor Mass Screening explode all
trees in MeSH products 
#3 (#1 AND #2) 
#4 screening in Record Title and diabetes in
Record Title in all products 
#5 (#3 OR #4)
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Appendix 1
Search strategies
The UK NSC criteria for evaluating screeningprogrammes were adapted from the WHO
criteria published in 1966.  The criteria are
published by the NSC on their website
(http://www.nsc.nhs.uk/pdfs/criteria.pdf).
The condition
1. The condition should be an important health
problem.
2. The epidemiology and natural history of the
condition, including development from latent
to declared disease, should be adequately
understood and there should be a detectable
risk factor, disease marker, latent period or
early symptomatic stage.
3. All the cost-effective primary prevention
interventions should have been implemented
as far as practicable.
4. If the carriers of a mutation are identified as a
result of screening the natural history of
people with this status should be understood,
including the psychological implications.
The test
5. There should be a simple, safe, precise and
validated screening test.
6. The distribution of test values in the target
population should be known and a suitable
cut-off level defined and agreed.
7. The test should be acceptable to the
population.
8. There should be an agreed policy on the
further diagnostic investigation of individuals
with a positive test result and on the choices
available to those individuals.
9. If the test is for mutations the criteria used to
select the subset of mutations to be covered by
screening, if all possible mutations are not
being tested, should be clearly set out.
The treatment
10. There should be an effective treatment or
intervention for patients identified through
early detection, with evidence of early
treatment leading to better outcomes than late
treatment.
11. There should be agreed evidence-based
policies covering which individuals should be
offered treatment and the appropriate
treatment to be offered.
12. Clinical management of the condition and
patient outcomes should be optimised in all
healthcare providers prior to participation in
a screening programme.
The screening programme
13. There should be evidence from high-quality
RCTs that the screening programme is
effective in reducing mortality or morbidity. 
14. There should be evidence that the complete
screening programme (test, diagnostic
procedures, treatment/ intervention) is
clinically, socially and ethically acceptable to
health professionals and the public.
15. The benefit from the screening programme
should outweigh the physical and
psychological harm (caused by the test,
diagnostic procedures and treatment).
16. The opportunity cost of the screening
programme (including testing, diagnosis and
treatment, administration, training and
quality assurance) should be economically
balanced in relation to expenditure on
medical care as a whole (i.e. value for money).
17. There should be a plan for managing and
monitoring the screening programme and an
agreed set of quality assurance standards.
18. Adequate staffing and facilities for testing,
diagnosis, treatment and programme
management should be available prior to the
commencement of the screening programme.
19. All other options for managing the condition
should have been considered (e.g. improving
treatment, providing other services), to ensure
that no more cost-effective intervention could
be introduced or current interventions
increased within the resources available.
20. Evidence-based information, explaining the
consequences of testing, investigation and
treatment, should be made available to
potential participants to assist them in making
an informed choice.
Health Technology Assessment 2007; Vol. 11: No. 17
109
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Appendix 2
The NSC criteria
21. Public pressure for widening the eligibility
criteria for reducing the screening interval,
and for increasing the sensitivity of the testing
process, should be anticipated. Decisions
about these parameters should be scientifically
justifiable to the public.
22. If screening is for a mutation, the programme
should be acceptable to people identified as
carriers and to other family members.
Appendix 2
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Early detection and primary
prevention of type 2 diabetes
This section starts by looking at the conclusions of
reviews published since the last NSC review of the
topic; then at primary studies published since
then; and lastly at studies on the management of
‘prediabetes’.
Background (reviews of studies
published prior to 2002)
Two of the reviews mentioned in this opening
section are chapters contained in Williams and
colleagues.247 They are not, in the true sense of
the term, ‘systematic reviews’ in that they were not
planned and carried out according to guidelines
such as those advocated by the Cochrane
Collaboration. Nevertheless, they provide a
reasonably comprehensive and critical coverage of
the literature up until the date of publication of
that text. The third is a consensus statement
issued as part of the WHO (World Health
Authority) diabetes programme. It was the result
of the deliberations of an expert group which met
in May 2002 in Geneva. 
‘Prevention of type 2 diabetes’, RF Hamman248
The work cited by Hamman is summarised in
Table 23 and the studies that he cited in Table 24.
His overall summary of this body of evidence was
as follows:
SUMMARY
The available data now provide a firm answer that
type 2 diabetes can be delayed or prevented in high-
risk subjects. Trials currently underway should
provide substantial evidence about the impact of
specific pharmacologic interventions on diabetes
prevention. 
With the current level of information, it is reasonable
to recommend a programme of moderate levels of
physical activity, weight maintenance or modest
weight loss (for overweight people), and a low-fat,
calorie-moderated diet for the positive effects this will
have on cardiovascular and other risks for large
numbers of people. In addition, subjects at high risk
should have specific risk factors for cardiovascular
disease treated (e.g. lipids, blood pressure). The
recent results from ACE-inhibitor trials suggest that
such agents may also lower diabetes risk as an
important benefit.
The phrase “… for the positive effects this will
have on cardiovascular and other risks for large
numbers of people.” is interesting in the light of
the fact that very few of the studies identified had
cardiovascular risk factors as primary end-points.
These included RCTs carried out as a follow-up to
the Bedford study249,250 in which tolbutamide
(500 mg twice daily) with and without dietary
advice was compared with placebo with and
without dietary advice. No significant differences
were found between any of the groups. Paasikivi251
investigated the same dose of tolbutamide versus
placebo and found that the difference in CVD
mortality seen at 18 months did not persist
beyond that time. The Malmöhus study,252 which
made similar comparisons, found no significant
differences in CVD mortality. 
‘The evidence to screen for type 2 diabetes’,
Engelgau and Narayan253
Table 25 provides a summary of the results (costs in
US dollars and cost per QALY gained) derived
from the lifestyle simulation model described in
their reference 76 (CDC Diabetes Cost-
Effectiveness Study Group, 1998).131 These results
and scrutiny of other evidence as it was then led to
the following conclusions:
CONCLUSIONS
The effectiveness of diabetes screening has not been
directly demonstrated. Indirect examination of the
potential benefits of screening using data from RCTs
of treatment of diagnosed diabetes, observational
studies and disease models lend some support to the
idea that early improvement in glycaemic control may
help reduce the lifetime occurrence of microvascular
disease. There is little convincing evidence that there
will be macrovascular disease reductions. The
physical, psychological and social effects of screening
and early diagnosis and treatment remain unclear.
Thus, on balance, there is only modest evidence, at
best, supporting screening for type 2 diabetes. (Level
of evidence II-3; Strength of Recommendation B.)
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TABLE 23 Search strategy and results
Search question:
To identify existing guidelines for prediabetes/T2DM: prevention, screening, early identification
Keywords – thesaurus/free text/MeSH Prediabetes, prediabetic state, type 2 diabetes, non-insulin-
dependent diabetes mellitus, prevention and control,
primary prevention, screening, impaired glucose tolerance,
impaired fasting tolerance
Publication types – guidelines, systematic reviews, press Studies, reviews or best evidence only
releases, conference proceedings, published statistics, etc.
Limitations
Language English




Evidence-based resources including Cochrane, Clinical 
Evidence and guidelines
Public health and health management and knowledge HMIC
bases (HMIC , NPHS Library catalogues 
Clinical databases (MEDLINE, EMBASE, CINAHL) MEDLINE, EMBASE
Specialist databases
Grey Literature Sources (SIGLE, HMIC), specific Databases 
(Dissertation Abstracts, NRR Research Registers and ASSIA, 
CRD)
Internet – health gateways – OMNI 
Specialised collections relevant to topic (Royal Colleges, 
professional Associations)
UK Health Departments
Affiliated organisations – HPA, HP
Wider NHS – NeLH, PHOs, HDA
Non-NHS – LAs, academia
European/international authoritative sources – EU, WHO
Expert opinion
Frequently cited authors within specialist field, colleagues, 




1 prediabetes.mp. or *Impaired Glucose Tolerance/ 1,165
2 "PREVENTION AND CONTROL"/ or PRIMARY PREVENTION/ 5,385
3 1 and 2 7
4 limit 3 to (human and english language and yr=1999–2004) 6
5 from 4 keep 1–3 3
6 *SCREENING/ 3,907
7 Non Insulin Dependent Diabetes Mellitus/ or type 2 diabetes.mp. 32,844
8 (7 or 1) and 6 21
9 8 21
10 limit 9 to (human and english language and yr=1999–2004) 4
11 from 10 keep 1–2 2
continued
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TABLE 23 Search strategy and results (cont’d)
MEDLINE
Search history Results
1 Mass Screening/ 20,579
2 Prediabetic State/or prediabetes.mp. 310
3 *DIABETES MELLITUS, TYPE II/pc [Prevention & Control] 676
4 2 or 3 972
5 *PRIMARY PREVENTION/ 1,692
6 (2 or 3) and (5 or 1) 91
7 limit 6 to (human and english language and yr=1999–2004) 48
HMIC
Search history Results
1 prediabetes.mp. or exp PREDIABETIC STATE/ 2
2 exp DIABETES/ 834
3 prevention.mp. or exp PREVENTIVE MEASURES/ 12,489
4 exp SCREENING/ 2,750
5 type 2.mp. 124
6 1 and (3 or 4) 0
7 impaired glucose.mp. 17
TABLE 24 Studies cited by Hamman248
1. Intervention: combined lifestyle interventions (mainly dietary modification aimed at weight loss and
increased physical activity)
Type Study group Outcome No. of Referencesa
studies
Randomised trials Normal glucose tolerance Glucose 9 45–50, 52–54, 56, 63, 64, 67, 280
Overweight, normal glucose tolerance Glucose 2 60, 62
Hyperinsulinaemia Glucose 2 43, 44
Glucose intolerance Diabetes 1 42
IGT Diabetes 3 55, 59, 68, 69
Non-randomised Glucose intolerance Diabetes 1 73
trials or cohort IGT Diabetes 1 57
studies IGT Mortality 1 77
Family history of diabetes Diabetes 1 78,79
2. Intervention: physical activity alone
Type Study group Outcome No. of Referencesa
studies
Randomised trials None
Non-randomised Various (mostly mixtures of subjects Diabetes 19 76, 103–111, 113, 114, 116–122, 





TABLE 24 Studies cited by Hamman248 (cont’d)
3. Intervention: dietary modification alone





Cohort studies Various (mostly mixtures of subjects Diabetes 20 5, 107, 114, 123, 140–143, 146–150, 
with normal and abnormal glucose 154, 155, 157–159, 161, 162, 238
tolerance)
4. Intervention: pharmacological agents (with or without lifestyle modification)
Type Study group Outcome No. of Referencesa
studies
Tolbutamide vs Glucose intolerance Glucose, 5 181, 184–186, 190, 192, 194, 196, 





study – had 
CVD as 
outcome)
Tolbutamide vs Glucose intolerance Diabetes 1 187, 188
phenformin vs 
placebo
Chlorpropamide vs Glucose intolerance Normalisation 1 195
tolbutamide vs of glucose 
phenformin tolerance
Glicazide vs IGT, IFG or fasting hyperglycaemia Glucose 2 56, 199, 281
placebo tolerance
Glibenclamide (G) Glucose intolerance Glucose 1 202
vs Biguanide (B) vs tolerance
G + B vs placebo
Phenformin vs Glucose intolerance Diabetes 1 204, 205
placebo
Phenformin + diet Glucose intolerance Glucose 1 206
tolerance
Metformin vs High waist:hip ratio; subjects with IGT Glucose 4 70–72, 207–210, 212
placebo or IGT + overweight or obesity tolerance, 
lipids, diabetes
Troglitazone vs Normal, overweight or IGT or GDM Glucose or 5 216, 218, 217, 221, 220
placebo diabetes
Acarbose vs placebo IGT Diabetes 2 222, 223




Ramipril vs placebo Mixed normal and hypertensive Diabetes 1 225
Pravastatin vs Non-diabetic men with elevated Diabetes 1 240
placebo cholesterol
a These are references numbered as in the original review,248 not in the present report.
‘Screening for type 2 diabetes. Report of a WHO
and IDF meeting’
The consensus report of this meeting (May 2002)
led to the following conclusions and
recommendations:
CONCLUSIONS
1. Screening for T2DM is important in terms of
individual health, day-to-day clinical practice and
public health policy. 
2. There is currently no direct evidence that
individuals will benefit from the early detection of
T2DM through screening (direct evidence is that
from RCTs specifically designed to answer questions
related to early detection through screening). 
3. Despite this lack of direct evidence, early detection
through screening is already taking place both by
inviting individuals from the general population to
come forward for screening and, opportunistically,
when individuals perceived to be at high risk of
developing diabetes attend for healthcare (usually
primary healthcare) for other reasons.
4. These activities present opportunities for collecting
observational data, which, although no substitute
for direct RCT evidence, can provide important,
circumstantial evidence.
5. Following a demonstration of any benefits of
screening, the most important epidemiological
considerations determining whether to screen in
any given population will be (a) the prevalence of
undiagnosed T2DM in a population and (b) the
degree to which T2DM is associated with risk of
CVD and other important health outcomes in that
population. 
6. The most important health systems considerations
will be the capacity (a) to carry out the screening,
(b) to provide effective healthcare for those who
screen positive, (c) to address the psycho-social
needs of all those who undergo screening and (d)
to implement effective prevention in those who,
although not confirmed to have diabetes at the
time, are at high risk of its future development.
7. The most important economic considerations are
(a) the cost of early detection to the health system
and to the individual, (b) the extra costs of treatment
following early detection and (c) the relative cost-
effectiveness of early detection compared with that
of improving the care of clinically detected (as
opposed to screen-detected) cases. 
8. Screening for T2DM is a dynamic topic in which
new evidence will become available and further
considerations will arise over time. 
RECOMMENDATIONS
1. Health authorities and professional organisations
should formulate policies on screening for T2DM
even if the policy is that screening is not currently
to be advocated. 
2. There is an urgent need for direct RCT evidence
on the effects of early detection of T2DM through
screening. (Such evidence should include health
outcomes related to diabetes CVD, psychosocial
outcomes and economic considerations for
individuals, health systems and the wider society.
Although RCTs directed to answering these
questions may be costly and logistically difficult,
there is, in the current state of knowledge, no
ethical reason why they should not be undertaken.)
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TABLE 25 Effectiveness of screening for type 2 diabetes from lifestyle simulation models
Lifetime cumulative incidence (%) LYG QALYs Cost (US$)
ESRD Blindness LEA
gained
Per LYG Per QALY 
gained
Total population age 25 years
Without screening 3.5 9.1 4.6
With screening 2.6 5.9 3.6
Absolute risk reduction 0.9 3.2 1.0
NNT 111 31 100 0.02 0.08 236,449 56,649
Total population age 25–34 years
Without screening 19.2 32.4 19.0
With screening 15.9 25.9 16.0
Absolute risk reduction 3.3 6.5 3.0
NNT 30 15 33 0.12 0.35 35,768 13,376
Total population age 65 years
Without screening 0.3 1.7 1.0
With screening 0.2 1.1 0.7
Absolute risk reduction 0.1 0.5 0.3
NTT 1000 200 333 0.00 0.01 NA 575,241
NA, not applicable; NNT, number-needed-to-treat.
Adapted from Engelgau and Narayan (2002).253
3. Since the results of such RCTs will not be available
for some time (if ever), there is also an urgent
need to develop a framework (or model) which
would permit countries to evaluate the cost-
effectiveness of the early detection of diabetes
compared with other preventive and therapeutic
interventions. 
4. The testing of apparently unaffected individuals at
increased risk of having diabetes when these
individuals attend for healthcare for other reasons
(sometimes called ‘opportunistic screening’) may
be justified provided that (a) the reasons for
testing are adequately explained to the individual,
(b) the health system has the capacity for the
clinical management of those who screen positive, 
(c) methods with adequate sensitivity and
specificity are available, (d) the psychosocial needs
of those who screen positive and those who screen
negative can be met and (e) the health system can
implement effective preventive strategies for those
confirmed to be at high risk for the future
development of diabetes.
5. If such opportunistic screening is being advocated,
then this should be carried out according to a
policy which should (a) be clear and relevant in its
aims and objectives, (b) be based as far as possible
on sound evidence, (c) take into account the
epidemiology of T2DM and related CVD risk in
the population and (d) be sensitive to competing
local health priorities.
6. Where screening is already taking place, formal
evaluation should be integral to these activities.
The results of such evaluations could contribute to
the general assessment of the value of early
detection and should, when appropriate,
contribute to the modification or curtailment of
the local activities being evaluated. 
7. Given the dynamic nature of this topic, policies for
screening for T2DM must be reviewed from time
to time as new evidence accumulates. 
Early detection and primary prevention
of type 2 diabetes (review of work
published from 2002 onwards with
particular emphasis on published
guidelines for the detection of
‘prediabetes’)
Search strategy
The complete search strategy is given in Table 23.
In brief, the search question was:
To identify existing guidelines for prediabetes/T2DM:
prevention, screening, early detection
and was of publications, available in English and
published in the major databases such as
Cochrane, HMIC, MEDLINE and EMBASE. 
The search was for items published from 1999
onwards. This summary concentrates on those
published from 2002 onwards.
Summary of findings
Reviews and position statements
The ADA, in its review of the prevention or delay of
T2DM,254 concluded that there was substantial
evidence that T2DM could be prevented or delayed
but commented that it was “not yet known” whether
the interventions (lifestyle change and/or
pharmaceutical interventions) that had been shown
to be successful “will cost-effectively reduce the
morbidity and mortality associated with diabetes”.
However, it did comment that lifestyle
modifications which were specifically directed
towards modest weight loss and increased physical
activity were likely to have additional health benefits
over and above their specific effects in relation to
type diabetes. It recommended “some” of the
following prevention policies (listed in Table 2 of
the original publication – strength of the evidence
given as A–E in descending order of certainty):
● Individuals at high risk of developing diabetes
need to become aware of the benefits of modest
weight loss and participating in regular physical
activity (A).
● Screening based on current screening
guidelines for diabetes [(reference 49 in the
original – Expert Committee on the Diagnosis
and Classification of Diabetes Mellitus (2003)],
men and women 45 years of age, particularly
those with BMI 25 kg/m2, are candidates for
screening to detect prediabetes (IFG or IGT).
Screening should be considered in younger
individuals with a BMI 25 kg/m2 who have
additional risk factors [given in Table 3 of the
original] (B).
● In individuals with normoglycaemia,
rescreening at 3-year intervals is reasonable (C).
● How to screen: screening should be carried out
only as part of a healthcare office [sic] visit.
Either an FPG test or a 2-hour OGTT (75-g
glucose load) is appropriate, and positive test
results should be confirmed on another day (B).
● Intervention strategy: patients with prediabetes
(IFG or IGT) should be given counselling on
weight loss and also instruction for increasing
physical activity (A).
● Follow-up counselling appears important for
success (B).
● Monitoring for the development of diabetes
should be performed every 1–2 years (E).
● Close attention should be given to, and
appropriate treatment given for, other CVD risk
factors (e.g. tobacco use, hypertension,
dyslipidaemia (A).
● Drug therapy should not be routinely used to
prevent diabetes until more information is
known about its cost-effectiveness (E).
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Among the eight recommendations for further
research, the most relevant to this review is the
first mentioned [particularly the section in (our)
italics]:
What is the cost-effectiveness of a DPP-like lifestyle
intervention? Are there more cost-effective 
strategies, and how would they affect the morbidity 
and mortality associated with diabetes? The issue of
whether the preventive or delaying strategies are
effective in preventing or delaying CVD is not 
directly tackled in this review, thus recognising 
the relative lack of evidence relating to the effect 
on CVD risk of interventions shown to be effective 
in preventing or delaying the onset of diabetes 
itself.
A further position statement issued by the ADA255
concludes that “there is sufficient indirect evidence
to justify opportunistic screening in a clinical
setting of individuals at high risk”. The screening
test advocated for this opportunistic screening is
the FPG. Again, no direct reference is made to the
management of prediabetes in relation to
reduction of CVD risk. 
Davies and colleagues256 reviewed the evidence
with a specific focus on its relevance to the UK
setting. They point out that none of the available
RCTs have been carried out in the UK and
question whether their findings can be 
replicated in the UK given possible difference 
in the pathophysiology of IGT (which, frankly,
seems unlikely), a lower rate of progression to
diabetes (which is possible) and low levels of
awareness of the importance of IGT (which 
are documented257,258). The authors conclude 
that it is unlikely that a study of the effects on
diabetes incidence or CVD outcomes of 
‘upstream’ interventions (i.e. primary prevention
measures in total populations) will ever be
conducted.
Key publications 2002 onwards
In addition to the studies listed in Table 24, key
publications from 2002 onwards are summarised
in Table 26.
Studies specifically dealing with
management of ‘prediabetes’
In relation to reducing diabetes risk
Davies and colleagues256 present a comparison, in
terms of number-needed-to-treat of the
interventions tested in the Da Qing,88 TRIPOD,259
Diabetes Prevention Programme (DPP),90 Diabetes
Prevention Study (DPS),89 STOP-NIDDM169 and
XENDOS260 trials. These are summarised in 
Table 27.
Further pharmacological interventions are
summarised by Gerstein.261 These include:
● Metformin: as in DPP mentioned above.
● Acarbose: as in STOP-NIDDM mentioned above.
● Orlistat: as in XENDOS mentioned above.
● Thiazolidinediones: troglitazome (as in DPP,
withdrawn as a result of adverse effects) and
TRIPOD. 
● ACEIs: ramipril (as in HOPE); lisinopril (as in
ALLHAT); captopril (as in CAPP); enalapril (as
in D-SOLVD); and others.
● Insulin and insulin secretagogues: of theoretical
benefit.
● Statins and fibrates: pravastatin (as in
WOSCOPS), significant reduction in conversion
to diabetes; no effect found for atorvostatin
(ASCOT), simvastatin (Heart Protection Study),
pravastatin (LIPID).
● Oestrogen: reduction in conversion to diabetes
found by Kanaya and colleagues.262 Adverse
effects on CVD risk render this an unsuitable
therapeutic approach.
In relation to reducing cardiovascular disease risk
The only diabetes prevention RCT which has
reported a positive effect on CVD risk is the
STOP-NIDDM trial of acarbose. Chiasson and
colleagues169 reported a significant reduction in
new cases of hypertension, MI and any CVD event
in those taking acarbose. Given the fact that 30%
of those randomised to the active intervention
stopped taking the drug and this analysis was
based on intention-to-treat, the effect of acarbose
on CVD incidence may well be even greater than
that described. However, this unexpectedly large
effect needs to be replicated in other trials and has
not been reported as a result of lifestyle changes
or in relation to other pharmacological
interventions. 
Ongoing work with the DiabetesForcaster™ 
model (McEwan and colleagues, in preparation)
provides numerical estimates of the effects 
on CVD morbidity and mortality of delaying 
the onset of type 2 diabetes. Shown in Table 28
are the expected cardiovascular events, total
simulation costs and QALYs obtained by running
the model over a 20-year time horizon for two
scenarios: scenario 1 provides a linear increase in
risk over the time after the onset of diabetes
whereas scenario 2 provides a stepwise change in
risk at diagnosis. For scenario 1, a 10-year delay in
the onset of diabetes roughly halves the number of
deaths from CVD, reduces direct healthcare costs
to around one-third and provides an average gain
in QALYs per person of 3.31.
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TABLE 26 Key studies published from 2002 onwards
Group Study/level Title Authors Year Source Population Intervention Outcomes Follow-up/ Comments: Treatment 
evidence
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TABLE 26 Key studies published from 2002 onwards (cont’d)
Group Study/level Title Authors Year Source Population Intervention Outcomes Follow-up/ Comments: Treatment 
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DM, diabetes mellitus; ITT, intention-to-treat; PY, person-year; ROC, receiver operating characteristic; TG, triglycerides.
Conclusions
1. There is still no evidence from RCTs specifically
designed to show whether early detection through
screening is worthwhile and that individuals will
benefit from the early detection of T2DM. The
definitive RCT is unlikely to be undertaken.
2. Given that opportunistic screening and
screening by invitation are happening in
primary care in the UK, standards and
guidelines are required in order to achieve
equitable access to good practice.
3. Screening activities, whether opportunistic or
by invitation, may, depending on cut-offs used,
identify more people with IGT and/or IFG than
people with previously undiagnosed diabetes.
4. There is convincing RCT evidence that
interventions relating to lifestyle change and
some pharmacological treatments (as yet
unlicensed for this use) are effective in delaying
transition from IGT to diabetes, particularly in
people who are overweight or obese.
5. It is, as yet, an unanswered question as to
whether the efficacy of these interventions in
the RCT context can be translated into




TABLE 27 Number-needed-to-treat (NNT) to avoid one case of progression from IGT to T2DM in published trials 
Study Cumulative incidence of Intervention NNT Duration 
T2DM vs placebo (%) (years)
Da Qing (Pan et al., 1997)88 66 vs 44 Lifestyle 4.5 6
TRIPOD (Azen et al., 1998)259 30 vs 14 Troglitazone 6 2.5
Diabetes Prevention Program 29 vs 14 Lifestyle 7 3
(DPP Research Group, 2002)90
Diabetes Prevention Study 42 vs 32 Lifestyle 8 4
(Tuomilehto et al., 2001)89
STOP-NIDDM (Chiasson et al., 2003)169 42 vs 32 Acarbose 11 4
Diabetes Prevention Program 29 vs 22 Metformin 14 3
(DPP Research Group, 2002)90
XENDOS (Sjostrom et al., 2002)260 9 vs 6 Xenical 36 3
Adapted from Davies and colleagues (2004).256
TABLE 28 Summary of cardiovascular results, total costs and QALYs obtained over a 20-year time horizon running the model with no
delay in diabetes and 1, 3, 5 and 10 years’ delay for scenarios 1 and 2: values shown are expected cumulative events (when running the
model with no delay), and expected events/costs avoided and gain in QALYs
Events Events avoided (or QALYs per person gained)
No 1-year delay 3-year delay 5-year delay 10-year delay
delay
Scenario Scenario Scenario Scenario Scenario Scenario Scenario Scenario 
1 2 1 2 1 2 1 2
CHD 421 24 15 44 61 81 95 121 181
Stroke 269 18 20 49 56 88 84 151 159
CVD death 271 17 10 40 47 73 70 133 131
Costs and QALYs Effect on costs and QALYs
Costs per subject:
Non-discounted (£) 18,303 –£703.48 –839.69 –2119 –2237 –3441 –3616 –6026 –6604
Discounted (£) 13,145 –605.91 –687.02 –1722 –1823 –2717 –2869 –4547 –4978
QALYs per subject:
Non-discounted 9.74 0.41 0.37 1.13 1.19 1.85 1.85 3.17 3.31
Discounted 7.53 0.34 0.32 0.93 0.98 1.48 1.49 2.43 2.53
Adapted from McEwan and colleagues (in preparation).268
6. It is also an unanswered question as to whether
delaying transition to diabetes delays or
prevents the cardiovascular outcomes
associated with diabetes.
7. It is highly likely that the effectiveness and cost-
effectiveness of early identification of diabetes,
IGT and IFG will be enhanced by combining
this with the early identification and
management of CVD risk.
8. A care pathway for the early detection and
prevention of T2DM and associated CVD risk
based on the best evidence available (or at least
consensus) is required to guide primary care
professionals and others on current and future
practice. 
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